This Preliminary Official Statement and the information contained herein are subject to completion or amendment. Under no circumstances shall this Preliminary Official Statement constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of the Series 2018D Bonds in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration, qualification or exemption under the securities laws of such jurisdiction. * Preliminary, subjecttochange. Dated: May__,2018 HAS NOTAXINGPOWER. PRICE OF, PREMIUM, IF ANY, OR INTEREST ON THE SERIES 2018D BONDS. SUBDIVISION THEREOF BE LIABLE THE FOR THE AUTHORITY PAYMENT OF THE PRINCIPAL OR PURCHASE POLITICAL ANY OR PENNSYLVANIA OF COMMONWEALTH THE COUNTY, THE SHALL NOR THEREOF, SUBDIVISION POLITICAL ANY OR PENNSYLVANIA OF COMMONWEALTH THE OR COUNTY TO THE OF DEEMED OBLIGATIONS BE OR AUTHORITY BONDS THE OF 2018D OBLIGATIONS GENERAL SERIES BE THE SHALL NOR BONDS, 2018D SERIES THE ON THE FOR PLEDGED INTEREST OR ANY, IF PREMIUM, IS OF, PRICE PURCHASE OR PRINCIPAL THE OF PAYMENT THEREOF SUBDIVISION POLITICAL ANY COMMONWEALTH OR THE PENNSYLVANIA “COUNTY”), OF (THE THE PENNSYLVANIA OF POWER MONTGOMERY, TAXING OF OR CREDIT COUNTY THE NOR AUTHORITY THE OF CREDIT GENERAL THE NEITHER HEREIN. DESCRIBED AND THEREIN TO REFERRED SOURCES THE FROM SECURED UNDER THE PROVISIONS OF THE 2018D INDENTURE AND ARE PAYABLE SOLELY Dated: DateofDelivery NEW ISSUE ‑ BOOK herein andAPPENDIX Dattachedhereto. the of BONDS” rights 2018D SERIES THE and FOR PAYMENT OF payable SOURCES AND “SECURITY amounts See Trustee. the The to assigned been has Bonds 2018D Indenture. Series the for Master Note Master the the under Authority to pursuant Group, Obligated the of Members the of all of Revenues Gross the by secured Group Obligated the of Members other the and TJU of obligation several and joint a is Note Master The Trustee. Master and Group, Obligated the of behalf on Agent, Group Obligated the by Indenture”), “Master the (collectively, supplemented as 2017, 1, December on effective and 2017 1, February of as dated Agreement) (Security Indenture Trust Master Restated and Amended Authority) at the times and in amounts sufficient to pay the debt service on the Series 2018D Bonds when due, TJU as “Obligated Group Agent” has issued a Master Note under the Obligated GroupandalloftheircontrolledAffiliates.TheSeries2018DBondsarepayablesolelyfromthesourcesidentifiedinIndenture,includingPledged Revenues. and of FINANCE” Members other OF the TJU, “PLAN to collectively See refer to used is Project. “University” term 2018 the Statement, the Official this of of purposes costs For the herein. FUNDS” of OF USES portion AND SOURCES a “ESTIMATED or all fund to herein, described sources other the with together applied, be will and Agreement, Loan herein. Variable RatewithadifferentPeriod,asdescribedherein. a including rate interest new a at interest bear to converted are Bonds 2018D Series the TJU, of option the at until, and unless Rate Weekly Variable the at interest bear to continue purchase. For so long as the Series 2018D Bonds are in the Variable Rate Mode, the Series 2018D Bonds will not be supported by any liquidity facility. The Series 2018D Bonds will for tendered Bonds 2018D Series any of price purchase the pay to obligated are Group Obligated the of Members the nor Authority the Neither Indenture. 2018D the in identified as funds other and Bonds 2018D Series such of remarketing the of proceeds the from only made be will purchase for tendered are which Bonds 2018D Series for Payment Mode. Rate Variable the in while herein described as tender mandatory and optional to subject are Bonds 2018D Series The 2018. 1, June commencing month, each of Day Business first herein. will bedeterminedasdescribedhereinforSeries2018DBondsintheVariableRateMode.See“DESCRIPTIONOFTHESERIESBONDS”herein. ENTRY ONLYSYSTEM”herein. 2018D Bonds by the Trustee in its capacity as Paying Agent and bond registrar, to be subsequently disbursed to the Beneficial Owners, as more fully described herein. See, “BOOK- Series the of owner registered as DTC for nominee as Co., & Cede to directly made be will Bonds 2018D Series the on interest or of Price Redemption or price purchase principal representing their interests in Series 2018D Bonds so purchased. So long as DTC, or its nominee, Cede & Co., is the registered owner of the Series 2018D Bonds, all payments of the (as described herein). So long as Cede & Co. is the registered owner of the Series 2018D Bonds, purchasers of beneficial interests (“Beneficial Owners”) will not receive certificates Mode Rate Variable the in are Bonds 2018D Series the as long so for thereof excess in $5,000 of multiple integral be any or $25,000 will of denominations in only Bonds form book-entry in made 2018D Series the in interests beneficial of Purchases Bonds. 2018D Series the for depository securities as act will which York, New York, New (“DTC”), Company not definedonthiscoverpagearewithinOfficialStatement. terms Capitalized Indenture. 2018D the to pursuant Bonds”) 2018D “Series (the (R-Floats) 2018D Series Bonds, Revenue Rate Variable University Jefferson Thomas its of amount by CozenO’Connor,Philadelphia,Pennsylvania. TheSeries2018DBondsareexpectedtobedeliveredthroughthebook‑entry systemofDTConoraboutMay3,2018. Ballard SpahrLLP,Philadelphia,Pennsylvania, initscapacityascounsel,includingDisclosureCounsel,toTJU.Certain legalmatterswillbepasseduponfortheUnderwriter Authority by Douglas B. Breidenbach, Jr, Esquire, Pottstown, Pennsylvania. Certain legal matters will be passed upon for the University by the without anynotice,andsubjecttotheapproving opinionofBallardSpahrLLP,Philadelphia,Pennsylvania,BondCounsel. Certainlegalmatterswillbepasseduponforthe Office of University Counsel and investment decision. Potential investors must read the entire Official Statement (including the cover page and all appendices attached hereto) to obtain information essential to the making of an informed in Pennsylvania.See“TAXMATTERS”herein. Series 2018D Bonds is exempt from Pennsylvania personal income tax and corporate net income tax, and the Series 2018D Bonds are exempt from personal property taxes circumstances describedunder“TAX MATTERS” herein.BondCounselisalsooftheopinion that,underthelawsofCommonwealthPennsylvania,intereston alternative minimumtax;however,interestpaidtocertaincorporateholdersoftheSeries2018DBondsindirectlymaybesubjecttaxunder continuing compliancewiththerequirementsoffederaltaxlaws.InterestonSeries2018DBondsisnotapreferenceitemforpurposesindividual As security for the payment obligations of TJU under the 2018D Loan Agreement, including the obligation to make loan payments to the applicable Trustee (as assignee of the 2018D the to pursuant (“TJU”), corporation nonprofit Pennsylvania a University, Jefferson Thomas to Authority the by loaned be will Bonds 2018D Series the of proceeds The Provisions” Redemption – BONDS 2018D SERIES THE OF “DESCRIPTION See herein. described as maturity, to prior redemption to subject are Bonds 2018D Series The Interest on the Series 2018D Bonds will accrue from the date of delivery, and while bearing interest at a Variable Weekly Rate in the Variable Rate Mode, will be payable on the Mode” Rate Variable – BONDS 2018D SERIES THE OF “DESCRIPTION See Mode. Rate Variable the in while only Bonds 2018D Series the describes Statement Official This The initial interest rate for the Series 2018D Bonds will be communicated by the Remarketing Agent to the prospective purchasers of such Series 2018D Bonds, and thereafter Trust Depository The for nominee as Co., & Cede of name the in registered be will issued, when and, bonds registered fully as only issued be will Bonds 2018D Series The principal aggregate in $49,950,000* of “Authority”) (the Authority Health and Education Higher County Montgomery the by issuance the to relates Statement Official This The Series 2018D Bonds are offered when, as, and if issued by the Authority and received by the Underwriter, subject to prior sale, withdrawal or modification of the offer Bonds. 2018D Series the to relating matters the of summary a be, to intended not is and not, is It only. reference quick for information limited contains page cover This Investment intheSeries2018DBondsissubjecttocertainrisks.See“CERTAININVESTMENT CONSIDERATIONS”herein. ARE AUTHORITY, THE OF OBLIGATIONS LIMITED ARE BONDS 2018D SERIES THE In theopinionofBallardSpahrLLP,BondCounsel,interestonSeries2018DBondsisexcludablefromgrossincomeforpurposesfederaltax,assuming - ENTRY ONLY
MONTGOMERY COUNTY HIGHER EDUCATION AND HEALTH AUTHORITY THOMAS JEFFERSONUNIVERSITYVARIABLERATEREVENUEBONDS,
PRELIMINARY OFFICIAL STATEMENT DATED APRIL 25, 2018 SERIES 2018D(R BofA MerrillLynch $49,950,000* - FLOATS) See “RATINGS’’herein Due: September1,2050 RATINGS:
$49,950,000* MONTGOMERY COUNTY HIGHER EDUCATION AND HEALTH AUTHORITY THOMAS JEFFERSON UNIVERSITY VARIABLE RATE REVENUE BONDS, SERIES 2018D (R-FLOATS)
Price: 100.000
Last Day of Initial Rate Period: May 10, 2018
First Variable Rate Determination Date: Prior to Date of Delivery
First Interest Payment Date: June 1, 2018
Variable Weekly Rate Determination Dates: Generally, Thursday of each week.
Interest Payment Dates: Generally, the first Business Day of each month.
Maturity Date: September 1, 2050
CUSIP No.† _____
* Preliminary, subject to change. † CUSIP numbers have been assigned to the Series 2018D Bonds by an organization not affiliated with the Authority and are included solely for the convenience of the owners of the Series 2018D Bonds. Neither the Authority, the Underwriter nor the Obligated Group is responsible for the selection or use of the CUSIP numbers set forth herein nor is any representation made as to the accuracy of the CUSIP numbers as to the Series 2018D Bonds or as indicated above. The CUSIP number for a specific maturity is subject to being changed after the issuance of the Series 2018D Bonds as a result of procurement of secondary market portfolio insurance or other similar enhancement by investors that is applicable to all or a portion of certain maturities of the Series 2018D Bonds. MONTGOMERY COUNTY HIGHER EDUCATION AND HEALTH AUTHORITY
BOND COUNSEL
Ballard Spahr LLP Philadelphia, Pennsylvania
COUNSEL TO THE AUTHORITY
Douglas B. Breidenbach, Jr., Esquire Pottstown, Pennsylvania
COUNSEL TO THE UNIVERSITY
Office of University Counsel Philadelphia, Pennsylvania
Ballard Spahr LLP Philadelphia, Pennsylvania
FINANCIAL ADVISOR TO THE UNIVERSITY
Echo Financial Products, LLC King of Prussia, Pennsylvania
UNDERWRITER
Merrill Lynch, Pierce, Fenner & Smith Incorporated New York, New York
COUNSEL TO THE UNDERWRITER
Cozen O’Connor Philadelphia, Pennsylvania
No dealer, broker, salesman or any other person has been authorized by the Authority, the University or the Underwriter to give any information or to make any representation, other than those contained in this Official Statement, and, if given or made, such other information or representations must not be relied upon as having been authorized by the Authority, the University, the Underwriter or any other person. Except as otherwise indicated, the information contained in this Official Statement, including in the appendices, has been obtained from representatives of the Authority (but only with respect to the information under the captions “INTRODUCTION - The Authority; Authority for Issuance,” “THE AUTHORITY” and “LITIGATION - The Authority”), the University and from public documents, records and other sources considered to be reliable.
This Official Statement does not constitute a contract between the Authority, the Obligated Group, or the Underwriter and any one or more owners of the Series 2018D Bonds, nor does it constitute an offer to sell or the solicitation of an offer to buy the Series 2018D Bonds in any jurisdiction to any person to whom it is unlawful to make such offer, solicitation or sale in such jurisdiction.
The information set forth herein has been obtained from the Authority (but only with respect to the information under the captions “INTRODUCTION - The Authority; Authority for Issuance,” “THE AUTHORITY” and “LITIGATION - The Authority”), the University, and other sources which are believed to be reliable, but is not guaranteed as to accuracy or completeness by, and is not to be construed as a representation of, the Underwriter or of the Authority. The Underwriter has provided the following statement for inclusion in this Official Statement: The Underwriter has reviewed the information in this Official Statement in accordance with, and as part of, its responsibilities to investors under the federal securities laws as applied to the facts and circumstances of this transaction, but the Underwriter does not guaranty the accuracy or completeness of such information. The information and expressions of opinion herein are subject to change without notice and neither the delivery of this Official Statement nor any sale made hereunder shall, under any circumstances, create any implication that there has been no change in the affairs of the Authority or the University since the date hereof or the earliest date as of which such information is given. Any statements in this Official Statement involving estimates, assumptions and matters of opinion, whether or not expressly stated, are intended as such and not as representations of fact.
THE SERIES 2018D BONDS HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION UNDER THE SECURITIES ACT OF 1933, AS AMENDED, NOR HAS THE 2018D INDENTURE BEEN QUALIFIED UNDER THE TRUST INDENTURE ACT OF 1939, AS AMENDED, IN RELIANCE UPON EXEMPTIONS CONTAINED IN SUCH ACTS. THE REGISTRATION OR QUALIFICATION OF THE SERIES 2018D BONDS IN ACCORDANCE WITH APPLICABLE PROVISIONS OF THE SECURITIES LAWS OF THE STATES, IF ANY, IN WHICH THE SERIES 2018D BONDS HAVE BEEN REGISTERED OR QUALIFIED, IF ANY, AND THE EXEMPTION FROM REGISTRATION OR QUALIFICATION IN CERTAIN OTHER STATES CANNOT BE REGARDED AS A RECOMMENDATION THEREOF. NEITHER THESE STATES NOR ANY OF THEIR AGENCIES HAVE PASSED UPON THE MERITS OF THE SERIES 2018D BONDS OR THE ACCURACY OR COMPLETENESS OF THIS OFFICIAL STATEMENT. ANY REPRESENTATION TO THE CONTRARY MAY BE A CRIMINAL OFFENSE.
In making an investment decision, investors must rely on their own examination of the University and the terms of the offering, including the merits and risks involved.
IN CONNECTION WITH THE OFFERING OF THE SERIES 2018D BONDS, THE UNDERWRITER MAY OVER-ALLOT OR EFFECT TRANSACTIONS THAT STABILIZE OR MAINTAIN THE MARKET PRICE OF THE SERIES 2018D BONDS OFFERED HEREBY AT LEVELS ABOVE THOSE THAT MIGHT OTHERWISE PREVAIL IN THE OPEN MARKET. SUCH STABILIZING, IF COMMENCED, MAY BE DISCONTINUED AT ANY TIME. THE UNDERWRITER MAY OFFER AND SELL THE SERIES 2018D BONDS TO CERTAIN DEALERS AND OTHERS AT PRICES LOWER THAN THE PUBLIC OFFERING PRICES STATED ON THE INSIDE COVER PAGE OF THIS OFFICIAL STATEMENT, AND SUCH PUBLIC OFFERING PRICES MAY BE CHANGED FROM TIME TO TIME BY THE UNDERWRITER.
The order and placement of information in this Official Statement, including the appendices, are not an indication of relevance, materiality or relative importance, and this Official Statement, including the appendices, must be read in its entirety. The captions and headings in this Official Statement are for convenience only and in no way define, limit or describe the scope or intent, or affect the meaning or construction, of any provision or section in this Official Statement.
This Official Statement is being provided to prospective purchasers either in bound printed form (“Original Bound Format”) or in electronic format on the following websites: www.munios.com and www.emma.msrb.org. Prospective purchasers may rely on the information contained in this Official Statement in the Original Bound Format or in electronic format; provided, however, that prospective purchasers must read the entire Official Statement (including the cover page and all appendices attached hereto) to obtain all of the information essential to the making of an informed investment decision.
REFERENCES TO WEBSITE ADDRESSES PRESENTED HEREIN ARE FOR INFORMATIONAL PURPOSES ONLY AND MAY BE IN THE FORM OF A HYPERLINK SOLELY FOR THE READER’S CONVENIENCE. UNLESS SPECIFIED OTHERWISE, SUCH WEBSITES AND THE INFORMATION OR LINKS CONTAINED THEREIN ARE NOT INCORPORATED INTO, AND ARE NOT PART OF, THIS OFFICIAL STATEMENT FOR ANY PURPOSE INCLUDING FOR PURPOSES OF RULE 15c2-12 PROMULGATED BY THE SECURITIES AND EXCHANGE COMMISSION.
THIS PRELIMINARY OFFICIAL STATEMENT IS IN A FORM DEEMED FINAL BY THE AUTHORITY AND TJU ON BEHALF OF THE OBLIGATED GROUP FOR PURPOSES OF RULE 15c2-12 ISSUED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, EXCEPT FOR CERTAIN INFORMATION PERMITTED TO BE OMITTED PURSUANT TO RULE 15c2-12(B)(1).
TABLE OF CONTENTS
Page
OFFICIAL STATEMENT ...... 1 INTRODUCTION ...... 1 General ...... 1 The Authority; Authority for Issuance ...... 1 Description of the Series 2018D Bonds ...... 2 Purpose of the Series 2018D Bonds ...... 2 Security and Sources of Payment for the Series 2018D Bonds ...... 3 The University ...... 5 Investment Considerations ...... 6 Continuing Disclosure ...... 6 Other Information ...... 6 PLAN OF FINANCE ...... 7 General ...... 7 New Money Project ...... 7 2018 Refunding Project ...... 7 ESTIMATED SOURCES AND USES OF FUNDS ...... 8 THE OBLIGATED GROUP MEMBERS AND THE UNIVERSITY ...... 9 General ...... 9 Merger Plans ...... 9 THE AUTHORITY ...... 10 General ...... 10 Members of the Authority ...... 10 Financings of the Authority ...... 11 DESCRIPTION OF THE SERIES 2018D BONDS ...... 12 General ...... 12 Variable Rate Mode ...... 13 Optional Tender of Series 2018D Bonds in Variable Rate Mode ...... 17 Mandatory Tender of Series 2018D Bonds in the Variable Rate Mode ...... 17 Variable Rate Non-Remarketed Bonds ...... 18 Conversion of Series 2018D Bonds ...... 19 Redemption Provisions ...... 19 Transfer and Exchange of Series 2018D Bonds; Persons Treated as Owners ...... 21 BOOK-ENTRY ONLY SYSTEM ...... 22 SECURITY AND SOURCES OF PAYMENT FOR THE SERIES 2018D BONDS ...... 25 General ...... 25 Trust Estate ...... 25 2018D Loan Agreement ...... 26
i
Master Indenture ...... 26 Certain Covenants of the Obligated Group under the Master Indenture ...... 27 Direct Placement Bonds ...... 30 Interest Rate Swaps ...... 30 Additional Long Term Indebtedness ...... 31 Obligated Group Members and the Master Indenture ...... 32 Addition, Exclusion and Release of Entities with Respect to the Requirements of the Master Indenture ...... 33 New Obligated Group and New Master Indenture ...... 35 Limited Obligations ...... 36 OUTSTANDING INDEBTEDNESS OF THE OBLIGATED GROUP ...... 37 Existing Obligations ...... 37 Swap Agreements ...... 38 Estimated Debt Service Requirements ...... 39 CERTAIN INVESTMENT CONSIDERATIONS ...... 40 General ...... 40 Covenant to Maintain Tax-Exempt Status of the Series 2018D Bonds ...... 40 Unrelated Business Income ...... 41 Decreases in Federal and Commonwealth Research and Other Grants and Contract Funding ...... 41 Local Tax Assessments ...... 41 Enforceability of Obligations of Obligated Group Members ...... 42 Enforceability of Remedies ...... 43 Potential Effects of Bankruptcy ...... 43 Continued Utilization of University Hospital Facilities and Factors That Could Result in Increased Competition ...... 44 Health Care Industry Factors Affecting the University ...... 45 Overview of Medicare and Medicaid Program ...... 48 Medicare Reimbursement ...... 48 Medicaid Reimbursement ...... 57 Third Party Payers ...... 60 The Fraud and Abuse Laws ...... 63 Antitrust ...... 66 Exposure to Liability ...... 67 Medical Professional Liability Insurance Market ...... 67 Charity Care ...... 68 Tax Law Changes that May Impact Charitable Giving (Tax Cuts and Jobs Act) ...... 68 Other Legislative and Regulatory Actions ...... 69 Emergency Medical Treatment and Active Labor Act ...... 69 Health Insurance Portability and Accountability Act ...... 70 Corporate Compliance ...... 71 Cyber-Security Risks ...... 72 Increased Enforcement Affecting Academic Research ...... 72 Fluctuations in Market Value of Investments ...... 72 Other Potential Transactions ...... 73
ii
Other Risk Factors Relating to the Finances and Operations of the University ...... 74 LITIGATION ...... 76 The Authority ...... 76 The University ...... 76 TAX MATTERS ...... 76 Federal Tax Matters Applicable to the Series 2018D Bonds ...... 76 Commonwealth of Pennsylvania Tax Matters ...... 77 LEGAL MATTERS ...... 77 CONTINUING DISCLOSURE ...... 77 RATINGS ...... 78 UNDERWRITING ...... 78 REMARKETING ...... 79 General ...... 79 Certain Considerations Concerning the Remarketing of the Series 2018D Bonds ...... 80 INDEPENDENT ACCOUNTANTS ...... 81 FINANCIAL ADVISOR ...... 81 CERTAIN RELATIONSHIPS ...... 82 FORWARD-LOOKING STATEMENTS ...... 82 MISCELLANEOUS ...... 83 AUTHORIZATION OF AND CERTIFICATION OF OFFICIAL STATEMENT ...... 84
APPENDIX A - DESCRIPTION OF THE UNIVERSITY APPENDIX B-1 - THOMAS JEFFERSON UNIVERSITY CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2017 AND 2016 APPENDIX B-2 - UNAUDITED CONSOLIDATING SCHEDULES APPENDIX C - DEFINITIONS OF CERTAIN TERMS AND SUMMARIES OF CERTAIN PROVISIONS OF THE 2018D INDENTURE AND THE 2018D LOAN AGREEMENT APPENDIX D - DEFINITIONS OF CERTAIN TERMS AND SUMMARIES OF CERTAIN PROVISIONS OF THE MASTER INDENTURE APPENDIX E - PROPOSED FORM OF OPINION OF BOND COUNSEL APPENDIX F - FORM OF CONTINUING DISCLOSURE AGREEMENT
iii
OFFICIAL STATEMENT
relating to
$49,950,000* MONTGOMERY COUNTY HIGHER EDUCATION AND HEALTH AUTHORITY THOMAS JEFFERSON UNIVERSITY VARIABLE RATE REVENUE BONDS, SERIES 2018D (R-FLOATS)
INTRODUCTION
General
This Introduction is not a summary of this Official Statement and is intended only for quick reference. It is only a brief description of and guide to, and is qualified in its entirety by reference to, the more complete and detailed information contained in the entire Official Statement, including the cover page and the appendices attached hereto, and the documents summarized or described herein. A full review should be made of the entire Official Statement and of the documents summarized or described herein, if necessary. The offering of the Series 2018D Bonds (as defined below) to potential investors is made only by means of the entire Official Statement, including the appendices attached hereto. No person is authorized to detach this Introduction from this Official Statement or to otherwise use it without the entire Official Statement, including the appendices attached hereto.
The purpose of this Official Statement, including the cover page, inside cover page, and the appendices attached hereto, is to provide certain information in connection with the issuance and sale by the Montgomery County Higher Education and Health Authority (the “Authority”) of $49,950,000* aggregate principal amount of its Thomas Jefferson University Variable Rate Revenue Bonds, Series 2018D (R-Floats) (the “Series 2018D Bonds”). All capitalized terms used and not defined herein shall have the meanings assigned to them in “APPENDIX C - DEFINITIONS OF CERTAIN TERMS AND SUMMARIES OF CERTAIN PROVISIONS OF THE 2018D INDENTURE AND THE 2018D LOAN AGREEMENT,” and “APPENDIX D - DEFINITIONS OF CERTAIN TERMS AND SUMMARIES OF CERTAIN PROVISIONS OF THE MASTER INDENTURE” attached hereto.
The Authority; Authority for Issuance
The Authority is a body corporate and politic created by the County of Montgomery, Pennsylvania (the “County”). See “THE AUTHORITY” herein. The Authority is authorized and empowered to issue the Series 2018D Bonds pursuant to the Municipality Authorities Act, 53 Pa. Cons. Stat. § 5601 et seq., as amended (the “Act”), resolutions of the Authority adopted on November 13, 2017 and March 12, 2018 (collectively, the “Resolutions”), and that certain Series 2018D Trust Indenture dated as of May 1, 2018 (the “2018D Indenture”), between the Authority and The Bank of New York Mellon Trust Company, N.A., as trustee (the “2018D Trustee” or the “Trustee”).
* Preliminary, subject to change.
Description of the Series 2018D Bonds
Interest on the Series 2018D Bonds will accrue from the date of delivery, and while bearing interest at a Variable Weekly Rate in the Variable Rate Mode, will be payable on the first Business Day of each month, commencing June 1, 2018. The Series 2018D Bonds are subject to optional and mandatory tender as described herein while in the Variable Rate Mode. Payment for Series 2018D Bonds which are tendered for purchase will be made only from the proceeds of the remarketing of such Series 2018D Bonds and other funds as identified in the 2018D Indenture. Neither the Authority nor the Members of the Obligated Group are obligated to pay the purchase price of any Series 2018D Bonds tendered for purchase. For so long as the Series 2018D Bonds are in the Variable Rate Mode, the Series 2018D Bonds will not be supported by any liquidity facility. The Series 2018D Bonds will continue to bear interest at the Variable Weekly Rate unless and until, at the option of TJU, the Series 2018D Bonds are converted to bear interest at a new interest rate mode including a Variable Rate with a different Rate Period, as described herein.
This Official Statement describes the Series 2018D Bonds only while in the Variable Rate Mode. See “DESCRIPTION OF THE SERIES 2018D BONDS – Variable Rate Mode” herein.
The Series 2018D Bonds are subject to redemption prior to maturity, as described herein. See “DESCRIPTION OF THE SERIES 2018D BONDS – Redemption Provisions” herein.
Purpose of the Series 2018D Bonds
The proceeds of the Series 2018D Bonds will be loaned by the Authority to Thomas Jefferson University, a Pennsylvania nonprofit corporation (“TJU”), pursuant to that certain Series 2018D Loan Agreement dated as of May 1, 2018 (the “2018D Loan Agreement”), between the Authority and TJU, and will be applied, together with the proceeds of the Series 2018A Bonds, Series 2018B Bonds and the Series 2018C Bonds (each as defined below) to fund all or a portion of the costs of the 2018 Project (as defined and described herein), which includes the New Money Project and the 2018 Refunding Project (each as defined herein). See “PLAN OF FINANCE” and “ESTIMATED SOURCES AND USES OF FUNDS” herein.
For purposes of this Official Statement, the term “University” is used to refer collectively to TJU, the other Members of the Obligated Group and all of their controlled Affiliates, excluding any Excluded Affiliate (each as defined herein), and the term “Audit Group” is used to refer to TJU and any other Person whose financial results are set forth in the Financial Statements of the University (excluding any Excluded Affiliate unless otherwise provided for by the Master Indenture (as defined herein)). As of the date of this Official Statement, the University has no Excluded Affiliates.
In addition to the issuance of the Series 2018D Bonds, the Authority, at the request of TJU, is proposing to issue $356,285,000 in aggregate principal amount of its Thomas Jefferson University Fixed Rate Revenue Bonds, Series 2018A (the “Series 2018A Bonds”), $35,075,000 in aggregate principal amount of its Thomas Jefferson University Taxable Fixed Rate Revenue Bonds, Series 2018B (the “Series 2018B Bonds”) and $100,000,000 in aggregate principal amount of its Thomas Jefferson University Variable Rate Revenue Bonds, Series 2018C (the “Series 2018C Bonds” and together with the Series 2018A Bonds, the Series 2018B Bonds and the Series
2
2018D Bonds, the “2018 Bonds”) pursuant to that certain Series 2018A/B Trust Indenture and Series 2018C Trust Indenture, each dated as of May 1, 2018, between the Authority and The Bank of New York Mellon Trust Company, N.A. as trustee, which Series 2018A Bonds, Series 2018B Bonds, and Series 2018C Bonds will be marketed and sold via a separate official statement and are not being offered under this Official Statement. The proceeds of the Series 2018A Bonds and Series 2018B Bonds will be loaned by the Authority to TJU pursuant to that certain Series 2018A/B Loan Agreement dated as of May 1, 2018 (the “2018A/B Loan Agreement”), between the Authority and TJU. The proceeds of the Series 2018C Bonds will be loaned by the Authority to TJU pursuant to that certain Series 2018C Loan Agreement dated as of May 1, 2018 (the “2018C Loan Agreement, ” and together with the 2018A/B Loan Agreement and the 2018D Loan Agreement, the “2018 Loan Agreements”), between the Authority and TJU.
See “PLAN OF FINANCE” and “ESTIMATED SOURCES AND USES OF FUNDS” herein.
Security and Sources of Payment for the Series 2018D Bonds
2018D Indenture and 2018D Loan Agreement. The Series 2018D Bonds are limited obligations of the Authority payable solely from the sources identified in the 2018D Indenture, including Pledged Revenues (as defined herein), which in the case of the 2018D Indenture consist generally of all amounts payable to the Trustee with respect to the principal or purchase price of, premium, if any, and interest on the Series 2018D Bonds under the 2018D Loan Agreement by TJU and investment income with respect to certain funds held by the Trustee under the 2018D Indenture, and amounts payable by the Obligated Group under the Master Note issued with respect to the 2018D Bonds under the Master Indenture.
Pursuant to the 2018D Loan Agreement, TJU agrees to make payments at such times and in such amounts as necessary to provide for the payment of the principal of, premium, if any, and interest on the Series 2018D Bonds. The obligation of TJU under the 2018D Loan Agreement is a general obligation of TJU, the full faith and credit of which is pledged to the payment of all such sums due thereunder.
In order to secure the payment of the principal or purchase price of, premium, if any, and interest on the Series 2018D Bonds, the Authority has assigned to the 2018D Trustee, under the 2018D Indenture, and granted a security interest in: (i) all of its right, title and interest in, to and under the 2018D Loan Agreement, and all payments received or receivable by the Authority from TJU under the 2018D Loan Agreement (excluding the Authority’s rights to payment of its fees and expenses, to indemnification and as otherwise expressly set forth in the 2018D Loan Agreement), (ii) all of the right, title and interest of the Authority in: the Thomas Jefferson University Obligated Group Master Note (MCHEHA-TJU Series 2018D Bonds), Obligation No. 35 (the “2018D Master Note” or the “Master Note”), with respect to the 2018D Indenture and issued by TJU, as Obligated Group Agent on behalf of the Obligated Group, pursuant to the Master Indenture, and all payments, revenues and receipts receivables by the Authority thereunder except as provided therein, and (iii) all of the right, title and interest of the Authority in and to all Funds and Accounts established under the 2018D Indenture (except for the Rebate Fund) and all moneys and investments held therein and all present and future Pledged Revenues within the meaning of the 2018D Indenture.
3
See “SECURITY AND SOURCES OF PAYMENT FOR THE SERIES 2018D BONDS” herein for a more detailed discussion of the Trust Estate under the 2018D Indenture, the Trustee’s rights under the 2018D Indenture, and, the Master Trustee’s (as defined herein) rights under the Master Indenture, and the obligations of the Obligated Group under the Master Indenture. See also “APPENDIX C - DEFINITIONS OF CERTAIN TERMS AND SUMMARIES OF CERTAIN PROVISIONS OF THE 2018D INDENTURE AND THE 2018D LOAN AGREEMENT” and “APPENDIX D – DEFINITIONS OF CERTAIN TERMS AND SUMMARIES OF CERTAIN PROVISIONS OF THE MASTER INDENTURE” attached hereto for summaries of the 2018D Indenture, the 2018D Loan Agreement, the Master Indenture and certain definitions contained therein.
Master Indenture. TJU and each of the other Members of the Obligated Group (as defined herein) are parties to a certain Amended and Restated Master Trust Indenture (Security Agreement) dated as of February 1, 2017 and effective on December 1, 2017 (the “Amended and Restated Master Trust Indenture”), as supplemented by a Fourth Supplement to the Amended and Restated Master Trust Indenture (Security Agreement), dated as of May 1, 2018 (the "Fourth Supplement,” and together with the Amended and Restated Master Trust Indenture, the “Master Indenture”), executed by the Obligated Group Agent, on behalf of the Obligated Group, and The Bank of New York Mellon Trust Company, N.A. as master trustee (the “Master Trustee”). TJU is the Obligated Group Agent under the Master Indenture. Under and pursuant to the Master Indenture, the Obligated Group Members are jointly and severally liable for the payment of the Obligations (as defined in the Master Indenture) of the Obligated Group, and have agreed to comply with certain financial and operational covenants contained therein. See generally “SECURITY AND SOURCES OF PAYMENT FOR THE SERIES 2018D BONDS - Master Indenture” herein and “APPENDIX D - DEFINITIONS OF CERTAIN TERMS AND SUMMARIES OF CERTAIN PROVISIONS OF THE MASTER INDENTURE” attached hereto. The Obligated Group Agent, on behalf of all of the Obligated Group Members, will issue to the 2018D Trustee the Master Note as an additional Obligation pursuant to the Master Indenture to secure TJU’s payment obligations under the 2018D Loan Agreement.
The Master Indenture contains the covenants and grant of security of the Obligated Group, including the Gross Revenues pledge of all of the Members of the Obligated Group, including TJU, to secure existing and future debt and the payment obligations of the Obligated Group. The Obligated Group’s obligations under the Master Note will be secured on a parity basis equally and ratably with all other outstanding Obligations (other than Subordinated Obligations) and Parity Indebtedness (as such terms are defined in the Master Indenture) heretofore or hereafter issued or incurred in accordance with the Master Indenture.
For a description of the outstanding Obligations and Parity Indebtedness of the Obligated Group, see “OUTSTANDING INDEBTEDNESS OF THE OBLIGATED GROUP” herein, including the information under the sub-section captioned “Existing Obligations” and the table under the sub-section captioned “Estimated Debt Service Requirements” thereunder.
See “SECURITY AND SOURCES OF PAYMENT FOR THE SERIES 2018D BONDS - Certain Covenants of the Obligated Group under the Master Indenture - Gross Revenues Pledge” herein for a further description of the Gross Revenue pledge by the Obligated Group pursuant to the Master Indenture.
4
THE SERIES 2018D BONDS ARE LIMITED OBLIGATIONS OF THE AUTHORITY, ARE SECURED UNDER THE PROVISIONS OF THE 2018D INDENTURE AND ARE PAYABLE SOLELY FROM THE SOURCES REFERRED TO IN THE 2018D INDENTURE AND DESCRIBED HEREIN. NEITHER THE GENERAL CREDIT OF THE AUTHORITY NOR THE CREDIT OR TAXING POWER OF THE COUNTY OF MONTGOMERY, PENNSYLVANIA, THE COMMONWEALTH OF PENNSYLVANIA OR ANY POLITICAL SUBDIVISION THEREOF IS PLEDGED FOR THE PAYMENT OF THE PRINCIPAL OR PURCHASE PRICE OF, PREMIUM, IF ANY, OR THE INTEREST ON THE SERIES 2018D BONDS, NOR SHALL THE SERIES 2018D BONDS BE DEEMED TO BE GENERAL OBLIGATIONS OF THE AUTHORITY OR OBLIGATIONS OF THE COUNTY OF MONTGOMERY, PENNSYLVANIA, THE COMMONWEALTH OF PENNSYLVANIA OR ANY POLITICAL SUBDIVISION THEREOF, NOR SHALL THE COUNTY OF MONTGOMERY, PENNSYLVANIA, THE COMMONWEALTH OF PENNSYLVANIA OR ANY POLITICAL SUBDIVISION THEREOF BE LIABLE FOR THE PAYMENT OF THE PRINCIPAL OR PURCHASE PRICE OF, PREMIUM, IF ANY, OR THE INTEREST ON THE SERIES 2018D BONDS. THE AUTHORITY HAS NO TAXING POWER.
The University
As of the date of the delivery of the Series 2018D Bonds, each of TJU, TJUH System, Thomas Jefferson University Hospitals, Inc. (“TJUH”), Jefferson University Physicians (“JUP”), Abington Health, Abington Memorial Hospital (“AMH”), Abington Health Foundation (“AHF”), Lansdale Hospital (“LH”), Aria Health System, Aria Health (“Aria Health”), Philadelphia University, Kennedy Health System, Inc. (“Kennedy Health”), Kennedy Health Facilities, Inc. (“KHF”), Kennedy University Hospital, Inc. (“KUH”), Kennedy Medical Group Practice, P.C. (“Kennedy Medical Group”) and The Magee Memorial Hospital for Convalescents (“Magee”) (collectively, the “Obligated Group,” the “Obligated Group Members,” or “Members of the Obligated Group,” and, individually, a “Member”) are the entities obligated to make payments on the Series 2018D Bonds. TJU currently has approximately 64 controlled Affiliates. TJU is the borrower under each of the 2018 Loan Agreements and pursuant thereto has promised to make loan repayments which correspond to amounts and due dates for the debt service on the 2018 Bonds. The other Members of the Obligated Group are the largest (by revenues, assets and/or visibility) of TJU’s controlled Affiliates (the Obligated Group’s revenues constitute approximately 93% of the consolidated University revenues and the Obligated Group’s assets constitute approximately 95% of the consolidated University assets) and as such have, or, as of the time of issuance of the Series 2018D Bonds, will have, become Members of the Obligated Group. TJU and each other Member of the Obligated Group expressly commits to be jointly and severally liable to repay the Obligations issued thereunder, including the Master Note and separate master notes constituting Obligations under the Master Indenture related to the Series 2018A Bonds, Series 2018B Bonds, and Series 2018C Bonds, respectively, and pledges its Gross Revenues pursuant to the Master Indenture to secure such repayment. None of TJU’s controlled Affiliates is currently designated as an Excluded Affiliate and therefore the credit currently available to repay the 2018 Bonds is that of TJU, the other Members of the Obligated Group and their controlled Affiliates.
For purposes of this Official Statement, the term “University” is used to refer collectively to the affiliated group of Persons comprised of all of the Members of the Obligated Group and their Affiliates, but excluding Excluded Affiliates if any in the future, and the term “Audit Group”
5
is used to refer to TJU and any other Person whose financial results are set forth in the Financial Statements of the University. As of the date of this Official Statement, the University has no Excluded Affiliates. For information concerning the terms by which a controlled Affiliate of TJU could become an Excluded Affiliate in the future, see “SECURITY AND SOURCES OF PAYMENT FOR THE SERIES 2018D BONDS - Addition, Exclusion and Release of Entities with Respect to the Requirements of the Master Indenture” herein. See also “APPENDIX A - DESCRIPTION OF THE UNIVERSITY,” “APPENDIX B-1 - THOMAS JEFFERSON UNIVERSITY CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2017 AND 2016,” and “APPENDIX B-2 - UNAUDITED CONSOLIDATING SCHEDULES” attached hereto for additional information regarding the Members of the Obligated Group and other entities comprising the University.
Investment Considerations
Investment in the Series 2018D Bonds is subject to certain risks. See “CERTAIN INVESTMENT CONSIDERATIONS” herein.
Continuing Disclosure
The Authority has determined that no financial or operating data concerning the Authority is material to any decision to purchase, hold, or sell the Series 2018D Bonds, and the Authority will not provide any such information. TJU has undertaken all responsibility for any continuing disclosure to Beneficial Owners of the Series 2018D Bonds, as described below, and the Authority will have no liability to such Beneficial Owners of the Series 2018D Bonds or any other person with respect to such disclosures.
In order to assist the Underwriter (as defined herein) in complying with Rule 15c2-12(b)(5) of the Securities and Exchange Commission (the “SEC”) promulgated pursuant to the Securities Exchange Act of 1934, as in effect on the date hereof (the “Rule”), simultaneously with the issuance of the Series 2018D Bonds, TJU, on behalf of itself and the other Members of the Obligated Group, will enter into a Continuing Disclosure Agreement, to be dated as of the date of the issuance of the 2018D Bonds, with the 2018D Trustee (the “Disclosure Agreement”) for the benefit of the Beneficial Owners, under which TJU, on behalf of the Obligated Group, will provide continuing disclosure with respect to the Series 2018D Bonds. TJU also has, by separate agreement, retained Digital Assurance Certification, L.L.C. (“DAC”) as dissemination agent to assist TJU in connection with certain of its obligations under the Disclosure Agreement. See “CONTINUING DISCLOSURE” herein and “APPENDIX F - FORM OF CONTINUING DISCLOSURE AGREEMENT” attached hereto.
Other Information
This Official Statement speaks only as of its date, and the information contained herein is subject to change. This Official Statement and the appendices attached hereto contain brief descriptions of, among other matters, the Authority, the University and the Obligated Group, the Series 2018D Bonds, and the sources of payment for the Series 2018D Bonds, the 2018D Indenture, the 2018D Loan Agreement, the Master Indenture, the Master Note and the Disclosure Agreement. Such descriptions and information do not purport to be comprehensive or definitive.
6
The summaries of various, statutes, regulatory provisions, the 2018D Indenture, the 2018D Loan Agreement, the Master Indenture and the Disclosure Agreement and other documents are intended as summaries only and are qualified in their entirety by reference to such laws or documents, and references herein to the Series 2018D Bonds are qualified in their entirety by reference to the form thereof included in the 2018D Indenture. Copies of the 2018D Indenture, the 2018D Loan Agreement, the Master Indenture and the Disclosure Agreement and other relevant documents may be viewed at the office of The Bank of New York Mellon Trust Company, N.A., in Philadelphia, Pennsylvania, and will be provided to any prospective purchaser requesting the same upon payment by such prospective purchaser of the cost of complying with such request.
PLAN OF FINANCE
General
Proceeds of the 2018 Bonds will be loaned by the Authority to TJU pursuant to the 2018 Loan Agreements to be applied by the applicable trustee to fund: (i) all or a portion of the costs of the 2018 Project, which is described below, and (ii) the costs of issuance of the 2018 Bonds. See “ESTIMATED SOURCES AND USES OF FUNDS” herein. The 2018 Project consists of two main components: the “New Money Project” and the “2018 Refunding Project.”
New Money Project
The “New Money Project” consists of the payment of (or the reimbursement to TJU and the other Obligated Group Members for) the costs of the acquisition, construction and development of various capital assets and the making of other capital improvements in various academic health care, research, education and clinical care facilities of TJU and the other Obligated Group Members, including, but not limited to the (i) the construction, renovation, expansion, development and equipping of a new health science center building, associated site work, storm water management and related improvements at the East Falls campus of TJU (ii) the construction, renovation, expansion, development and equipping of a patient care tower, including, but not limited to, an intensive care unit, multiple medical/surgical nursing units and surgical suites, diagnostic testing space and rooftop helipad, and related support areas at the Cherry Hill, New Jersey campus of TJU, and (iii) the construction, development, renovation, improvement and equipping of approximately 92,000 gross square feet of patient rooms, therapy gyms and relocation of an existing pharmacy at the hospital facility of Magee located in Center City Philadelphia.
2018 Refunding Project
The “2018 Refunding Project” consists of (a) the current refunding of the Authority’s Thomas Jefferson University Revenue Bonds, Series 2017E (the “Series 2017E Bonds”) outstanding in the principal amount of $247,825,000 (the “Refunded 2017E Bonds”); and (b) the payment or defeasance of (i) certain commercial loans issued in the maximum principal amount of $71,000,000 for the benefit of KUH (the “Kennedy Commercial Loans”), (ii) certain commercial mortgage loans incurred for the benefit of KUH in the aggregate original principal amount of $1,659,000 which are guaranteed by Kennedy Health (the “Kennedy Mortgage Loans”), and (iii) certain commercial loans incurred for the benefit of Aria Health System and its affiliates, in the aggregate original principal amount of approximately $17,370,000 (the “Aria Commercial
7
Loans,” and collectively with the Kennedy Commercial Loans and the Kennedy Mortgage Loans, the “Commercial Loans”). The Refunded 2017E Bonds and the Commercial Loans are collectively, referred to herein as the “Refunded Obligations.”
A portion of the proceeds of the 2018 Bonds will be applied on the date of issuance of the 2018 Bonds to retire, or reimburse TJU in connection with the retirement of, the Refunded Obligations.
ESTIMATED SOURCES AND USES OF FUNDS
The proceeds of the 2018 Bonds are expected to be applied as follows:
Series 2018A Series 2018B Series 2018C Series 2018D (1) (1) (1) Source of Funds Bonds Bonds Bonds Bonds Total Par Amount $356,285,000 $35,075,000 $100,000,000 $49,950,000 $541,310,000 Net Original Issue Premium 33,195,006 ------33,195,006 TOTAL SOURCES $389,480,006 $35,075,000 $100,000,000 $49,950,000 $574,505,006
Uses of Funds Refunding/Redemption of Refunded 2017E Bonds $247,866,000 $ -- $ -- $ -- $247,866,000 Pay-off of Kennedy Commercial Loans -- 20,547,787 1,113,936 49,506,064 71,167,787 Pay-off of Kennedy Mortgage Loans -- 1,018,000 -- -- 1,018,000 Pay-off of Aria Commercial Loans -- 13,211,656 -- -- 13,211,656 Deposit to Project Account 138,509,889 -- 98,000,000 -- 236,509,889 Deposit to Costs of Issuance Account(2) 3,104,117 297,557 886,064 443,936 4,731,674 TOTAL USES $389,480,006 $35,075,000 $100,000,000 $49,950,000 $574,505,006 ______(1) While part of a common plan of finance with the Series 2018D Bonds, the Series 2018A/B/C Bonds are not being offered pursuant to this Official Statement. (2) Includes Underwriter’s discount, legal and accounting fees, consultant fees, fees of the Authority and the Trustee, rating agency fees, printing costs, and other miscellaneous fees and costs.
[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]
8
THE OBLIGATED GROUP MEMBERS AND THE UNIVERSITY
General
The University is a large academic medical center, located in the greater Philadelphia region, with a tripartite mission of education, research and patient care. The University has approximately 30,000 employees. As of the date of the delivery of the Series 2018D Bonds, the Members of the Obligated Group consist of TJU and TJU’s controlled Affiliates: TJUH System, TJUH, JUP, Abington Health, AMH, AHF, LH, Aria Health System, Aria Health, Philadelphia University, Kennedy Health, KHF, KUH, Kennedy Medical Group and Magee. For purposes of this Official Statement, the term “University” is used to refer to the Members of the Obligated Group together with their Affiliates, but excluding any Excluded Affiliate, of which there are currently none.
For the twelve-month period ended June 30, 2017 on an unaudited pro forma basis, the University had total operating revenues, gains and other support of approximately $4.7 billion. At February 28, 2018 on an unaudited consolidated basis the University had total assets of approximately $7.2 billion, total liabilities of approximately $3.4 billion, and total net assets of approximately $3.9 billion. The Obligated Group’s revenues constitute approximately 93% of the consolidated University revenues and the Obligated Group’s assets constitute approximately 95% of the consolidated University assets. For more detailed information concerning the University, see “APPENDIX A - DESCRIPTION OF THE UNIVERSITY,” “APPENDIX B-1 - THOMAS JEFFERSON UNIVERSITY CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2017 AND 2016,” and “APPENDIX B-2 – UNAUDITED CONSOLIDATING SCHEDULES” attached hereto.
Merger Plans
TJU has entered into a letter of intent with Albert Einstein Healthcare Network (“EHN”) dated March 28, 2018 (the “Letter of Intent”), which sets forth certain binding and non-binding obligations relating to a potential transaction (the “Transaction”) whereby TJU and EHN would combine assets and operations. For a further discussion with respect to the Letter of Intent, the Transaction and related matters, see “MANAGEMENT DISCUSSION AND ANALYSIS – Einstein Health Letter of Intent” and “Other Potential Transactions” within Appendix A to this Official Statement.
As part of its ongoing strategic planning process, from time to time, the University considers and will consider potential joint ventures, affiliations, acquisitions, divestitures and similar transactions. Such transactions may result in additional entities becoming part of the Obligated Group in the future; in addition, in certain cases, existing Affiliates of TJU may no longer be part of the Obligated Group. There can be no assurance as to the impact that any such transaction would have on the operations, properties and financial results of the Obligated Group. See “APPENDIX A - DESCRIPTION OF THE UNIVERSITY.”
9
THE AUTHORITY
General
The Authority is a body corporate and politic organized under the Act by a resolution adopted by the Board of County Commissioners of the County of Montgomery, Pennsylvania (the "County"). On October 1, 1968, the Secretary of the Commonwealth of Pennsylvania (the “Commonwealth”) issued a Certificate of Incorporation to the Authority under the name of "Montgomery County Hospital Authority." The Authority originally was formed for the purpose of acquiring, holding, constructing, equipping, furnishing, improving, maintaining, owning, leasing, either in the capacity of lessor or lessee, and operating hospital facilities or parts thereof in the County. On July 2, 1984, the Secretary of the Commonwealth issued a Certificate of Amendment to the Authority under which the name of the Authority was changed to "Montgomery County Higher Education and Health Authority" and the purposes of the Authority were amended to enable the Authority to participate in additional projects authorized by the Act. On October 24, 1985, the Secretary of the Commonwealth issued a Certificate of Amendment to the Authority under which the purposes of the Authority were amended to enable the Authority to participate in such buildings, projects, facilities, and parts thereof in such locations as the Board of County Commissioners of the County may direct, and as authorized by the Act, and to grant to the Authority all of the powers granted by the Act.
Members of the Authority
The governing body of the Authority is a board consisting of seven members appointed by the Board of County Commissioners of the County. Members of the Authority are appointed for staggered five-year terms and may be reappointed to an unlimited number of successive terms. Board members serve until the dates indicated below and thereafter until replaced or reappointed. Current members of the Authority are as follows:
Members Office Term Expires James A. Konnick Chairman 12/31/2017* Jeffrey Bevington Vice Chairman 09/13/2016* James H. Shacklett, III Assistant Secretary 12/31/2015* Robert L. Williams, Jr. Assistant Secretary 09/13/2016* J. Mark Lankford Assistant Secretary 12/31/2015* Harriet Weiss Assistant Secretary 12/31/2017* ______* Serves until a successor is appointed.
The address of the Authority is 1200 East High Street, Suite 301, Pottstown, Pennsylvania 19464.
10
Financings of the Authority
The Authority has financed transactions for health care and higher education projects. Each such issue is payable solely from revenues derived from the project being financed or from special funds established therefor, is separately secured, and is separate and independent, as to sources of payment and security, from the Series 2018D Bonds.
Certain of these series of revenue bonds issued by the Authority currently are, and in the past have been, in default. None of these defaulted bonds were issued for any member of the Obligated Group, nor are they otherwise secured by or payable from the applicable security or sources of payment herein described with respect to the Series 2018D Bonds, and thus the Obligated Group, does not believe that disclosure with respect to such defaulted issues is appropriate or material to a reasonable investor.
The Authority may, from time to time, enter into further financing transactions for other hospital, health care and higher education projects, which transactions will provide for the issuance of bonds or notes that will be limited obligations of the Authority, payable from and secured by revenues derived from such projects. The Authority may also, from time to time, enter into refinancing transactions for obligations previously issued.
THE SERIES 2018D BONDS ARE LIMITED OBLIGATIONS OF THE AUTHORITY, ARE SECURED UNDER THE PROVISIONS OF THE 2018D INDENTURE AND ARE PAYABLE SOLELY FROM THE SOURCES REFERRED TO IN THE 2018D INDENTURE AND DESCRIBED HEREIN. NEITHER THE GENERAL CREDIT OF THE AUTHORITY NOR THE CREDIT OR TAXING POWER OF THE COUNTY OF MONTGOMERY, PENNSYLVANIA, THE COMMONWEALTH OF PENNSYLVANIA OR ANY POLITICAL SUBDIVISION THEREOF IS PLEDGED FOR THE PAYMENT OF THE PRINCIPAL OR PURCHASE PRICE OF, PREMIUM, IF ANY, OR THE INTEREST ON THE SERIES 2018D BONDS, NOR SHALL THE SERIES 2018D BONDS BE DEEMED TO BE GENERAL OBLIGATIONS OF THE AUTHORITY OR OBLIGATIONS OF THE COUNTY OF MONTGOMERY, PENNSYLVANIA OR OF THE COMMONWEALTH OF PENNSYLVANIA OR ANY POLITICAL SUBDIVISION THEREOF, NOR SHALL THE COUNTY OF MONTGOMERY, PENNSYLVANIA, THE COMMONWEALTH OF PENNSYLVANIA OR ANY POLITICAL SUBDIVISION THEREOF BE LIABLE FOR THE PAYMENT OF THE PRINCIPAL OR PURCHASE PRICE OF, PREMIUM, IF ANY, OR THE INTEREST ON THE SERIES 2018D BONDS. THE AUTHORITY HAS NO TAXING POWER.
[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]
11
ALTHOUGH THE AUTHORITY HAS EXECUTED THIS OFFICIAL STATEMENT AND AUTHORIZED ITS DISTRIBUTION, THE AUTHORITY IS NOT RESPONSIBLE FOR AND DOES NOT REPRESENT OR WARRANT IN ANY WAY THE ACCURACY OR COMPLETENESS OF ANY INFORMATION OR ANY STATEMENTS MADE HEREIN, EXCEPT THE INFORMATION AND STATEMENTS SET FORTH UNDER THE HEADINGS “INTRODUCTION - THE AUTHORITY; AUTHORITY FOR ISSUANCE,” “THE AUTHORITY” AND “LITIGATION - THE AUTHORITY.” ACCORDINGLY, EXCEPT AS AFORESAID, THE AUTHORITY DISCLAIMS RESPONSIBILITY FOR THE DISCLOSURE SET FORTH HEREIN MADE IN CONNECTION WITH THE SALE AND DISTRIBUTION OF THE SERIES 2018D BONDS OR OTHERWISE.
The Authority is not responsible for providing any purchaser of the Series 2018D Bonds with any information relating to the Series 2018D Bonds or any of the parties or transactions referred to in this Official Statement.
DESCRIPTION OF THE SERIES 2018D BONDS
General
The Series 2018D Bonds will be dated the date of their delivery and will mature on September 1, 2050 and the interest thereon will be subject to change as set forth on the inside front cover page of this Official Statement and under “DESCRIPTION OF THE SERIES 2018D BONDS - Variable Rate Mode” herein. The Series 2018D Bonds will be issuable only as fully registered Series 2018D Bonds in denominations of $25,000 or any integral multiple of $5,000 in excess thereof. Interest on the Series 2018D Bonds is payable as described below. The Series 2018D Bonds are subject to redemption and optional and mandatory tender for purchase prior to maturity as described under “DESCRIPTION OF THE SERIES 2018D BONDS - Optional Tender of Series 2018D Bonds in Variable Rate Mode” and “ - Mandatory Tender of Series 2018D Bonds in the Variable Rate Mode” herein.
The Series 2018D Bonds are issuable in the form of fully registered bonds without coupons, and, when issued, will be registered in the name of Cede & Co., as registered owner and nominee for The Depository Trust Company (“DTC”), New York, New York. DTC will act as securities depository for the Series 2018D Bonds. Purchases of the Series 2018D Bonds will be made in book-entry form. Beneficial Owners (as defined herein) will not receive certificates representing their interest in the Series 2018D Bonds purchased. So long as Cede & Co. is the registered owner, as nominee of DTC, references herein to the registered owners shall mean Cede & Co., as aforesaid, and shall not mean the Beneficial Owners of the Series 2018D Bonds. See “BOOK- ENTRY ONLY SYSTEM” herein.
Payments of principal, premium, if any, and interest on the Series 2018D Bonds will be paid through The Bank of New York Mellon Trust Company, N.A., as Trustee and Paying Agent. So long as DTC or its nominee, Cede & Co., is the registered owner, such payments will be made directly to Cede & Co. Disbursements of such payments to DTC’s participants is the responsibility of DTC and disbursements of such payments to the Beneficial Owners is the responsibility of the DTC Participants and the Indirect Participants, as more fully described herein. Transfers of beneficial ownership in the Series 2018D Bonds will be accomplished by book entries made by
12
DTC and, in turn, by the Direct Participants, as appropriate. See “BOOK-ENTRY ONLY SYSTEM” herein.
The record date for any regular interest payment date for Series 2018D Bonds (as described herein under “DESCRIPTION OF THE SERIES 2018D BONDS - Variable Rate Mode - Interest Payment Dates for Series 2018D Bonds”) while bearing interest at a Variable Weekly Rate or Variable Monthly Rate is the close of business on the last Business Day of the related Interest Period. With respect to any Interest Period for Series 2018D Bonds with a Variable Term Rate Period of 180 days or less, the regular record date is the 15lh day (whether or not a Business Day) prior to the Interest Payment Date for such Interest Period. With respect to any Interest Period for Series 2018D Bonds with a Variable Term Rate Period of more than 180 days, the regular record date is the 15th day of the month immediately preceding the Interest Payment Date and the 15Ih day (whether or not a Business Day) prior to the end of such Variable Term Rate Period. If sufficient funds for the payment of interest becoming due on any regular interest payment date for Series 2018D Bonds are not on deposit with the Trustee on such date, the interest so becoming due shall forthwith cease to be payable to the registered owner otherwise entitled thereto as of such date. If sufficient funds thereafter become available for the payment of such overdue interest, the Trustee shall establish a special interest payment date (any such date being herein referred to as a “Special 2018D Interest Payment Date”) on which such overdue interest shall be paid and a Special Record Date relating thereto (any such date being herein referred to as a “Special 2018D Record Date”), and shall mail a notice of each such date to the registered owner thereof at least 10 days prior to the Special 2018D Record Date, but not more than 30 days prior to the Special 2018D Interest Payment Date.
Variable Rate Mode
Under the terms of the 2018D Indenture, the Series 2018D Bonds can be issued in various interest rate modes (“Interest Rate Modes”), including a Variable Rate Mode. All Series 2018D Bonds will be issued initially in the Variable Rate Mode in a Variable Weekly Rate Period.
This Official Statement does not describe the terms of the Series 2018D Bonds in any Interest Rate Mode other than the Variable Rate Mode. If Series 2018D Bonds are converted to another Interest Rate Mode, the affected Series 2018D Bonds must be purchased from the Holders pursuant to the mandatory tender provisions of the 2018D Indenture and simultaneously remarketed to investors in the new Interest Rate Mode. See “APPENDIX C - DEFINITIONS OF TERMS AND SUMMARIES OF CERTAIN PROVISIONS OF THE 2018D INDENTURE AND THE 2018D LOAN AGREEMENT.”
While the Series 2018D Bonds are in the Variable Rate Mode, there shall be no liquidity facility supporting the payment of the purchase price. Moreover, the Obligated Group is not obligated to purchase Series 2018D Bonds that are tendered but not remarketed.
Series 2018D Bonds in the Variable Rate Mode may be in a Variable Daily Rate Period, Variable Weekly Rate Period, a Variable Monthly Rate Period, or a Variable Term Rate Period. All Series 2018D Bonds in the Variable Rate Mode shall be in the same Variable Rate Period, and
13
all Series 2018D Bonds in a Variable Term Rate Period shall have the same Variable Term Rate Period.
During the Variable Rate Mode, TJU may elect to establish the applicable Variable Rate Period. All Series 2018D Bonds initially will be issued in a Variable Rate Mode with a Variable Weekly Rate. The TJU may from time to time elect to change the Variable Rate Period for any Series 2018D Bonds in the Variable Rate Mode. Any change in the Variable Rate Period may be effective only on a Variable Rate Reset Date.
TJU’s election to change the Variable Rate Period to a Variable Daily Rate Period, Variable Weekly Rate Period or to a Variable Monthly Rate Period must be given in writing to the Trustee and the Remarketing Agent (as defined herein) not less than five Business Days prior to the Variable Rate Reset Date when the change is to be effective (unless a shorter period is acceptable to the Trustee and Remarketing Agent). TJU’s election to establish a Variable Term Rate Period must be given to the Trustee and the Remarketing Agent not less than 20 days prior to the first day of the proposed Variable Term Rate Period (unless a shorter period is acceptable to the Trustee and the Remarketing Agent). Series 2018D Bonds in a Variable Daily Rate Period, a Variable Weekly Rate Period or a Variable Monthly Rate Period shall remain in such period unless TJU elects to change the period.
The Trustee will notify holders of the Series 2018D Bonds of each change to a Variable Daily Rate Period, Variable Weekly Rate Period or a Variable Monthly Rate Period at least five Business Days, but not more than 60 days prior to the effective date of such change. Bondholders shall be notified of each change to a Variable Term Rate Period as part of the mandatory tender notification process set forth in the 2018D Indenture.
Variable Daily Rate. If the Interest Rate Mode for the Series 2018D Bonds is the Variable Daily Rate, the interest rate on the Series 2018D Bonds for a particular Variable Daily Rate Period shall be the rate established by the Remarketing Agent no later than 5:00 p.m. (New York City time) on each Business Day for applicability on the following day during the Variable Daily Rate Period (or the Business Day preceding the Conversion of the Interest Rate Mode to the Variable Daily Rate). The Variable Daily Rate shall be the minimum rate of interest necessary, in the reasonable judgment of the Remarketing Agent, to enable the Remarketing Agent to sell the Series 2018D Bonds on such Business Day at a price equal to the principal amount thereof, plus accrued Stated Interest, if any, thereon. The Variable Daily Rate for any day that is not a Business Day shall be the same as the Variable Daily Rate for the immediately preceding Business Day. In the event that the Remarketing Agent fails to establish a Variable Daily Rate for any day, then the Variable Daily Rate for such day shall be the same as the Variable Daily Rate for the immediately preceding Business Day and such rate shall continue until the earlier of (A) the date on which the Remarketing Agent determines a new Variable Daily Rate or (B) the fifth consecutive Business Day succeeding the first such Business Day on which such Variable Daily Rate is not determined by the Remarketing Agent. In the event that the Remarketing Agent fails to determine a new Variable Daily Rate for a period of five consecutive Business Days as described in clause (B) of the immediately preceding sentence, the Variable Daily Rate shall be equal to the Maximum Rate until a new Variable Daily Rate is established by the Remarketing Agent.
14
Variable Weekly Rate. The Variable Weekly Rate shall be set initially on a date prior to the initial delivery date of the Series 2018D Bonds to be effective the date of initial delivery of the Series 2018D Bonds. After the date of delivery of the Series 2018D Bonds, the Variable Weekly Rate shall be set on each Thursday (each Thursday being a “Variable Rate Reset Date” with respect to Series 2018D Bonds in a Variable Weekly Rate Period) while the Series 2018D Bonds are in a Variable Weekly Rate Period, beginning May 10, 2018, and the interest rate on the Series 2018D Bonds for a particular Variable Weekly Rate Period shall be the rate established by the Remarketing Agent no later than 5:00 p.m. (New York City time) on each Thursday, or, if such day is not a Business Day, on the last Business Day prior to such Thursday (each such date being a “Rate Determination Date” with respect to Series 2018D Bonds in a Variable Weekly Rate Period), as the minimum rate of interest necessary, in the reasonable judgment of the Remarketing Agent, to enable the Remarketing Agent to sell the Series 2018D Bonds on such Business Day at a price equal to the principal amount thereof, plus accrued Stated Interest, if any, thereon. The Variable Weekly Rate so determined shall be effective on the Variable Rate Reset Date and shall remain in effect until (and including) the following Wednesday; provided that the initial Variable Weekly Rate shall apply from the initial delivery date of the Series 2018D Bonds until and including May 9, 2018.
Variable Monthly Rate. If the Interest Rate Mode for the Series 2018D Bonds is the Variable Monthly Rate, the interest rate on the Series 2018D Bonds for a particular Variable Monthly Rate Period shall be the rate established by the Remarketing Agent no later than 5:00 p.m. (New York City time) on the last Business Day of each month during the Variable Monthly Rate Period (each such date being a “Rate Determination Date” with respect to Series 2018D Bonds in a Variable Monthly Rate Period), as the minimum rate of interest necessary, in the reasonable judgment of the Remarketing Agent, to enable the Remarketing Agent to sell the Series 2018D Bonds on such Business Day at a price equal to the principal amount thereof, plus accrued Stated Interest, if any, thereon. The Variable Monthly Rate so determined shall be effective on the first day of the Variable Monthly Rate Period or the first Business Day following such Rate Determination Date (each such date being a “Variable Rate Reset Date” with respect to Series 2018D Bonds in a Variable Monthly Rate Period), as the case may be, and shall remain in effect until (and including) the day immediately prior to the first Business Day of the following month.
Variable Term Rate Periods and Variable Term Rate. TJU may elect a Variable Term Rate Period, which must be more than 35 days and must end on the last day of a calendar month prior to the Maturity Date for the Series 2018D Bonds. If TJU elects a Variable Term Rate Period that ends on a day that is not in fact immediately prior to a Business Day, then such Variable Term Rate Period shall automatically extend to the next day that is immediately prior to a Business Day. An election by TJU to establish a Variable Term Rate Period may provide that successive Variable Term Rate Periods of specified length shall be established with respect to Series 2018D Bonds in the Variable Rate Mode, and if such notice is delivered no additional notice shall be required from TJU with respect to the subsequent Variable Term Rate Periods so specified.
If the Interest Rate Mode for the Series 2018D Bonds is the Variable Term Rate, the interest rate on the Series 2018D Bonds for a particular Variable Term Rate Period shall be the rate established by the Remarketing Agent no later than 5:00 p.m. (New York City time) on the last Business Day immediately prior to the first day of the Variable Term Rate Period (or the Business Day preceding the Conversion of the Interest Rate Mode to the Variable Term Rate) (each such
15
date being a “Rate Determination Date” with respect to Series 2018D Bonds in a Variable Term Rate Period) as the minimum rate of interest necessary, in the reasonable judgment of the Remarketing Agent, to enable the Remarketing Agent to sell the Series 2018D Bonds on such Business Day at a price equal to the principal amount thereof, plus accrued Stated Interest, if any, thereon. The Variable Term Rate so determined shall be effective on the first day of the Variable Term Rate Period (each such date being a “Variable Rate Reset Date” with respect to Series 2018D Bonds in a Variable Term Rate Period) and shall remain in effect until (and including) the last day of such Variable Term Rate Period.
Upon the expiration of any Variable Term Rate Period, the Variable Rate Period shall automatically revert to a Variable Weekly Rate Period unless TJU makes a timely election to change the Variable Rate Period to the Variable Monthly Rate Period or another Variable Term Rate Period.
Remarketing Agent Sets Variable Rates. Variable Rates shall be set by the Remarketing Agent as described above taking into account relevant market conditions and credit rating factors as they exist on such date. If the Remarketing Agent fails to determine the Variable Rate on any Rate Determination Date, the Variable Rate on the following Variable Rate Reset Date shall be the lesser of 12% per annum and the maximum rate permitted by law (the “Maximum Rate”).
Interest on Non-Remarketed Bonds. A Series 2018D Bond that is not successfully remarketed on a Variable Rate Tender Date is referred to in the 2018D Indenture as a “Variable Rate Non-Remarketed Bond.” During the period from when a Series 2018D Bond is not purchased from a Holder after such Holder tenders such Series 2018D Bond for purchase pursuant to a Variable Rate Tender and ending on the date that all Variable Rate Non-Remarketed Bonds are successfully remarketed (defined in the 2018D Indenture as a “Variable Rate Special Non- Remarketing Period”), if the Series 2018D Bonds are not already in a Variable Weekly Rate Period, the Variable Rate Period for the Series 2018D Bonds shall automatically change to a Variable Weekly Rate Period, and all Series 2018D Bonds in the Variable Rate Mode (including any Series 2018D Bonds in the Variable Rate Mode that are not Variable Rate Non-Remarketed Bonds) shall bear interest at the Maximum Rate.
Calculation of Interest Payments for Series 2018D Bonds. Interest on Series 2018D Bonds at the Variable Daily Rate, the Variable Weekly Rate or Variable Monthly Rate shall be computed on the basis of a 365- or 366-day year, as the case may be, for the actual number of days elapsed. Interest on Series 2018D Bonds at the Variable Term Rate shall be computed upon the basis of a 360-day year, consisting of twelve 30-day months.
Interest Payment Dates for Series 2018D Bonds. Interest on Series 2018D Bonds in the Variable Rate Mode with a Variable Daily Rate Period, a Variable Weekly Rate Period or a Variable Monthly Rate Period shall be payable in arrears (i) on the first Business Day of each month, beginning June 1, 2018, (ii) on the Conversion Date if the Series 2018D Bonds are converted to another Interest Rate Mode, and (iii) on the Maturity Date.
Interest on Series 2018D Bonds in the Variable Rate Mode with a Variable Term Rate Period of 180 days or less shall be payable on the day immediately following the end of the Variable Term Rate Period (which must be a Business Day).
16
Interest on Series 2018D Bonds in the Variable Rate Mode with a Variable Term Rate Period of more than 180 days shall be payable on (i) each March 1 and September 1 during such Variable Term Rate Period, and (ii) the day immediately following the end of the Variable Term Rate Period (which must be a Business Day).
Optional Tender of Series 2018D Bonds in Variable Rate Mode
The holder of any Series 2018D Bond in the Variable Rate Mode at the Variable Daily Rate, the Variable Weekly Rate or the Variable Monthly Rate shall have the right to tender such Series 2018D Bond to the Trustee for purchase on the following dates (each, a “Variable Rate Optional Tender Date”), in whole or in part, at a purchase price equal to the principal amount thereof plus accrued Stated Interest, if any, to the Variable Rate Optional Tender Date:
(a) if such Series 2018D Bond is in a Variable Daily Rate Period or Variable Weekly Rate Period, any Business Day may be a Variable Rate Optional Tender Date; and
(b) if such Series 2018D Bond is in a Variable Monthly Rate Period, any Interest Payment Date may be a Variable Rate Optional Tender Date.
In order to exercise such option with respect to a Series 2018D Bond in a Variable Daily Rate Period, a Variable Weekly Rate Period or a Variable Monthly Rate Period, the holder must deliver notice to the Remarketing Agent, the Tender Agent and the Trustee on or before 5:00 p.m. (New York City time) on a Business Day not later than the seventh day prior to the related Variable Rate Optional Tender Date. Notices of optional tender for Series 2018D Bonds in a Variable Daily Rate Period, a Variable Weekly Rate Period or a Variable Monthly Rate Period shall state the principal amount (or portion thereof) of the Series 2018D Bond to be purchased, the Variable Rate Optional Tender Date on which such Series 2018D Bond is to be purchased and shall irrevocably request such purchase and indicate the agreement to deliver such Series 2018D Bond.
Holders of Series 2018D Bonds in the Variable Rate Mode with a Variable Term Rate Period shall not have the right to tender such Series 2018D Bonds for purchase during such Variable Term Rate Period, but shall be required to tender such Series 2018D Bonds for purchase on the day immediately following the end of the Variable Term Rate Period.
Mandatory Tender of Series 2018D Bonds in the Variable Rate Mode
The holder of any Series 2018D Bond in the Variable Rate Mode shall be required to tender such Series 2018D Bond to the Trustee for purchase on (i) the first day of each new Variable Rate Period with respect to such Series 2018D Bond other than a Conversion to the Variable Daily Rate or the Variable Weekly Rate from the Variable Daily Rate or the Variable Weekly Rate and (ii) the date of conversion of such Series 2018D Bond to another Interest Rate Mode (each, a “Variable Rate Mandatory Tender Date”), at a purchase price equal to the principal amount thereof, plus accrued Stated Interest, if any, thereon to the Variable Rate Mandatory Tender Date. If any Variable Rate Mandatory Tender Date is not a Business Day, the Variable Rate Mandatory Tender Date shall be the next succeeding Business Day. See also “DESCRIPTION OF THE SERIES 2018D BONDS - Conversion of Series 2018D Bonds” herein.
17
Variable Rate Non-Remarketed Bonds
Funds for the purchase of Series 2018D Bonds pursuant to a Variable Rate Tender shall be derived solely from (i) Remarketing Proceeds or (ii) funds that TJU elects to provide for such purchase, if any; provided, however, that TJU shall not be required to provide funds for the purchase of Series 2018D Bonds tendered pursuant to a Variable Rate Tender. If the Remarketing Agent cannot successfully remarket all or any portion of the Series 2018D Bonds which are the subject of an optional tender or mandatory tender for purchase, such Series 2018D Bonds shall constitute Variable Rate Non-Remarketed Bonds under the 2018D Indenture and a Bondholder shall not have the right to have such Variable Rate Non-Remarketed Bond purchased upon tender from any source other than Remarketing Proceeds. THE SERIES 2018D BONDS WILL NOT INITIALLY BE SUPPORTED BY ANY LIQUIDITY FACILITY. See “DESCRIPTION OF THE SERIES 2018D BONDS - Variable Rate Mode - Interest on Non-Remarketed Bonds” herein.
If adequate funds are not available in the Bond Purchase Fund on any Variable Rate Tender Date to pay the Purchase Price of all Series 2018D Bonds tendered for purchase pursuant to the Variable Rate Tender provisions of the 2018D Indenture, no Series 2018D Bonds in the Variable Rate Mode shall be purchased on such Variable Rate Tender Date pursuant to the Variable Rate Tender provisions of the 2018D Indenture. The Trustee shall return all Variable Rate Non-Remarketed Bonds to the Holders thereof, and the Trustee shall return any Remarketing Proceeds deposited in the Bond Purchase Fund with respect to such Variable Rate Non-Remarketed Bonds to the Remarketing Agent for return to the Persons providing such Remarketing Proceeds.
The date on which a Series 2018D Bond in the Variable Rate Mode is returned to the Holder shall be the first day of a Variable Rate Special Non-Remarketing Period with respect to such Series 2018D Bond. During the Variable Rate Special Non-Remarketing Period, if such Series 2018D Bonds are not already in a Variable Weekly Rate Period, the Variable Rate Period for the Series 2018D Bonds shall automatically change to a Variable Weekly Rate Period. During any Variable Rate Special Non-Remarketing Period, all Series 2018D Bonds in the Variable Rate Mode (including Series 2018D Bonds in the Variable Rate Mode that are not Variable Rate Non- Remarketed Bonds) shall bear interest at the Maximum Rate. During any Variable Rate Special Non-Remarketing Period, the Remarketing Agent shall continue to use its best efforts to remarket Variable Rate Non-Remarketed Bonds. If the Variable Rate Special Non-Remarketing Period with respect to any Variable Rate Non-Remarketed Bond lasts more than 180 consecutive days (a “Variable Rate Term-Out Event”), all Series 2018D Bonds in the Variable Rate Mode are subject to mandatory redemption as described herein under “DESCRIPTION OF THE SERIES 2018D BONDS - Redemption Provisions - Special Mandatory Redemption of Variable Rate Non- Remarketed Bonds” (the “Variable Rate Mandatory Redemption Provisions”). If all Variable Rate Non-Remarketed Bonds are successfully remarketed or are successfully converted to another Interest Rate Mode before a Variable Rate Term-Out Event redemption occurs, redemption of Series 2018D Bonds in the Variable Rate Mode shall not be required under the 2018D Indenture.
18
Conversion of Series 2018D Bonds
The Interest Rate Mode for the Series 2018D Bonds is subject to Conversion to a different Interest Rate Mode from time to time in whole or in part by TJU. Any Conversion of the Interest Rate Mode for the Series 2018D Bonds must occur on a Business Day and in the case of a Conversion from a Variable Term Rate Period or a Variable Monthly Rate Period, must be on an Interest Payment Date. Any Conversion by TJU of the Interest Rate Mode to the Long Term Rate or the Variable Term Rate may be made conditional on the initial interest rate determined for such Interest Rate Mode being within certain limits established by TJU. The Trustee shall notify the Bondholders of each Conversion at least 15 days (30 days in the case of Conversion from a Variable Term Rate) but not more than 60 days before the Conversion Date. In the case of Series 2018D Bonds bearing interest in the Variable Rate Mode, the Trustee shall notify Bondholders of a Conversion to a Variable Daily Rate, a Variable Weekly Rate or a Variable Monthly Rate at least three Business Days, but not more than 60 days before the effective date of such Conversion. The notice must state, among other things: (i) the proposed Conversion Date; (ii) that the Series 2018D Bonds will be subject to mandatory purchase on the Conversion Date (other than upon a Conversion between the Daily Rate and the Weekly Rate, or a Conversion between the Variable Daily Rate and the Variable Weekly Rate); (iii) if the Conversion is conditional, the interest rate limitations; and (iv) if the Remarketing Agent fails to determine the initial interest rate for a new Interest Rate Mode, there shall be no Conversion. See “DESCRIPTION OF THE SERIES 2018D BONDS - Mandatory Tender of Series 2018D Bonds in the Variable Rate Mode” and “DESCRIPTION OF THE SERIES 2018D BONDS - Variable Rate Non-Remarketed Bonds” herein and “APPENDIX C - DEFINITIONS OF TERMS AND SUMMARIES OF CERTAIN PROVISIONS OF THE 2018D INDENTURE AND THE 2018D LOAN AGREEMENT.”
Redemption Provisions
Optional Redemption. Series 2018D Bonds in the Variable Rate Mode are subject to optional redemption, in whole or in part, at the option of the Authority, upon the written direction of TJU, at a redemption price equal to 100% of the principal amount to be redeemed plus accrued interest thereon to the date of redemption on the following dates:
(a) Series 2018D Bonds in a Variable Daily Rate Period, a Variable Weekly Rate Period or a Variable Monthly Rate Period are subject to optional redemption on the first Business Day of each month.
(b) Series 2018D Bonds in a Variable Term Rate Period are subject to optional redemption on the day following the end of such Variable Term Rate Period (which must be a Business Day).
(c) During any Variable Rate Special Non-Remarketing Period, all Series 2018D Bonds in the Variable Rate Mode are subject to optional redemption on any Business Day.
Special Mandatory Redemption of Variable Rate Non-Remarketed Bonds. If a Variable Rate Term-Out Event occurs while any Variable Rate Non-Remarketed Bond is in a Variable Rate Special Non-Remarketing Period, all Series 2018D Bonds in the Variable Rate Mode (including Series 2018D Bonds in the Variable Rate Mode that are not Variable Rate Non-Remarketed
19
Bonds) shall be redeemed, at a redemption price equal to 100% of the principal amount to be redeemed plus accrued interest thereon to the redemption date on the first March 1 or September 1 that is at least 24 months after the Variable Rate Term-Out Event occurs; provided that, if the Series 2018D Bonds are successfully remarketed, prior to the scheduled redemption date, then the Series 2018D Bonds shall not be redeemed pursuant to this section.
Mandatory Sinking Fund Redemption. The Series 2018D Bonds are subject to mandatory sinking fund redemption prior to maturity in part by lot, on September 1 in the years and in the principal amounts set forth in the table below, at a redemption price equal to 100% of the principal amount thereof, without premium, plus accrued interest to the redemption date.
Year Principal (September 1)* Amount* 2049 $24,790,000 2050** 25,160,000
______*Preliminary, subject to change. **Final maturity.
In the event of any partial redemption of Series 2018D Bonds (other than mandatory sinking fund redemption) within a maturity or any purchase and surrender thereof to the Trustee for cancellation prior to maturity, the principal amount so redeemed or purchased shall be credited against a principal amount of Series 2018D Bonds of the same maturity thereafter coming due upon mandatory redemption in such amounts and on such dates as shall be designated by TJU; provided, however, that if no such designation is made at or prior to the time of the required notice of any such redemption or at or prior to the purchase in question, such credit shall be applied against such redemption amounts in their inverse order of due dates.
Purchase In Lieu of Redemption of Series 2018D Bonds. In lieu of redemption under the 2018D Indenture, the Trustee may, at the request of the Authority upon written direction from TJU, use funds otherwise available under the 2018D Indenture to purchase Series 2018D Bonds identified by TJU in the open market for cancellation at a price specified by TJU not exceeding the applicable redemption price.
Selection of Series 2018D Bonds for Redemption. In the case of any partial optional redemption of Series 2018D Bonds, the particular Series 2018D Bonds of such maturity to be called for redemption shall be selected by the Trustee from maturities selected by the Authority (at the written direction of TJU), and within a maturity by lot.
Notice of Redemption. Notice of any redemption of Series 2018D Bonds shall be made as provided in the 2018D Indenture upon at least 20 days’ but not more than 45 days’ notice by mailing a copy of the redemption notice by first class mail to the registered holder of the Series 2018D Bonds to be redeemed at the address shown on the bond registration books maintained by the Trustee. However, failure to mail any notice or any defect therein or in the mailing thereof, as it affects any particular Series 2018D Bond, shall not affect the validity of the proceedings for redemption of any other Series 2018D Bonds for which notice was properly given.
20
The notice of the call for redemption of Series 2018D Bonds shall identify the Series 2018D Bonds to be redeemed (and, in the case of partial redemption of any Series 2018D Bonds, the respective principal amounts thereof to be redeemed), shall specify the redemption date and the redemption price and when any Stated Interest accrued to the redemption date will be payable, and shall state that on the redemption date the redemption price of the Series 2018D Bonds called for redemption will be payable at the corporate trust office or corporate trust agency office of the Trustee and/or of one or more Paying Agents identified in such notice and from that date interest will cease to accrue. The Trustee may use “CUSIP” numbers in notices of redemption as a convenience to Bondholders, provided that any such notice shall state that no representation is made as to the correctness of such numbers either as printed on the Series 2018D Bonds or as contained in any notice of redemption and that reliance may be placed only on the identification numbers containing the prefix established under the 2018D Indenture.
If, at the time of mailing of any notice of optional redemption, the Authority shall not have deposited with the Trustee moneys sufficient to redeem all the Series 2018D Bonds called for optional redemption, such notice shall state that it is subject to the deposit of the redemption moneys with the Trustee not later than the redemption date and shall be of no effect unless such moneys are so deposited and available.
For so long as DTC is effecting book-entry transfers of the Series 2018D Bonds, the Trustee will provide the redemption notices described above to DTC. It is expected that DTC will, in turn, notify the Direct Participants, and that the Direct Participants, in turn, will notify or cause to be notified the Beneficial Owners of the Series 2018D Bonds to be redeemed. The Authority, the Trustee and TJU will have no responsibility or liability in connection with any failure on the part of DTC or a Participant, or failure on the part of a nominee of a Beneficial Owner of a Bond, to notify the Beneficial Owner of the Series 2018D Bond so affected, and such failure shall not affect the validity of the redemption of such Series 2018D Bond. See “BOOK-ENTRY ONLY SYSTEM” herein.
Transfer and Exchange of Series 2018D Bonds; Persons Treated as Owners
Any action to be taken by Bondholders may be evidenced by one or more concurrent written instruments of similar tenor signed or executed by such Bondholders in person or by agent appointed in writing. The fact and date of the execution by any person of any such instrument may be proved by acknowledgement before a notary public or other officer empowered to take acknowledgements or by an affidavit of a witness to such execution. Any action by the holder of any Series 2018D Bond will bind all future holders of the same Series2018D Bond in respect of anything done or suffered by the Authority or the Trustee in pursuance thereof. The ownership of Series 2018D Bonds will be proved by the Bond Register.
The Trustee is not required to transfer or exchange any Series 2018D Bond during the 15 days immediately preceding the date of mailing of notice of redemption or at any time following the mailing of any such notice, if the Series 2018D Bond to be transferred or exchanged has been called for such redemption in whole or in part.
The Authority, the Trustee, the bond registrar and any authenticating agent may deem and treat the Person in whose name any Series 2018D Bond is registered as the absolute owner thereof
21
(whether or not such Series 2018D Bond is overdue and notwithstanding any notation of ownership or other writing thereon) for the purpose of receiving payment of or on account of the principal of (and premium, if any, on), and (subject to certain provisions of the 2018D Indenture) interest on, such Series 2018D Bonds, and for all other purposes, and neither the Authority, the Trustee, the bond registrar nor the authenticating agent will be affected by any notice to the contrary.
So long as the Series 2018D Bonds are held in book-entry form, transfers of the Series 2018D Bonds by Beneficial Owners may only be made as described under “BOOK-ENTRY ONLY SYSTEM” herein. At any other time, any Series 2018D Bond may be transferred or exchanged only upon the books kept for the registration and transfer of Series 2018D Bonds as provided in the 2018D Indenture.
BOOK-ENTRY ONLY SYSTEM
The information in this section concerning DTC and DTC’s book-entry system has been obtained from DTC and neither the Authority, the Obligated Group nor the Underwriter makes any representation or warranty or take any responsibility for the accuracy or completeness of such information.
DTC will act as securities depository for the Series 2018D Bonds. The Series 2018D Bonds will be issued as fully-registered securities, registered in the name of Cede &Co. (DTC’s partnership nominee) or such other name as may be requested by an authorized representative of DTC. One fully registered bond certificate will be issued for each maturity of the Series 2018D Bonds as set forth on the inside front cover of this Official Statement, each in the aggregate principal amount of such maturity and will be deposited with DTC.
DTC is a limited-purpose trust company organized under the New York Banking Law, a “banking organization” within the meaning of the New York Banking Law, a member of the Federal Reserve System, a “clearing corporation” within the meaning of the New York Uniform Commercial Code, and a “clearing agency” registered pursuant to the provisions of Section 17A of the Securities Exchange Act of 1934. DTC holds and provides asset servicing for over 3.5 million issues of U.S. and non-U.S. equity issues, corporate and municipal debt issues, and money market instruments that DTC’s participants (“Direct Participants”) deposit with DTC. DTC also facilitates the post-trade settlement among Direct Participants of sales and other securities transactions in deposited securities, through electronic computerized book-entry transfers and pledges between Direct Participants’ accounts. This eliminates the need for physical movement of securities certificates. Direct Participants include both U.S. and non-U.S. securities brokers and dealers, banks, trust companies, clearing corporations, and certain other organizations. DTC is a wholly-owned subsidiary of The Depository Trust & Clearing Corporation (“DTCC”). DTCC is the holding company for DTC, National Securities Clearing Corporation and Fixed Income Clearing Corporation, all of which are registered clearing agencies. DTCC is owned by the users of its regulated subsidiaries. Access to the DTC system is also available to others such as both U.S. and non-U.S. securities brokers and dealers, banks, trust companies, and clearing corporations that clear through or maintain a custodial relationship with a Direct Participant, either directly or indirectly (“Indirect Participants”). The DTC Rules applicable to its Participants are on file with the SEC. More information about DTC can be found at www.dtcc.com.
22
Purchases of Series 2018D Bonds under the DTC system must be made by or through Direct Participants, which will receive a credit for the Series 2018D Bonds on DTC’s records. The ownership interest of each actual purchaser of each Series 2018D Bond (“Beneficial Owner”) is in turn to be recorded on the Direct and Indirect Participants’ records. Beneficial Owners will not receive written confirmation from DTC of their purchase. Beneficial Owners are, however, expected to receive written confirmations providing details of the transaction, as well as periodic statements of their holdings, from the Direct or Indirect Participant through which the Beneficial Owner entered into the transaction. Transfers of ownership interests in the Series 2018D Bonds are to be accomplished by entries made on the books of Direct and Indirect Participants acting on behalf of Beneficial Owners. Beneficial Owners will not receive certificates representing their ownership interests in the Series 2018D Bonds, except in the event that use of the book-entry system for the Series 2018D Bonds is discontinued.
To facilitate subsequent transfers, all Series 2018D Bonds deposited by Direct Participants with DTC are registered in the name of DTC’s partnership nominee, Cede & Co., or such other name as may be requested by an authorized representative of DTC. The deposit of the Series 2018D Bonds with DTC and their registration in the name of Cede & Co. or such other DTC nominee do not affect any change in beneficial ownership. DTC has no knowledge of the actual Beneficial Owners of the Series 2018D Bonds, DTC’s records reflect only the identity of the Direct Participants to whose accounts such Series 2018D Bonds are credited, which may or may not be the Beneficial Owners. The Direct and Indirect Participants will remain responsible for keeping account of their holdings on behalf of their customers.
Conveyance of notices and other communications by DTC to Direct Participants, by Direct Participants to Indirect Participants, and by Direct Participants and Indirect Participants to Beneficial Owners will be governed by arrangements among them, subject to any statutory or regulatory requirements as may be in effect from time to time. Beneficial Owners of Series 2018D Bonds may wish to take certain steps to augment the transmission to them of notices of significant events with respect to the Series 2018D Bonds, such as redemptions, tenders, defaults, and proposed amendments to the 2018D Indenture. For example, Beneficial Owners of Series 2018D Bonds may wish to ascertain that the nominee holding the Series 2018D Bonds for their benefit has agreed to obtain and transmit notices to Beneficial Owners. In the alternative, Beneficial Owners may wish to provide their names and addresses to the bond registrar and request that copies of the notices be provided directly to them.
Redemption notices shall be sent to DTC. If less than all of the Series 2018D Bonds within a maturity are being redeemed, DTC’s practice is to determine by lot the amount of the interest of each Direct Participant in such maturity to be redeemed.
Neither DTC nor Cede & Co. (nor any other DTC nominee) will consent or vote with respect to the Series 2018D Bonds unless authorized by a Direct Participant in accordance with DTC’s procedures. Under its usual procedures, DTC mails an Omnibus Proxy to the Trustee as soon as possible after the record date. The Omnibus Proxy assigns Cede & Co.’s consenting or voting rights to those Direct Participants to whose accounts the Series 2018D Bonds are credited on the record date (identified in a listing attached to the Omnibus Proxy).
23
Principal, purchase price, premium, if any, and interest payments on the Series 2018D Bonds will be made to Cede & Co. or such other nominee as may be requested by an authorized representative of DTC. DTC’s practice is to credit Direct Participants’ accounts upon DTC’s receipt of funds and corresponding detail information from the Paying Agent on the payment date in accordance with their respective holdings shown on DTC’s records. Payments by Participants to Beneficial Owners will be governed by standing instructions and customary practices, as is the case with securities held for the accounts of customers in bearer form or registered in “street name,” and will be the responsibility of such Participant and not of DTC, the Paying Agent, or the Authority, subject to any statutory or regulatory requirements as may be in effect from time to time. Payment of principal, purchase price, premium, if any, and interest on the Series 2018D Bonds, as applicable, to Cede & Co. (or such other nominee as may be requested by an authorized representative of DTC) is the responsibility of the Paying Agent, disbursement of such payments to Direct Participants will be the responsibility of DTC, and disbursement of such payments to the Beneficial Owners shall be the responsibility of Direct and Indirect Participants.
A Beneficial Owner shall give notice to elect to have its Series 2018D Bonds purchased or tendered, through its Participant to the Remarketing Agent, and shall effect delivery of such Series 2018D Bonds by causing the Direct Participant to transfer the Participant’s interest in the Series 2018D Bonds, on DTC’s records, to the Remarketing Agent. The requirement for physical delivery of Series 2018D Bonds in connection with an optional tender or a mandatory purchase will be deemed satisfied when the ownership rights in the Series 2018D Bonds are transferred by Direct Participants on DTC’s records and followed by a book-entry credit of tendered Series 2018D Bonds to the Remarketing Agent’s DTC account.
DTC may discontinue providing its services as depository with respect to the Series 2018D Bonds of a series at any time by giving reasonable notice to the Authority or Paying Agent. Under such circumstances, in the event that a successor depository is not obtained, Series 2018D Bond certificates are required to be printed and delivered.
The Authority may, at the direction of TJU, decide to discontinue use of the system of book-entry only transfers through DTC (or a successor securities depository). In that event, Series 2018D Bonds certificates will be printed and delivered to DTC.
SO LONG AS CEDE & CO. IS THE REGISTERED OWNER OF THE SERIES 2018D BONDS, AS NOMINEE OF DTC, REFERENCES HEREIN TO THE HOLDER OF THE SERIES 2018D BONDS OR REGISTERED OWNERS OF THE SERIES 2018D BONDS SHALL MEAN DTC AND SHALL NOT MEAN THE BENEFICIAL OWNERS OF THE APPLICABLE SERIES 2018D BONDS.
The Authority, the Obligated Group, and the Paying Agent do not have any responsibility or obligation to the Direct Participants, Indirect Participants or the Beneficial Owners with respect to (a) the accuracy of any records maintained by DTC or any Direct Participant or Indirect Participant; (b) the payment by DTC or any Direct Participant or Indirect Participant of any amount due to any Beneficial Owner in respect of the principal, purchase price and redemption price of and interest on the Series 2018D Bonds; (c) the delivery or timeliness of delivery by DTC or any Direct Participant or Indirect Participant of any notice to any Beneficial Owner, which is required
24
or permitted under the terms of the 2018D Indenture to be given to Holders; or (d) any consent given or other action taken by DTC, or its nominee, Cede & Co., as Holders.
NONE OF THE AUTHORITY, THE OBLIGATED GROUP OR THE TRUSTEE SHALL HAVE ANY OBLIGATION WITH RESPECT TO ANY DEPOSITORY PARTICIPANT OR BENEFICIAL OWNER OF THE SERIES 2018D BONDS DURING SUCH TIME AS THE SERIES 2018D BONDS ARE REGISTERED IN THE NAME OF A SECURITIES DEPOSITORY PURSUANT TO A BOOK-ENTRY ONLY SYSTEM OF REGISTRATION.
SECURITY AND SOURCES OF PAYMENT FOR THE SERIES 2018D BONDS
General
The Series 2018D Bonds are being issued by the Authority under and pursuant to the 2018D Indenture. The Series 2018D Bonds are limited obligations of the Authority payable solely from the sources identified in the 2018D Indenture including Pledged Revenues (as defined in the 2018D Indenture) and amounts payable under the Master Note as described below.
Pursuant to the 2018D Loan Agreement, the Authority will lend the proceeds of the Series 2018D Bonds to TJU for the purpose of undertaking the 2018 Project and TJU will agree to make payments at such times and in such amounts as to provide for payment of the principal, purchase price and redemption price of, and interest on, the Series 2018D Bonds.
As further described below, TJU, as the Obligated Group Agent, will deliver the Master Note to the 2018D Trustee to evidence and secure TJU’s obligations under the 2018D Loan Agreement. The Master Note is secured by a pledge of the Gross Revenues of each Member of the Obligated Group on a joint and several basis, and equally and ratably with existing Obligations (other than Subordinated Obligations), any Parity Indebtedness, and any additional Obligations (other than Subordinated Obligations) secured from time to time under the Master Indenture.
The Authority has assigned its rights under the 2018D Loan Agreement (other than rights to be reimbursed for certain expenses and indemnification) and the Master Note to the 2018D Trustee as security for its obligations with respect to the Series 2018D Bonds.
See also “OUTSTANDING INDEBTEDNESS OF THE OBLIGATED GROUP” herein for a description of the indebtedness and swaps secured under the Master Indenture.
Trust Estate
Pursuant to the 2018D Indenture, the Trust Estate includes: (a) all right, title and interest (but not the obligations) of the Authority under and pursuant to the terms of the 2018D Loan Agreement in and to all Loan Payments and all other payments, revenues and receipts receivable by the Authority under the 2018D Loan Agreement except as provided therein, (b) all of the right, title and interest of the Authority in and to the Master Note, and all payments, revenues and receipts receivable by the Authority thereunder except as provided therein, and (c) all of the right, title and interest of the Authority in and to all Funds and Accounts established under the 2018D Indenture (except for the Rebate Fund) and all moneys and investments now or hereafter held therein and all present and future Pledged Revenues (as defined in the 2018D Indenture). See “APPENDIX
25
C - DEFINITIONS OF CERTAIN TERMS AND SUMMARIES OF CERTAIN PROVISIONS OF THE 2018D INDENTURE AND THE 2018D LOAN AGREEMENT.”
The 2018D Indenture defines “Pledged Revenues” as (a) all amounts payable to the Trustee with respect to the principal, purchase price or redemption price of, or interest on the Series 2018D Bonds (i) upon deposit in the Debt Service Fund under the 2018D Indenture from the proceeds of the Series 2018D Bonds or of obligations issued by the Authority to refund the Series 2018D Bonds; and (ii) by TJU under the 2018D Loan Agreement; (b) any proceeds of Series 2018D Bonds originally deposited with the Trustee for the payment of accrued interest on the Series 2018D Bonds or otherwise, and (c) investment income with respect to any moneys held by the Trustee in the Debt Service Fund and the Construction Fund under the 2018D Indenture.
The Series 2018D Bonds are not secured by any debt service reserve fund under the 2018D Indenture.
2018D Loan Agreement
TJU is required to make loan payments in amounts sufficient to pay when due the principal or purchase price of, premium, if any, and interest on the Series 2018D Bonds. The obligation of TJU to make loan payments constitutes a general obligation of TJU, the full faith and credit of which is pledged to the payment thereof. TJU is required to pay all loan payments and additional payments without notice or demand, and without abatement, diminution or deduction and regardless of any cause or circumstance whatever including, without limitation, any set-off, counterclaim, recoupment or defense.
The Obligated Group Agent has issued the Master Note under the Master Indenture as security for TJU’s obligations under the 2018D Loan Agreement. The Master Note is a joint and several obligation of TJU and the other Members of the Obligated Group. Each of TJU and the other Members of the Obligated Group has granted a lien on, and security interest in, its respective Gross Revenues to secure its obligations under the Master Indenture and the Master Note, as described under “Master Indenture.” The Authority has assigned its rights under the Master Note to the 2018D Trustee pursuant to the 2018D Indenture, and the 2018D Trustee will be a “Related Bond Trustee” for the benefit of holders of the 2018D Bonds under the Master Indenture. The 2018D Loan Agreement contains the agreements of TJU that it will not grant or permit another Member of the Obligated Group to grant a Lien on any of its Property or its Gross Revenues to secure its obligations with respect to any Obligation except as permitted by the Master Indenture.
In the 2018D Loan Agreement, TJU agrees to comply with the covenants contained in the Master Indenture for the benefit of holders of the Series 2018D Bonds.
Master Indenture
Pursuant to the Master Indenture, TJU and each other Member of the Obligated Group have agreed to comply with certain financial and operational covenants contained in the Master Indenture. The Master Indenture described herein governs the exercise of remedies by holders of Obligations (including Obligations with respect to Related Bonds (as defined in the Master Indenture) such as the Master Note for the 2018D Bonds), upon an event of default, and limits the ability of the holder of any Obligation to exercise remedies unilaterally. See
26
“APPENDIX D - DEFINITIONS OF CERTAIN TERMS AND SUMMARIES OF CERTAIN PROVISIONS OF THE MASTER INDENTURE” attached hereto.
Pursuant to the Master Indenture, TJU and each other Member of the Obligated Group has unconditionally and irrevocably (subject to the rights of Members to leave the Obligated Group) jointly and severally covenanted that it will promptly pay all amounts due under every Obligation issued under the Master Indenture and be liable therefor at the times and in the amounts (including principal, purchase price, interest and premium, if any, and all other amounts due thereunder) equal to the amounts to be paid upon any Related Bonds and upon any other financial obligations evidenced or secured by Obligations. In addition, to secure its obligations under the Master Indenture, each Obligated Group Member has granted to The Bank of New York Mellon Trust Company, N.A., as the Master Trustee, a lien on and security interest in its Gross Revenues.
See “Certain Covenants of the Obligated Group under the Master Indenture - Gross Revenues Pledge” below for a further description of the Gross Revenue pledge of the Members of the Obligated Group pursuant to the Master Indenture.
Affiliates of TJU and other Persons may become subject to the provisions of the Master Indenture or excluded or released from the provisions thereunder, subject to meeting certain conditions and/or tests as described herein. See “Addition, Exclusion and Release of Entities with Respect to the Requirements of the Master Indenture” below.
See “APPENDIX C - DEFINITIONS OF CERTAIN TERMS AND SUMMARIES OF CERTAIN PROVISIONS OF THE 2018D INDENTURE AND THE 2018D LOAN AGREEMENT” and “APPENDIX D – DEFINITIONS OF CERTAIN TERMS AND SUMMARIES OF CERTAIN PROVISIONS OF THE MASTER INDENTURE” attached hereto for summaries of the 2018D Indenture, the 2018D Loan Agreement, the Master Indenture and certain definitions contained therein.
Certain Covenants of the Obligated Group under the Master Indenture
Joint and Several Obligations of the Members of the Obligated Group. The obligations, agreements, covenants and restrictions of the Master Indenture are joint and several obligations, agreements and covenants of and restrictions relating to the Members of the Obligated Group.
Gross Revenues Pledge. In order to secure the prompt payment of amounts due on all Obligations (including the Master Note) issued under the Master Indenture, the Members of the Obligated Group have granted a lien on, and security interest in, their Gross Revenues.
“Gross Revenues” as defined under the Master Indenture consist of all receipts, revenues, income and other moneys received by or on behalf of each Member of the Obligated Group, and all rights to receive the same, whether in the form of accounts, accounts receivable, deposit accounts, contract rights, chattel paper, instruments, documents, general intangibles, letter of credit rights, investment property or other rights, and the proceeds thereof, and insurance thereon (all terms which are used in such definition which are defined in Uniform Commercial Code of the Commonwealth (the “UCC”) have the same meanings in such definition as defined in the UCC, unless the Master Indenture provides otherwise), whether now existing or hereafter coming into existence and whether now owned or held or hereafter acquired by a Member of the Obligated
27
Group, and including all Swap Receipts and Swap Termination Payments (as such terms are defined in the Master Indenture) payable to a Member of the Obligated Group; provided, however, that there shall be excluded from Gross Revenues any Excluded Property.
“Excluded Property” is defined under the Master Indenture to mean (i) any assets of “employee pension benefit plans,” including “multi-employer plans,” as defined in the Employee Retirement Income Security Act of 1974, as amended, or any similar funds established for provision of pension or other post-retirement benefits, (ii) any assets of a self-insurance trust which prohibits any application of such assets for purposes which are not related to claims as defined in the governing trust document, and (iii) all endowment funds and property derived from gifts, grants, research contracts, bequests, donations and contributions heretofore or hereafter made to or with any Member of the Obligated Group that are specifically restricted by the donor, testator or grantor to a particular purpose inconsistent with the payment of Debt Service Requirements on Obligations, and the income and gains derived therefrom, if so restricted.
The pledge by the Members of the Obligated Group of their Gross Revenues will secure the payments under the Master Note with respect to the Series 2018D Bonds on a parity basis with all other outstanding Obligations (other than Subordinated Obligations) and Parity Indebtedness heretofore issued or incurred in accordance with the Master Indenture. See “OUTSTANDING INDEBTEDNESS OF THE OBLIGATED GROUP” herein for a description of the Indebtedness secured by Obligations issued pursuant to the Master Indenture and other outstanding Indebtedness of the Obligated Group.
Such pledge by the Members of the Obligated Group of their Gross Revenues also secures any additional Obligations and Parity Indebtedness secured from time to time under the Master Indenture. See “SECURITY AND SOURCES OF PAYMENT FOR THE SERIES 2018D BONDS – Additional Obligations - Long Term Indebtedness” herein for a description of the Master Indenture provisions governing the incurrence of additional Long Term Indebtedness and “SECURITY AND SOURCES OF PAYMENT FOR THE SERIES 2018D BONDS - Direct Placement Bonds” herein for a description of certain provisions governing the Direct Placement Bonds. See also “The Obligations” and “Additional Obligations” under “CERTAIN PROVISIONS OF THE MASTER INDENTURE” in “APPENDIX D - DEFINITIONS OF CERTAIN TERMS AND SUMMARIES OF CERTAIN PROVISIONS OF THE MASTER INDENTURE” attached hereto for a summary of the provisions of the Master Indenture relating to the issuance of Obligations and the incurrence of Indebtedness by the Members of the Obligated Group.
Negative Pledge. Each Member of the Obligated Group agrees that it will not create, assume or suffer to exist any Lien upon the Gross Revenues or the Property of the Obligated Group, except for Permitted Encumbrances. Notwithstanding any other provision of the Master Indenture or any other agreement executed in connection with the issuance of any Obligations, TJU may not grant, or permit to be granted, a Lien on its Gross Revenues to secure any Obligations consisting of or arising under a Swap Agreement until the $60,420,000 Pennsylvania Higher Educational Facilities Authority Revenue Bonds (Thomas Jefferson University) Series 2006B (the “Series 2006B Bonds”) and the $42,195,000 Pennsylvania Higher Educational Facilities Authority Revenue Bonds (Thomas Jefferson University), Series 2012 (“Series 2012 Bonds”) have been paid in full, or provision for their payment in full has been made in accordance with the agreements
28
pursuant to which they were issued. See “APPENDIX D - DEFINITIONS OF CERTAIN TERMS AND SUMMARIES OF CERTAIN PROVISIONS OF THE MASTER INDENTURE – Negative Pledge; Permitted Encumbrances.”
The payments due under the Master Note related to the Series 2018D Bonds and the other Indebtedness evidenced or secured by other Obligations issued under the Master Indenture, including the Existing Swaps (as defined herein), are not secured by a mortgage on any real property of the Obligated Group. See “OUTSTANDING INDEBTEDNESS OF THE OBLIGATED GROUP - Interest Rate Swaps” herein for a description of the Existing Swaps.
Debt Service Coverage Ratio. Pursuant to the Master Indenture, within 180 days after the end of each Fiscal Year, commencing with the Fiscal Year ended June 30, 2017, TJU, as the Obligated Group Agent, shall compute the Debt Service Coverage Ratio for such Fiscal Year and furnish a Certificate of the Obligated Group Agent setting forth such computations to the Master Trustee.
The Obligated Group covenants that, if at the end of any Fiscal Year the Debt Service Coverage Ratio shall have been less than 1.10 to 1.0, it will use its best efforts to adopt a budget for the current Fiscal Year that will result in the Debt Service Coverage Ratio for such Fiscal Year to be at least 1.10 to 1.0. If the Debt Service Coverage Ratio is less than 1.0 for any Fiscal Year, the Obligated Group Agent will engage an Independent Consultant to advise the Obligated Group on possible steps to take to enhance future revenues and/or reduce future expenses in order to achieve a Debt Service Coverage Ratio not less than 1.10 to 1.0 in the future. Failure to maintain a Debt Service Coverage Ratio equal to 1.10 to 1.0 (or 1.0 to 1.0) shall not constitute an event of default so long as: (a) the Obligated Group Agent engages an Independent Consultant as/when required and considers such Independent Consultant’s recommendations, and (b) Liquid Unrestricted Net Assets is greater than 25% of the Obligated Group’s Outstanding Long Term Indebtedness. Copies of the recommendations of the Independent Consultant are required to be filed with the Master Trustee. Notwithstanding the foregoing, the failure of the Obligated Group to satisfy the minimum Debt Service Coverage Ratio covenant together with any nonpayment of debt service on the Series 2018D Bonds will result in an event of default under the 2018D Loan Agreement, the 2018D Indenture and the Master Indenture, and afford holders of the Series 2018D Bonds and the holders of Obligations and Related Bonds under the Master Indenture the ability to exercise remedies in accordance with such documents.
Notwithstanding the foregoing, any Person that is part of the University may permit the rendering of services or the use of its Property without charge or at reduced charges, at the discretion of the governing body of the Obligated Group Agent or an Audit Group member to the extent necessary for maintaining its tax-exempt status and its eligibility for grants, loans, subsidies or payments from governmental entities, or in compliance with any recommendation for free services that may be made by an Independent Consultant or as a result of Industry Restrictions. “Industry Restrictions” means federal, state or other applicable governmental laws or regulations or general industry standards or general industry conditions placing restrictions and limitations on the rates, fees and charges to be fixed, charged and collected by any member of the Audit Group.
Other Covenants. The Master Indenture also sets forth various covenants and other provisions applicable to the finances and operations of the Obligated Group. Such provisions
29
address, among other things, the (a) the incurrence of additional Indebtedness secured by Gross Revenues of the Obligated Group on a parity basis with, or subordinated basis to, obligations with respect to the Series 2018D Bonds, the existing Obligations and any additional Obligations issued from time to time under the Master Indenture, (b) the incurrence and securing of Swaps, including, subject to certain conditions, the securing of Swap Payments on a parity basis with Obligations issued from time to time under the Master Indenture, (c) the incurrence of Short Term Indebtedness, (d) requirements related to the consolidation, merger or transfer of all or substantially all of the assets of entities subject to the Master Indenture, (e) limitations on certain dispositions of real and personal property (including cash), (f) Permitted Encumbrances, and (g) the addition of persons as Members for purposes of the Master Indenture, the release of any Member from its obligations under the Master Indenture (other than the Obligated Group Agent (currently, TJU)), and the designation of entities as “Excluded Affiliates”. For a more extensive discussion of the provisions of the Master Indenture, see “APPENDIX D - DEFINITIONS OF CERTAIN TERMS AND SUMMARIES OF CERTAIN PROVISIONS OF THE MASTER INDENTURE.”
Direct Placement Bonds
The (i) $50,000,000 Montgomery County Higher Education and Health Authority Hospital Revenue Bonds, Series B of 2012 (Abington Memorial Hospital Obligated Group) (“Abington Series B of 2012 Bonds”), (ii) $35,125,000 Pennsylvania Higher Educational Facilities Authority Thomas Jefferson University Variable Rate Revenue Bonds, Series 2015C (“Series 2015C Bonds”), (iii) $34,875,000 Pennsylvania Higher Educational Facilities Authority Thomas Jefferson University Variable Rate Revenue Bonds, Series 2015D (“Series 2015D Bonds”), (iv) $35,125,000 Pennsylvania Higher Educational Facilities Authority Thomas Jefferson University Variable Rate Revenue Bonds, Series 2015E (“Series 2015E Bonds”), (v) $34,875,000 Pennsylvania Higher Educational Facilities Authority Thomas Jefferson University Variable Rate Revenue Bonds, Series 2015F (“Series 2015F Bonds”), (vi) $20,950,000 Pennsylvania Higher Educational Facilities Authority Thomas Jefferson University Variable Rate Revenue Bonds, Series 2015G (“Series 2015G Bonds”), (vii) $29,050,000 Pennsylvania Higher Educational Facilities Authority Thomas Jefferson University Variable Rate Revenue Bonds, Series 2015H (Taxable) (“Series 2015H Bonds”), (viii) $50,000,000 Philadelphia Authority for Industrial Development Thomas Jefferson University Variable Rate Revenue Bonds, Series 2017C (“Series 2017C Bonds”), and (ix) the Series 2017E Bonds (collectively, the “Direct Placement Bonds”) were purchased by various commercial banks (collectively, the “Direct Purchasers”). The Direct Placement Bonds are secured under the Master Indenture; and the Direct Purchasers are secured by Obligations issued under the Master Indenture and have the benefit of the same covenants pursuant to the Master Indenture. For certain additional information regarding the outstanding Direct Placement Bonds, see “OUTSTANDING INDEBTEDNESS OF THE OBLIGATED GROUP” herein.
Interest Rate Swaps
TJU currently has four fixed-payor swaps and two constant maturity swaps (collectively, the “Existing Swaps”). For a further description of the Existing Swaps see “INDEBTEDNESS – Interest Rate Derivatives” in APPENDIX A hereto.
30
Under certain circumstances, the Existing Swaps may be terminated early, in which case TJU may become obligated to make a substantial payment to one or more swap counterparties. In certain circumstances TJU may have an obligation under the swaps to post collateral with the swap counterparties depending, among other things, on the then-current bond ratings and the then- current mark-to-market value of the swaps and subject to compliance with the Master Indenture. For information about the fair values of the Existing Swaps as of June 30, 2017 see “Note 11. Derivative Financial Instruments” in “APPENDIX B-1 - THOMAS JEFFERSON UNIVERSITY CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2017 AND 2016” attached hereto.
The Master Indenture provides that Swap Termination Payments only may be secured as Subordinated Obligations under the Master Indenture, but may come due without resulting in an acceleration of the maturity of the other then outstanding Obligations. For a further description of the provisions of the Master Indenture relating to the incurrence and securing of Swaps, including, subject to certain conditions, the posting of collateral to secure Swaps, see “CERTAIN PROVISIONS OF THE MASTER INDENTURE – Additional Obligations – Swaps” and “CERTAIN PROVISIONS OF THE MASTER INDENTURE – Limitations of Certain Dispositions –Swaps” in “APPENDIX D - DEFINITIONS OF CERTAIN TERMS AND SUMMARIES OF CERTAIN PROVISIONS OF THE MASTER INDENTURE” and “Note 11. Derivative Financial Instruments” in “APPENDIX B-1 - THOMAS JEFFERSON UNIVERSITY CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2017 AND 2016” attached hereto.
Additional Long Term Indebtedness
Pursuant to the Master Indenture, the Obligated Group may not incur additional Long Term Indebtedness (whether through the creation of new Indebtedness, the assumption of existing Indebtedness or the guaranteeing of any new or existing Indebtedness) unless the Master Trustee receives, among other items, the following.
(a) a Certificate of TJU (as the Obligated Group Agent) stating that, (i) the proceeds of the Indebtedness, together with other available moneys, is expected to be sufficient for completion of the applicable project, and (ii) immediately following the incurrence of the Long Term Indebtedness and the application of the proceeds thereof, the Obligated Group will not be in default in the performance or observance of any covenant or condition to be performed by it under the Master Indenture and no Event of Default under the Master Indenture shall exist;
(b) a Certificate of TJU (as the Obligated Group Agent) demonstrating that either: (i) immediately following the incurrence of the Long Term Indebtedness and the application of the proceeds thereof, the Liquid Unrestricted Net Assets will be at least equal to 50% of the principal amount of Long Term Indebtedness of the Audit Group to be Outstanding; or (ii) the Net Revenues for each of the two preceding Fiscal Years (assuming that the Long Term Indebtedness in question was incurred on the last day of such Fiscal Year in question and the proceeds of such Long Term Indebtedness were applied on the last day of such Fiscal Year in question), will be equal to at least 110% of the Maximum Annual Debt Service on all Outstanding Long Term Indebtedness of the Obligated Group for such testing period; and
31
(c) a Certificate of TJU (as the Obligated Group Agent) demonstrating that immediately following the incurrence of the Long Term Indebtedness and the application of the proceeds thereof, the Maximum Annual Debt Service Requirements on all outstanding Long Term Indebtedness of the Obligated Group will not exceed an amount equal to 10% of the Total Unrestricted Expenses of the Audit Group.
In connection with a Person’s becoming a Member of the Obligated Group, the Obligated Group may secure any Indebtedness of such Person as Parity Indebtedness or as Subordinated Obligations under the Master Indenture so long as the Indebtedness in question could be incurred and secured in accordance with the other provisions of the Master Indenture.
See “CERTAIN PROVISIONS OF THE MASTER INDENTURE – Additional Obligations – Other Indebtedness Permitted” in “APPENDIX D - DEFINITIONS OF CERTAIN TERMS AND SUMMARIES OF CERTAIN PROVISIONS OF THE MASTER INDENTURE” attached hereto for a further description of provisions of the Master Indenture permitting the incurrence of additional types of Long Term Indebtedness without complying with, the requirements described in subparagraphs (b) and (c) above including: (a) Indebtedness for the completion of the construction, renovation or equipment of Operating Assets; (b) refunding Indebtedness that is certified to be in the best interest of the Obligated Group or University in a Certificate of the Obligated Group Agent delivered to the Master Trustee; and (c) Indebtedness incurred and outstanding in an amount not in excess of five percent of the Net Assets of the Audit Group for the preceding Fiscal Year end.
Obligated Group Members and the Master Indenture
The Master Indenture provides that TJU must cause existing or new Affiliates who become Material Affiliates (as such terms are defined below) to become Members of the Obligated Group requiring them to comply with all terms of the Master Indenture, unless the Affiliate in question is qualified as an Excluded Affiliate (as further described below). See “Existing Affiliates that Become Material Affiliates” and “Non-Affiliates that Become Affiliates in the Future (e.g. Mergers, Affiliations)” under “Addition, Exclusion and Release of Entities with Respect to the Requirements of the Master Indenture” below for a discussion of TJU’s obligation to monitor whether an Affiliate has become or would constitute a Material Affiliate and TJU’s ability to designate such an Affiliate as an “Excluded Affiliate.” As of the date of issuance of the Series 2018D Bonds, TJU has not designated any Person as an Excluded Affiliate. No assurance can be given regarding any future designation of Persons as Excluded Affiliates. Affiliates who have not become Members of the Obligated Group have not pledged their Gross Revenues for the benefit of the Master Trustee and Holders of Obligations and have not agreed to comply with the covenants of the Master Indenture.
The Master Indenture defines Affiliate, Material Affiliate and Excluded Affiliate to the following effect.
“Affiliate” means any Person that, directly or indirectly, controls or is controlled by or is under common control with TJU and the term “control” (and correlative terms) as used with respect to any Person means the power, directly or indirectly either to (a) vote 50% or more of securities having ordinary voting power for the election of directors, trustees or the similar
32
governing body of such Person or (b) direct or cause the direction of the management and policies of such person, whether by contract or otherwise.
“Material Affiliate” means an Affiliate (other than an Excluded Affiliate) whose Total Unrestricted Revenues are equal to at least five percent of the consolidated Total Unrestricted Revenues of the Audit Group or whose Net Assets are equal to at least five percent of the consolidated Net Assets of the Audit Group.
“Excluded Affiliate” means a Material Affiliate or any other Person that (a) is designated by the Obligated Group Agent as an “Excluded Affiliate” on or before the date by which such Person otherwise would be required to become a Member of the Obligated Group pursuant to the Master Indenture but is exempted from doing so by TJU in accordance with the Master Indenture or (b) has previously become a Material Affiliate but TJU demonstrates that the conditions of the Master Indenture for the release of a Member from the obligations of the Master Indenture would be satisfied were such Material Affiliate not to become a Member. An Excluded Affiliate, for purposes of the Master Indenture, is treated like any unrelated third party and is not subject to the provisions of the Master Indenture. In particular, the financial results of each Excluded Affiliate shall be excluded from any calculations measured by the financial results of the Obligated Group or the Audit Group. For a discussion of the particular provisions of the Master Indenture relating to the designation of a Person as an “Excluded Affiliate” under different circumstances, see “Addition, Exclusion and Release of Entities with Respect to the Requirements of the Master Indenture” below.
Addition, Exclusion and Release of Entities with Respect to the Requirements of the Master Indenture
The following describes generally the requirements of the Master Indenture governing the addition, exclusion and release of entities as Members of the Obligated Group. For a further description of such provisions, see “Entrance into the Obligated Group,” “Obligated Group Members; Excluded Affiliates,” and “Release of a Member” under “CERTAIN PROVISIONS OF THE MASTER INDENTURE – General Covenants” in “APPENDIX D - DEFINITIONS OF CERTAIN TERMS AND SUMMARIES OF CERTAIN PROVISIONS OF THE MASTER INDENTURE” attached hereto.
The Master Indenture, depending on particular circumstances, will either require or allow a new or existing Affiliate or other Person to become bound by the provisions of the Master Indenture. The Master Indenture also allows for existing or new Affiliates, which would otherwise be required to become bound by the Master Indenture, to be designated instead by TJU as Excluded Affiliates and thereby not be bound by the Master Indenture. In connection with any actions relating to joining, excluding or releasing a Person from the requirements of the Master Indenture, TJU must demonstrate that after giving effect to the action in question, the Financial Addition Test or Financial Release Test described below, as applicable, has been met.
TJU may not be released from any of the requirements under the Master Indenture. See “New Obligated Group and New Master Indenture” below regarding provisions allowing for the replacement of the Master Indenture with a substitute master trust indenture.
33
Financial Addition Test. With respect to the addition of a person as a Member of the Obligated Group, TJU, as the Obligated Group Agent, is required to deliver to the Master Trustee a Certificate demonstrating that either:
(a) the Debt Service Coverage Ratio of the Audit Group (calculated as if such Person were Member) for the Fiscal Year immediately preceding the Fiscal Year in which such Person is proposed to be added as a Member was at least 1.50, or
(b) the Debt Service Coverage Ratio of the Audit Group (calculated as if such Person were a Member) for the two most recent Fiscal Years immediately preceding the Fiscal Year in which such Person is proposed to be added as a Member was in each such preceding Fiscal Year at least 1.10, and the Debt Service Coverage Ratio of the Audit Group (calculated as if such Person were a Member) is forecasted in a report prepared by a Consultant to be at least 1.40 for each of the two complete Fiscal Years succeeding the Fiscal Year in which such Person is proposed to be added as a Member (the foregoing requirements, the “Financial Addition Test”).
Financial Release Test. With respect to the release of a person (other than the Obligated Group Agent) as a Member of the Obligated Group, TJU, as the Obligated Group Agent, is required to deliver to the Master Trustee a Certificate demonstrating that:
(a) either the Debt Service Coverage Ratio (calculated assuming such Person was not a Member) for the two most recent Fiscal Years immediately preceding the Fiscal Year in which such Person is proposed to be removed as a Member is, in each such preceding Fiscal Year, greater than 1.10; or (B) the Debt Service Coverage Ratio (calculated assuming that such Person is not a Member) for the next two succeeding Fiscal Years immediately subsequent to the Fiscal Year in which such Person is proposed to be removed as a Member is forecasted by TJU, as the Obligated Group Agent, in a Certificate to be at least equal to 1.25; and
(b) for the Fiscal Year immediately preceding the Fiscal Year in which such Person is proposed to be removed as a Member (calculated assuming that such person was not a Member) the Days Cash on Hand Ratio was not less than 75 days (the foregoing requirements, the “Financial Release Test”).
If the Member to be released from the Obligated Group is a party to any Related Loan Documents with respect to Related Bonds (e.g., the Series 2018D Bonds) which remain outstanding, another Member of the Obligated Group is required to issue an Obligation under the Master Indenture to evidence or assume the obligation of the Obligated Group in respect of such Related Bonds.
Existing Affiliates that Become Material Affiliates. Existing Affiliates of the Obligated Group Agent (i.e., TJU) who are not Material Affiliates and have not previously been designated as Excluded Affiliates but become Material Affiliates over time as determined upon TJU’s review of the annual audited Financial Statements of the University, must within 180 days of the date on which such Financial Statements of the University are completed by TJU either (a) become a Member of the Obligated Group (by delivering the items required by the Master Indenture for the addition of a Person as a Member of the Obligated Group), or (b) be designated as an Excluded
34
Affiliate subject to meeting the requirements described below under “Release - General Provisions” which include the satisfaction of the Financial Release Test.
Non-Affiliates that Become Affiliates in the Future (e.g. Mergers, Affiliations). If an entity which is not an Affiliate of TJU subsequently meets the requirements to become such an Affiliate (e.g. as a result of a merger, consolidation or affiliation agreement), then, if such new Affiliate would constitute a Material Affiliate as determined by TJU based upon TJU’s review of Financial Statements of the University on the date of consummation of such merger, consolidation or affiliation (which may be unaudited so long as prepared substantially in accordance with Generally Accepted Accounting Principles), then the new Affiliate must within 180 days of the date on which such Financial Statements are delivered to TJU either (a) become a Member of the Obligated Group (by delivering the items required by the Master Indenture for the addition of a Person as a Member of the Obligated Group), or (b) be deemed by TJU as an Excluded Affiliate without the need to satisfy any other condition of the Master Indenture.
Addition - General Provisions. Any Person may become a Member under the Master Indenture upon compliance with certain conditions including, among others: that the Master Trustee receives any agreements evidencing the pledge to the Master Trustee of such Person’s Gross Revenues, and that TJU deliver to the Master Trustee a Certificate of TJU which demonstrates that, after giving effect to the new Person becoming a Member, the Financial Addition Test would be met.
Release - General Provisions. Generally, any Member other than TJU may be released from its obligations and liabilities under the Master Indenture, and upon such release shall cease to be a Member thereunder, upon compliance with certain conditions including: that TJU deliver to the Master Trustee a Certificate of TJU which demonstrates that, after giving effect to the release of such person as a Member, the Financial Release Test would be met.
For a further description of the provisions relating to the addition, exclusion and release of Persons as Members with respect to the requirements of the Master Indenture generally described under this caption, see “Entrance into the Obligated Group,” “Obligated Group Members; Excluded Affiliates,” and “Release of a Member” under “CERTAIN PROVISIONS OF THE MASTER INDENTURE – General Covenants” in “APPENDIX D - DEFINITIONS OF CERTAIN TERMS AND SUMMARIES OF CERTAIN PROVISIONS OF THE MASTER INDENTURE” attached hereto.
New Obligated Group and New Master Indenture
The Master Indenture provides for effecting the affiliation of the Obligated Group with another entity or entities and the inclusion of the Members of the Obligated Group in another obligated group (the “New Obligated Group”) under a new master trust indenture (the “New Master Indenture”) executed by the members of the New Obligated Group and an independent corporate trustee (the “New Master Trustee”) (such transaction is referred to collectively in the Master Indenture as the “Obligated Group Transaction”) subject to certain conditions. Such conditions include, among others: (1) the New Obligated Group satisfying certain minimum ratings requirements for (i) new or replacement obligations issued by the New Obligated Group under the New Master Indenture to secure Indebtedness or Related Bonds (“Replacement
35
Obligations”) and (ii) Related Bonds of the New Obligated Group, (2) the Obligated Group Agent delivering a certificate demonstrating that after giving effect to the issuance of Replacement Obligations, and assuming the New Obligated Group constituted the Obligated Group under the Master Indenture, the New Obligated Group could meet certain tests for the incurrence of additional Long-Term Indebtedness, and (3) the New Master Indenture containing a pledge of Gross Revenues substantially similar to the pledge of Gross Revenues in the Master Indenture as of the date thereof. See also “CERTAIN PROVISIONS OF THE MASTER INDENTURE - Supplemental Master Indentures – Note and Document Substitution” in “APPENDIX D - DEFINITIONS OF CERTAIN TERMS AND SUMMARIES OF CERTAIN PROVISIONS OF THE MASTER INDENTURE” attached hereto.
Limited Obligations
Neither the Commonwealth nor any political subdivision thereof shall be liable for the payment of the principal, purchase price or redemption price of and the interest on any of the Series 2018D Bonds, or for the performance of any pledge, mortgage, obligation or agreement or indebtedness of the Authority, and the Series 2018D Bonds shall not be construed to constitute any indebtedness of the County, the Commonwealth or any political subdivision thereof within the meaning of any constitutional or statutory provision whatsoever. The 2018D Indenture does not pledge the general credit of the Authority nor the general credit nor the taxing power of the County, the Commonwealth or any political subdivision thereof within the meaning of any constitutional or statutory provision whatsoever.
Notwithstanding anything to the contrary in the 2018D Indenture, the Authority’s liability under the 2018D Indenture and the Series 2018D Bonds shall be enforceable only out of the Trust Estate and other property covered by the 2018D Indenture, and the lien of any judgment against the Authority shall be limited thereto. Nothing in the 2018D Indenture, however, shall limit the applicable Trustee’s rights against any Person (including without limitation TJU) other than the Authority. No recourse shall be had for any claim based on the 2018D Indenture or the Series 2018D Bonds, including but not limited to, the payment of the principal or Redemption Price of or interest on the Series 2018D Bonds, against the Authority or any member, officer, agent or employee, past, present or future, of the Authority or any successor body, as such, either directly or indirectly through the Authority or any such successor body, under the 2018D Indenture, the 2018D Loan Agreement, the Series 2018D Bonds or any constitutional provision, statute or rule of law or by the enforcement of any assessment or penalty or by any legal or equitable proceeding or otherwise. The lien of any judgment entered against the Authority shall similarly be expressly limited to the security as aforesaid.
The Authority is not liable for the debt or any portion of the debt evidenced by the Series 2018D Bonds or interest thereon, the 2018D Indenture or the 2018D Loan Agreement, neither is the Authority nor are the members of the Authority, or their respective heirs, personal representatives or successors generally or personally liable in connection with any matter, cause or things pertaining to the Series 2018D Bonds or the issuance thereof, the 2018D Indenture or any instruments and documents executed and delivered by the Authority in connection with the Series 2018D Bonds.
36
THE SERIES 2018D BONDS ARE LIMITED OBLIGATIONS OF THE AUTHORITY, ARE SECURED UNDER THE PROVISIONS OF THE 2018D INDENTURE AND ARE PAYABLE SOLELY FROM THE SOURCES REFERRED TO IN THE 2018D INDENTURE AND DESCRIBED HEREIN. NEITHER THE GENERAL CREDIT OF THE AUTHORITY NOR THE CREDIT OR TAXING POWER OF THE COUNTY OF MONTGOMERY, PENNSYLVANIA, THE COMMONWEALTH OF PENNSYLVANIA OR ANY POLITICAL SUBDIVISION THEREOF IS PLEDGED FOR THE PAYMENT OF THE PRINCIPAL OR PURCHASE PRICE OF, PREMIUM, IF ANY, OR THE INTEREST ON THE SERIES 2018D BONDS, NOR SHALL THE SERIES 2018D BONDS BE DEEMED TO BE GENERAL OBLIGATIONS OF THE AUTHORITY OR OBLIGATIONS OF THE COUNTY OF MONTGOMERY, PENNSYLVANIA, THE COMMONWEALTH OF PENNSYLVANIA OR ANY POLITICAL SUBDIVISION THEREOF, NOR SHALL THE COUNTY OF MONTGOMERY, PENNSYLVANIA, THE COMMONWEALTH OF PENNSYLVANIA OR ANY POLITICAL SUBDIVISION THEREOF BE LIABLE FOR THE PAYMENT OF THE PRINCIPAL OR PURCHASE PRICE OF, PREMIUM, IF ANY, OR THE INTEREST ON THE SERIES 2018D BONDS. THE AUTHORITY HAS NO TAXING POWER.
OUTSTANDING INDEBTEDNESS OF THE OBLIGATED GROUP
Existing Obligations
As of February 28, 2018, the Obligated Group had $1,412,809,852 of outstanding long- term bond indebtedness (including the Series 2017E Bonds to be refunded), which consisted of $694,794,852 of fixed-rate debt and $718,015,000 of variable rate debt, before factoring in the impact of interest rate swaps. $486,450,000 of the Obligated Group’s long-term bond indebtedness outstanding at February 28, 2018 consisted of the Direct Placement Bonds including the $247,825,000 of the Series 2017E Bonds to be refunded. Of the Direct Placement Bonds, excluding the Series 2017E Bonds: (i) $50,000,000 is subject to mandatory tender on February 13, 2020, (ii) $82,970,000 is subject to mandatory tender on March 1, 2023, (iii) $84,790,000 is subject to mandatory tender on March 1, 2025, and (iv) $50,000,000 is subject to mandatory tender on February 1, 2027.
The Master Indenture also secures a revolving line of credit in a maximum amount of $25,000,000 and a revolving line of credit in a maximum amount of $20,000,000, each in favor of TJU, neither of which had an outstanding balance as of February 28, 2018.
In connection with the issuance of the 2018 Bonds, certain additional debt, which is not secured under the Master Indenture, will be refunded. These obligations consist of: (i) the Kennedy Commercial Loans (consisting of a $51,000,000 commercial loan and a $20,000,000 commercial loan, each in favor of KUH), (ii) the Kennedy Mortgage Loans (consisting of $1,009,000 of outstanding commercial mortgage loans, in favor of Kennedy-related entities), and (iii) the Aria Commercial Loans (consisting of $13,922,140 of outstanding mortgage loans in favor of Aria-related entities).
37
Swap Agreements
TJU has entered into derivative transactions for the purpose of reducing the impact of fluctuations in interest rates under the terms of various debt obligations. See “SECURITY AND SOURCES OF PAYMENT FOR THE SERIES 2018D BONDS - Interest Rate Swaps” herein for more information regarding Swaps, including Existing Swaps. See also “INDEBTEDNESS – Interest Rate Derivatives” in APPENDIX A hereto.
[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]
38
Estimated Debt Service Requirements
The following table presents the estimated annual debt service for all outstanding Obligations and Parity Indebtedness upon the issuance of the 2018 Bonds and the refunding of the Refunded Obligations. See “PLAN OF FINANCE” herein. Currently, there are no annual debt service requirements related to any Subordinated Obligations. Fiscal Year Outstanding Series 2018A Series 2018B Series 2018C Series 2018D Ending Obligations and Parity Bonds Debt Bonds Debt Bonds Debt Bonds Debt Total Debt June 30 Indebtedness(1)(2)(3)(4) Service Service Service(5) Service(5) Service (1) 2018 $63,542,173 $ - $ - $ - $ - $63,542,173 2019 59,363,184 13,897,437 1,074,949 2,466,778 1,232,156 78,034,504 2020 55,278,241 19,630,975 2,219,665 2,980,000 1,488,510 81,597,391 2021 59,473,817 16,643,100 1,270,734 2,980,000 1,488,510 81,856,161 2022 56,865,640 18,139,725 2,121,548 2,980,000 1,488,510 81,595,423 2023 47,451,417 26,662,475 3,016,767 2,980,000 1,488,510 81,599,169 2024 47,435,727 26,676,100 3,018,541 2,980,000 1,488,510 81,598,878 2025 47,433,078 26,677,100 4,420,507 2,980,000 1,488,510 82,999,196 2026 63,784,822 14,930,600 995,106 2,980,000 1,488,510 84,179,038 2027 51,173,207 23,291,225 7,064,755 2,980,000 1,488,510 85,997,697 2028 53,648,915 21,048,975 8,829,047 2,980,000 1,488,510 87,995,447 2029 53,157,839 21,493,225 10,880,125 2,980,000 1,488,510 89,999,698 2030 53,038,585 33,265,975 1,223,280 2,980,000 1,488,510 91,996,350 2031 52,946,451 34,460,975 - 2,980,000 1,488,510 91,875,936 2032 68,007,025 19,402,350 - 2,980,000 1,488,510 91,877,885 2033 64,820,052 22,589,475 - 2,980,000 1,488,510 91,878,037 2034 67,906,930 19,503,975 - 2,980,000 1,488,510 91,879,415 2035 65,118,740 22,289,725 - 2,980,000 1,488,510 91,876,975 2036 66,994,106 20,414,725 - 2,980,000 1,488,510 91,877,341 2037 67,576,349 19,833,950 - 2,980,000 1,488,510 91,878,809 2038 67,984,127 19,423,175 - 2,980,000 1,488,510 91,875,812 2039 67,977,624 19,430,400 - 2,980,000 1,488,510 91,876,534 2040 67,982,551 19,424,800 - 2,980,000 1,488,510 91,875,861 2041 69,020,349 18,389,300 - 2,980,000 1,488,510 91,878,159 2042 69,002,035 18,408,650 - 2,980,000 1,488,510 91,879,195 2043 68,914,791 18,494,275 - 2,980,000 1,488,510 91,877,576 2044 71,163,748 16,242,875 - 2,980,000 1,488,510 91,875,133 2045 71,168,090 16,239,450 - 2,980,000 1,488,510 91,876,050 2046 71,222,736 16,188,525 - 2,980,000 1,488,510 91,879,771 2047 71,215,381 16,196,900 - 2,980,000 1,488,510 91,880,791 2048 54,036,967 33,373,950 - 2,980,000 1,488,510 91,879,427 2049 54,034,052 33,375,075 - 2,980,000 1,488,510 91,877,637 2050 54,032,163 8,960,700 - 2,980,000 25,909,139 91,882,002 2051 54,032,391 - - 12,313,823 25,534,884 91,881,097 2052 - - - 91,873,823 - 91,873,823 Total(1): $2,076,803,303 $675,000,162 $46,135,022 $199,034,423 $97,331,479 $3,094,304,389
______(1) Includes all outstanding debt service giving effect to the refunding by the 2018 Bonds. See “PLAN OF FINANCE” herein. (2) Interest rate assumed at 2.98% for tax-exempt unhedged variable rate bonds and 3.285% for taxable unhedged variable rate bonds. (3) $91.2 million of Series 2015C-H Bonds is subject to mandatory tender in 2023 and $98.8 million thereof is subject to mandatory tender in 2025; amortization reflected here is based on expected final maturity of September 1, 2041. (4) The Abington Series B of 2012 Bonds are subject to mandatory tender on February 13, 2020 with a nominal maturity date of June 1, 2035. (5) Interest rate assumed at 2.98%.
39
CERTAIN INVESTMENT CONSIDERATIONS
The following are certain investment considerations that have been identified by the University and should be carefully considered by prospective purchasers of the Series 2018D Bonds. Such discussion is not, and is not intended to be, exhaustive and should be read in conjunction with all other parts of this Official Statement and the appendices attached hereto and should not be considered as a complete description of all risks or other factors that could affect payment or the value of the Series 2018D Bonds. Prospective purchasers of the Series 2018D Bonds should analyze carefully the information contained in this Official Statement, including the Appendices attached hereto.
General
The Series 2018D Bonds are special limited obligations of the Authority and are payable solely from the respective sources identified in the 2018D Indenture including Pledged Revenues (as defined within the 2018D Indenture), which consist generally of all amounts payable to the Trustee with respect to the principal, purchase price or redemption price of and interest on the Series 2018D Bonds under the 2018D Loan Agreement by TJU and investment income with respect to certain funds held by the Trustee under the 2018D Indenture. The Trust Estate under the 2018D Indenture also includes certain funds held by the Trustee pursuant to the 2018D Indenture and payments made by the Obligated Group pursuant to the Master Note. No representation or assurance can be given to the effect that the Obligated Group will generate sufficient revenues to meet the payment obligations for its Indebtedness. Future legislation; regulatory actions; economic conditions; legal matters; competition from other health care providers; the capability of the University’s management; third-party reimbursement from payors, including government payors; pressures from third-party payors to limit and control healthcare costs; the availability and affordability of professional liability insurance; increases in the amount of bad debt; rising numbers of uninsured and underinsured individuals; the reduced benefit liability from commercial and governmental health insurance plans, health plans and thirty-party payor insolvencies; scientific and technological advances, new procedures, drugs and appliances; or other factors could adversely affect the University’s ability to generate such revenues. Neither the Underwriter nor the Authority have made any independent investigation of the extent to which any such factors could have an adverse impact on the revenues of the University or the University’s higher education and healthcare operations.
Covenant to Maintain Tax-Exempt Status of the Series 2018D Bonds
The tax-exempt status of the Series 2018D Bonds is based on the continued compliance by the Authority and the University with certain covenants contained in the 2018D Indenture, the 2018D Loan Agreement, and certain other documents executed by the Authority and TJU, on behalf of the Obligated Group in connection with the Series 2018D Bonds, the Series 2018A Bonds and the Series 2018C Bonds. These covenants are aimed at satisfying applicable requirements of the Internal Revenue Code of 1986, as amended (the “Code”) and relate generally to use of the proceeds of such series of 2018 Bonds, if applicable, maintenance of the status of the Members of the Obligated Group as organizations meeting the requirements of Section 501(c)(3) of the Code, arbitrage limitations, rebate of certain excess investment earnings to the federal government and restrictions on the amount of issuance costs financed with the proceeds of the Series 2018D Bonds,
40
the Series 2018A Bonds and the Series 2018C Bonds, if applicable. Failure to comply with such covenants could cause interest on the Series 2018D Bonds to become subject to federal income taxation retroactive to the date of issuance of the Series 2018D Bonds.
Unrelated Business Income
The IRS from time to time may undertake audits and reviews of the operations of tax-exempt hospitals with respect to their exempt activities and the generation of unrelated business taxable income (“UBTI”). The University participates in activities which generate UBTI. The University believes it has properly accounted for and reported UBTI; nevertheless, an investigation or audit could lead to a challenge which could result in taxes, interest, and penalties with respect to unreported UBTI, and may negatively affect the tax exempt status of the University and/or its entities.
Decreases in Federal and Commonwealth Research and Other Grants and Contract Funding
The University’s ability to retain research staff and meet budgetary forecasts depends, in part, on receiving research funding from federal and state agencies, as well as other sponsors. The continual reduction of the dollar amount and numbers of grants issued by the National Institutes of Health resulting from federal budget constraints has created an increasingly competitive environment for attracting grants.
Moreover, generally over the prior several fiscal years, the Governor of Pennsylvania proposed budgets that called for decreases in payments made to physicians under the Commonwealth’s programs known as “Physician Payment Initiative” and for the elimination of research grant dollars under the “Commonwealth Universal Research Enhancement Program.” No assurances can be given that future Commonwealth budgets, or with respect to certain educational programs at the University, State of Delaware budgets, will not reduce or eliminate, in total, dollars supporting these or other programs providing funds to the University. Any such reduction or elimination can have an adverse impact on the University’s financial performance and operations. See “RESEARCH ACTIVITIES” in “APPENDIX A - DESCRIPTION OF THE UNIVERSITY” attached hereto for a discussion of funding of research at the University and the amount of operating revenues from grants and contracts for certain recent fiscal years.
Local Tax Assessments
In recent years, a number of local taxing authorities in the Commonwealth have sought to subject the facilities of non-profit healthcare, higher educational and other traditionally exempt organizations to local real estate and business privilege taxes, primarily by challenging their status as “institutions of purely public charity” as described in the Pennsylvania Constitution, notwithstanding the fact that Pennsylvania nonprofit facilities historically have been viewed as exempt from such taxes. The Pennsylvania constitutional test is very subjective and frequently difficult to satisfy. Pennsylvania court decisions have been highly fact-specific and do not provide clear overall guidance on the question. In addition, the Pennsylvania law sets forth additional standards that must be satisfied for tax exemption. A Commonwealth Court decision within recent years which found that a nonprofit group home met the standards of the Pennsylvania law but not
41
the Constitutional requirements to qualify for property tax exemption, coupled with a special report of the Pennsylvania Auditor General that examined the additional tax revenues that might be available from tax-exempt organizations and the financial pressures on municipal and state governments, may increase the pressure on tax-exempt entities to enter into agreements with local counties to make payments in lieu of taxes (PILOT or SILOT agreements) or face lengthy and expensive litigation as to their status under the Constitution and the law. Therefore, there is no assurance that under current Pennsylvania law that the University will remain exempt from Commonwealth sales and use tax and county real estate and other local taxes.
Similar challenges have also occurred within the State and the New Jersey based Members of the Obligated Group recently entered into PILOT agreements with the municipalities in which they are located. There is no assurance that under New Jersey law that the applicable Members of the Obligated Group will remain exempt from real property and other New Jersey state and local taxes.
Enforceability of Obligations of Obligated Group Members
Limitation of Security Interest in Gross Revenues. The security interest in the Gross Revenues of a Member of the Obligated Group may not extend to any revenues generated from the use and operation of such Member’s property after any person other than such Member obtains possession of such property, whether by voluntary transfer, foreclosure under a mortgage or other security agreement or enforcement of a statutory or judicially created lien. The rights of the Master Trustee with respect to Gross Revenues may be subject to a preference claim under the Bankruptcy Code (as hereinafter defined) and to the exercise of discretion by a court of equity which, under certain circumstances, may have power to direct the use of such receipts to meet expenses of the University before paying debt service.
Joint and Several Obligations. All Members of the Obligated Group will be jointly and severally liable for all amounts due under the Master Note with respect to the 2018D Loan Agreement and 2018D Bonds, other Obligations (including Subordinated Obligations) and Parity Indebtedness. The state of insolvency, fraudulent conveyance and bankruptcy laws relating to the enforceability of guarantees or obligations issued by a corporation in favor of the creditors of another, or the obligation of one Member of the Obligated Group to make debt service payments on behalf of another Member is unsettled. The ability to enforce the provisions of the 2018D Loan Agreement, the Master Indenture or any Obligation, including the Master Note, against any Member of the Obligated Group, including future Members, which would be rendered insolvent thereby, may be subject to challenge.
Other Limitations. The effectiveness of the Master Indenture and the security interests created thereunder to secure loan payments related to the Series 2018D Bonds may be limited by a number of factors, including: present or future prohibitions against assignment contained in any federal statutes or regulations, commingling of Gross Revenues with other moneys of an Obligated Group Member or other Affiliate not so pledged; statutory liens; rights arising in favor of the United States of America or any agency thereof and the rights of third parties in Gross Revenues converted to cash and not in the possession of the Master Trustee.
42
Fraudulent Conveyance; Lack of Fair Consideration. Under the United States Bankruptcy Code and state fraudulent conveyance statutes, an obligation may be declared void and a transfer may be avoidable if (i) the obligation has been incurred or transfer effectuated (within two years of the filing of a petition under the Bankruptcy Code, or such longer look-back period as specified in applicable state fraudulent conveyance statutes) without receipt of fair consideration or of reasonably equivalent value of the obligor or transferor; and (ii) the obligor or transferor was insolvent at the time the obligation was incurred or transfer was effectuated, or the incurrence of such obligation, or effectuation of such transfer renders the obligor or transferor insolvent, as defined in the Bankruptcy Code or in the applicable state fraudulent conveyance statue.
Enforceability of Remedies
The remedies available to the Master Trustee, Trustee or Bondholders upon an Event of Default occurring under the Master Indenture, 2018D Indenture or the 2018D Loan Agreement, as applicable, are in many respects dependent upon judicial action which is subject to discretion or delay. Under existing law and judicial decisions, including specifically Title 11 of the United States Code (the “Bankruptcy Code”), the remedies (including, without limitation, specific performance) specified in the Master Indenture, the 2018D Indenture and the 2018D Loan Agreement may not be readily available to the Master Trustee, Trustee or Bondholders, as applicable, or may be limited.
The various legal opinions to be delivered concurrently with the original delivery of the Series 2018D Bonds will be qualified as to enforceability of the various legal instruments by limitations imposed by bankruptcy, reorganization, insolvency or other similar laws or equitable principles affecting creditors’ rights.
Potential Effects of Bankruptcy
Under existing law, if any Obligated Group Member were to file a petition for relief under the Bankruptcy Code, the filing would operate as an automatic stay of the commencement or continuation of any judicial or other proceeding against the applicable Member and its property. If the bankruptcy court so ordered, the Member’s property, including its revenues, could be used for the benefit of the Member despite the claims of its creditors (including the Master Trustee or Trustee).
In a bankruptcy proceeding, a Member of the Obligated Group could file a plan for the adjustment of its debts which modifies the rights of creditors generally or the rights of any class of creditors, secured or unsecured. The plan, when confirmed by the court, would bind all creditors who had notice or knowledge of the plan and discharge all claims against the debtor provided for in the plan. No plan may be confirmed unless, among other conditions, the plan is in the best interest of creditors, is feasible and has been accepted by each class of claims impaired thereunder.
Each class of claims has accepted the plan if at least two-thirds in dollar amount and more than one-half in number of the allowed claims of the class that are voted with respect to the plan are cast in its favor. Even if the plan is not so accepted, it may be confirmed if the court finds that
43
the plan is fair and equitable with respect to each class of non-accepting creditors impaired thereunder and does not discriminate unfairly.
In case of financial difficulties, Members of the Obligated Group may be able to commence state court receivership proceedings.
There can be no assurance that Bondholders or Beneficial Owners will receive all or any amount as payment with respect to the Series 2018D Bonds under any plan or court order resulting from the bankruptcy, receivership or other similar court action.
Continued Utilization of University Hospital Facilities and Factors That Could Result in Increased Competition
A significant portion of the University’s revenues are derived from the inpatient and outpatient treatment of patients at the Thomas Jefferson University Hospitals, Abington Memorial Hospital, Lansdale Hospital, Aria Health facilities, Kennedy Health facilities, and Magee facilities (collectively, the “University Hospitals”) by members of JUP and other medical staff members. Physicians on the University Hospitals’ medical staff who have clinical privileges at other hospitals or health care facilities may admit or treat patients at other hospitals or health care facilities that are not affiliated with the University Hospitals, which could result in the decrease of the University’s revenues.
If a significant number of the University Hospital-affiliated physicians leave the practice of medicine due to lower reimbursement rates and high costs of obtaining adequate malpractice insurance, the revenues of the University could decrease if the patients previously treated by these physicians receive services at another health care facility or if they otherwise do not receive services at the University Hospitals.
The University Hospitals currently face and will likely continue to face increased competition from other acute care hospitals, specialty hospitals, rehabilitation and therapy centers, freestanding diagnostic imaging centers, physician group practices, and health care facilities that offer comparable health care services to the population which the University presently serves. The University Hospitals could also face additional competition in the future due to the construction of new, or the renovation of existing, hospitals and health care facilities in the areas served by it. No assurance can be given that occupancy of the University Hospitals’ facilities will not be adversely affected by the availability of other hospital and healthcare facilities in their service area and elsewhere.
Expanded preventive medicine and outpatient treatment could also affect the University’s ability to maintain its market share at current levels. Additionally, competition to the University could come from health care providers that offer lower priced services to the same population as the University. For example, proliferation in minute clinics, eye care centers, and urgent care centers nationwide and in the Philadelphia region has resulted in increased competition for hospital systems. The allure of consumers to these clinics and centers may be due to lower out-of-pocket expenses because the limited services available at these facilities are less costly. Further, unlike hospitals, these facilities do not have the level of overhead costs that hospitals do. The convenience of obtaining prescription medications subsequent to receiving care at urgent care centers or minute
44
clinics located in retail pharmacies also contributes to their appeal. Indeed, services provided at these clinics and centers could be substituted for some of the revenue generating services offered by the University Hospitals.
Managed care companies and insurers are becoming increasingly selective in contracting with health care providers. The University also faces potential competition from alternative health care delivery arrangements, such as health maintenance organizations (“HMOs”), preferred provider organizations (“PPOs”), ambulatory surgical centers (“ASCs”), freestanding diagnostic imaging centers, accountable care organizations (“ACOs”) and unaffiliated physician group practices, many of which are designed to offer comparable services at lower prices. The federal government and private third-party payors, such as the Blue Cross programs, may increase their efforts to encourage the development and use of such arrangements. The revenues of the University could decrease significantly with the loss of certain third party payor contracts or if the mix of payor sources should change in materially adverse ways. The development of HMOs and other alternative health delivery programs could also result in decreased usage of inpatient hospital facilities and other facilities operated by the University.
Overall, the effects of such increased competition on the University’s revenue, including pressures for increased discounts in contracts with alternative delivery systems, cannot be predicted.
Health Care Industry Factors Affecting the University
The health care industry is subject to various factors that may limit the University’s ability to meet its obligations to make loan payments for debt service on the Series 2018D Bonds, a number of which are beyond the control of the University. Among other things, the University is subject to significant regulatory requirements of federal, state and local governmental agencies, independent professional organizations and accrediting bodies; technological advances and changes in treatment modes; various competitive factors; changes in third party reimbursement programs; and health care reform initiatives that serve to alter the financing of, payment for and delivery of hospital services.
Healthcare Reform. Since the enactment of the Patient Protection and Affordable Care Act and The Health Care and Education Reconciliation Act of 2010, collectively referred to as the “Affordable Care Act,” Federal and state governmental authorities, health care providers, health care insurers, employer group health plans and others in the health care industry have been engaged in implementing the far reaching changes to various aspects of the healthcare system introduced by the Affordable Care Act, including, among many others, substantial adjustments to Medicare reimbursement, establishment of individual mandates for healthcare coverage, extension of coverage to certain populations primarily through the expansion of Medicaid and private insurance, provision of incentives for employer-provided healthcare insurance and increased oversight provisions. While the Affordable Care Act is still the law of the land, since the inauguration of President Donald Trump in January 2017, the President, Congress and the administrative agencies responsible for its implementation (the Departments of Treasury, Health and Human Services, and Labor) have been systemically unwinding as much of the law and its implementing regulations as is within their legal authority. The need for continuing reform of the issues confronting the country's health care delivery and reimbursement system – including access
45
to coverage, quality care and improved outcomes, and high costs – is not disputed. There is no consensus on how to tackle these issues effectively.
The Affordable Care Act reforms the sources and methods by which consumers will pay for healthcare for themselves and their families. One of the primary goals of the Affordable Care Act is to make health care coverage accessible by making available, or subsidizing the premium costs of, healthcare insurance for consumers who are currently uninsured (or underinsured) and who fall below certain income levels. To the extent all or any of those provisions produce the intended result, an increase in utilization of healthcare services by those who are currently avoiding or rationing their healthcare can be expected and bad debt expenses may be reduced.
The Affordable Care Act also includes programs that link Medicare payments for hospitals and physicians with quality outcomes and the development of new patient care models that stress primary care and community-based care. The objective of these programs is to manage chronic diseases better and to reduce inpatient admissions and other high cost care provided by hospitals.
As noted above, beginning in 2017, President Donald Trump and the leadership of the Republican-controlled Congress commenced actions to repeal the entire Affordable Care Act but their efforts were not successful. In the wake of the failure to repeal the Affordable Care Act in its entirety, Congress and President Trump have turned to an incremental repeal approach. On December 22, 2017, President Trump signed the Tax Cuts and Jobs Act, which repeals the individual mandate requiring individuals to have health care coverage. Beginning in 2019, individuals will no longer face a tax penalty if they do not maintain health insurance coverage throughout the year. The Congressional Budget Office estimates that the elimination of the individual mandate will lead to 13 million individuals dropping health care coverage. This reduction in anticipated coverage after 2018 may increase the amount of uncompensated care provided by the University.
Frustrated with the progress of the legislature, President Trump, by Executive Order, directed the Department of Treasury, the Department of Labor, Department of Health and Human Services (“HHS”) and its Center for Medicare & Medicaid Services (“CMS”) to identify, review and amend or rescind Affordable Care Act regulations with the intent of reversing the Affordable Care Act’s reforms wherever possible. In response, the agencies shortened the 2018 enrollment period for the Marketplace Exchange plans, reduced the funding for the communication and outreach programs related to the enrollment period and published a number of proposed regulations that will allow individual insurance coverage to be sold on the private market without meeting the Affordable Care Act minimum essential benefits and subject only to state insurance regulation. More recently, President Trump issued another Executive Order calling for the government to stop making cost-sharing reduction payments to insurance companies under the Affordable Care Act. According to the Trump Administration, there is no appropriation for such payments. As the issuers of the exchange plans will still be obligated to bear the costs of the cost- sharing reductions, premiums for exchange plans that remain in the market would be expected to rise dramatically. Many plans have termination provisions which allow them to terminate their 2018 contracts if the cost-sharing subsidies are not paid. On October 13, 2017, eighteen states and the District of Columbia sued the administration to restore the funding. If funding is restored to issuers of the exchange plans, it could preclude such issuers from increasing premiums for exchange plans that remain in the market.
46
President Trump also issued an Executive Order requiring the relevant agencies to consider regulations or guidance allowing more employers to form association health plans (“AHPs”), and expanding the availability of short-term, limited-duration insurance (“STLDI”). In an HHS February 21, 2018 proposed rule stemming from this Executive Order, HHS proposed to allow STLDI to be sold for 12-month coverage periods, instead of the current three-month coverage period, and acknowledged that such STLDI policies would not be subject to Affordable Care Act rules, including requirements to cover 10 essential health benefits and pre-existing conditions without annual or lifetime limits. If the changes under the proposed rule come to fruition, younger and healthier people are expected to be siphoned from exchange products and into cheaper AHPs and STLDI plans—that will likely offer less adequate coverage—creating adverse selection. Premiums will rise for those left in the exchanges, making the cost of health care burdensome. These potential changes may in turn result in an increase in the amount of uncompensated care provided by the University.
HHS has also taken steps to reduce the federal government's Medicaid expenditures by, among other steps, streamlining the process for States to obtain waivers of the Medicaid coverage mandates. For example, CMS recently approved Kentucky’s plan to introduce employment requirements for Medicaid eligibility. While the Affordable Care Act cannot be repealed in its entirety through regulatory actions, the implementation of the law may be curtailed significantly by these regulatory actions and the changes may lead to further withdrawals by health insurance carriers from the Marketplace Exchanges, higher premiums or less comprehensive benefits coverage and an increase in the number of uninsured individuals in the future.
More recently, on February 26, 2018, a group of 20 states attorneys general filed a lawsuit in Texas federal court against the Affordable Care Act. With the elimination of the individual mandate under the Tax Cuts and Jobs Act, the coalition claims that the Affordable Care Act “must fall.” It is impossible to predict the effect of the lawsuit since it was just filed.
Under the Trump Administration there can be no guarantee that federal and state health insurance programs will continue to be funded at their current rate. Budgetary and financial constraints in states, as well as severe limitations on the method of acquiring increased federal financial participation payments through the use of provider taxes and donations, have called into question the ability of public agencies such HHS or the Department of Human Services in Pennsylvania (“DHS”) (formerly the Department of Public Welfare) to make adequate and timely payments to providers. Further, while expanded Medicaid coverage will likely result in fewer uninsured patients, rates paid for Medicaid patients have historically not covered the full costs of their care and there is no guarantee that the rates will ever cover the cost of such care. The interim or long term effects of the Affordable Care Act, or any legislation amending, repealing or replacing it on the University cannot be predicted with any degree of certainty. The impact of the changes to the Affordable Care Act and the rules regarding its implementation discussed above as well as other changes which Congress and the President may pass in the future cannot be currently ascertained, but they could have a material negative impact on the University’s operations. In addition, the factors described herein could have a material negative impact on the University’s operations.
47
Overview of Medicare and Medicaid Program
Medicare and Medicaid are the commonly used names for health care reimbursement or payment programs governed by certain provisions of the federal Social Security Act Amendments of 1965. The federal government, the largest health care purchaser in the country, uses reimbursement as a key tool to implement health care policies, to allocate health care resources and to control utilization, facility and provider development and expansion, and promote the use and development of health technology. These programs reflect the national policy that persons who are aged and persons who are poor should be entitled to receive medical care regardless of ability to pay. Medicare Part A covers inpatient hospital, home health, nursing home care and certain other services, and Medicare Part B covers certain physicians’ services and the services of other health care professionals, medical supplies and durable medical equipment. Medicare Part C, the Medicare Advantage program, enables Medicare beneficiaries to choose to obtain their benefits through a variety of private, managed care, risk-based plans. Medicare Part D makes outpatient prescription drug benefits available to Medicare beneficiaries. Some Medicare beneficiaries, however, enroll in Medicare Advantage plans, which reimburse providers on a contractually determined basis. Health care providers that participate in the Medicare program must agree to be bound by the terms and conditions of the program such as meeting the quality standards for rendering covered services and adopting and enforcing policies to protect patients from certain discriminatory practices.
Medicaid is designed to pay providers for care given to the indigent and other persons who qualify based on certain conditions. Medicaid is funded by federal and state appropriations and is administered by DHS.
Conditions of Participation. Hospitals must comply with standards called “Conditions of Participation” to be eligible for Medicare and Medicaid reimbursement. CMS is responsible for ensuring that hospitals meet these regulatory Conditions of Participation. Under applicable Medicare rules, hospitals accredited by The Joint Commission are deemed to meet the Conditions of Participation. Failure to maintain such accreditation or to otherwise comply with the Conditions of Participation or other applicable state licensing requirements could have a material adverse effect on the revenues of the University. In June 2014, The Joint Commission reaffirmed TJU’s accreditation for 10 years. Each of the University Hospitals has a current accreditation from The Joint Commission. There are no assurances that the University Hospitals will continue to receive such accreditation in the future.
Medicare Reimbursement
A substantial portion of the University’s revenues is derived from the Medicare program. Medicare is a federal health benefits program administered by CMS and Medicare Administrative Contractors. Available to individuals age 65 or over, and certain other classes of individuals, the Medicare program provides health care benefits that cover, within prescribed limits, the major costs of most medically necessary care for such individuals, subject to certain deductibles and co- payments, or in the case of the Medicare Advantage program, premiums.
Diverse and complex statutory and regulatory mechanisms, the effect of which is to limit the amount of money paid to health care providers under the Medicare program, have been enacted
48
and approved in recent years. It is impossible to predict what effect, if any, current and future legislative or regulatory initiatives will ultimately have on the operations of the University. Since revenues from Medicare account for a substantial portion of the University’s revenues, adverse developments or changes in Medicare reimbursement could have a material adverse effect on the financial condition and operations of the University Hospitals.
Under Medicare, the costs attributable to the deductible and coinsurance amounts that remain unpaid by the Medicare beneficiary can be added to the Medicare share allowable costs as cost reports are filed. The University and its entities generally receive interim pass-through payments during the cost report filing. Bad debts must meet specific criteria to be allowable.
The amounts uncollectible from specific beneficiaries are to be charged off as bad debts in the accounting period in which the accounts are deemed uncollectable. In determining reasonable costs for hospitals, the amount of bad debts otherwise treated as allowable costs is reduced by 35%. Amounts incurred by a hospital as reimbursement for bad debts are subject to audit and recoupment by the Medicare Administrative Contractor (“MAC”). Bad debt reimbursement has been a focus of MAC audit and recoupment efforts in the past.
Inpatient Operating Costs. Medicare payments for operating costs incurred in the delivery of inpatient hospital services are based on a prospective payment system (“PPS”) which pays acute care hospitals a fixed amount for each Medicare inpatient discharge based upon the diagnosis and certain other factors used to classify each patient into a diagnosis related group (“DRG”). DRG rates are adjusted annually by the use of an “update factor” based on the projected increase in a market basket inflation index which measures changes in the costs of goods and services purchased by hospitals, but the adjustments historically have not kept pace with inflation. Separate PPS payments are made for inpatient operating costs and inpatient capital-related costs. Some costs are also paid on the basis of “reasonable cost.”
As a general matter, payments are not adjusted for actual costs, variations in intensity of illness, or length of stay. If a hospital treats a patient and incurs less cost than the applicable DRG- based payment, the hospital is entitled to retain the difference. Conversely, if a hospital’s cost for treating the patient exceeds the DRG-based payment, the hospital generally will not be entitled to any additional payment. If, however, a case is unusually complex or expensive, it may qualify for an “outlier” payment, which is added to the DRG-adjusted base rate payment.
Medicare and Medicaid currently make additional payments to hospitals that serve a disproportionate share (“DSH”) of low-income patients. Beginning in 2014, the Affordable Care Act began incrementally decreasing the Medicare DSH payments by $22 billion from 2014 through 2019 and Medicaid DSH payments by $36 billion over a ten year period, based on an assumption that the Affordable Care Act’s new coverage and access provisions will substantially reduce uncompensated care provided by hospitals. Congress has repeatedly delayed the reductions to Medicaid DSH payments. In February 2018, Congress further delayed such payments through 2018 and 2019 in the Bipartisan Budget Act of 2018. Among other measures, the Bipartisan Budget Act of 2018 eliminates the fiscal year 2018 and fiscal year 2019 Medicaid DSH reductions, maintains the $4 billion in reductions for fiscal year 2020, and sets the amount of Medicaid DSH reductions for fiscal year 2021 through fiscal year 2025 at $8 billion per fiscal year.
49
The PPS amount and adjustments described above are calculated using formulae established by CMS that are revised periodically pursuant to federal budgetary policy. There can be no assurance that payments received by the University Hospitals will be sufficient to cover all actual costs of providing inpatient hospital services to Medicare patients.
Hospitals report certain quality measures under the Hospital Inpatient Quality Initiative. Hospitals that report these measures receive the full DRG inflation update - known as the “hospital market basket,” while non-participating hospitals suffer a reduction equal to one-quarter of the applicable annual payment rate update. The market basket update for federal fiscal year 2018 is 2.7%. Some or all of the University Hospitals may participate in CMS’s Hospital Quality Initiative. There is no assurance that future updates in DRG payments will keep pace with the increased costs in providing inpatient hospital services.
Joint Ventures. The University Hospitals participate in a number of joint ventures with tax-exempt or for-profit entities. Participation in joint ventures, particularly joint ventures with for-profit entities, that do not meet requirements of the Code, potentially may (a) result in a finding of inurement or undue private benefit which could result in loss of tax-exempt status, (b) result in a finding of an excess benefit transaction which could result in the imposition of an excise tax on the insider involved in the transaction or on the University Hospitals or their management that knowingly approved the transaction, or both, or (c) result in a finding that the activity is unrelated to the exempt purpose of the University Hospitals and a determination that certain income received by the tax-exempt organization from the joint-venture with the for-profit entity is taxable. See “TAX MATTERS” herein. Management of the University Hospitals does not believe that participation in any such presently existing joint venture will have a material adverse effect on the University Hospitals’ tax-exempt status or financial condition.
Quality-Based Initiatives. CMS periodically promulgates regulations to implement various quality improvement and patient safety programs. Two programs that focus on and reward value of care as opposed to volume of care provided are the Medicare Hospital Value-Based Purchasing (“VBP”) Program and the Hospital Readmissions Reduction (“HRR”) Program.
Under the VBP program, CMS withholds a certain percentage of all qualifying hospitals’ DRG payments and puts the withheld amounts into a fund. The withheld percentage varied until fiscal year 2017. Beginning with fiscal year 2017, the withheld percentage is two percent. CMS then redistributes the amounts withheld based on how well a particular hospital scores in comparison to its peers based on certain healthcare quality and cost measures during a performance period, and how much they improved the quality of care provider to hospital patients over time. There can be no assurance that the University Hospitals’ future scores will be enough to recoup the full percentage payment withholding or to qualify for a bonus under the VBP program.
Under the HRR Program, CMS requires a reduction to a hospital’s base operating DRG payment to account for excess hospital readmissions for certain applicable conditions. For fiscal year 2018 and subsequent fiscal years, CMS bases the HRR Program reduction on a hospital’s risk-adjusted readmission rate during a three year period for the following conditions: acute myocardial infarction, heart failure, pneumonia, chronic, obstructive pulmonary disease, total hip arthroplasty/total knee, arthroplasty, and coronary artery bypass graft. For fiscal year 2018, the applicable three year period is from July 1, 2013 through June 30, 2016. There can be no guarantee
50
that the University Hospitals will be able to avoid penalties under the HRR program for excess readmissions.
Serious, Preventable Events. Since 2008, Medicare has not reimbursed hospitals for the increased costs associated with treating a Medicare beneficiary who acquires certain hospital- acquired conditions (“HAC”) during an inpatient stay. Hospitals are further prohibited from billing Medicare beneficiaries for any charges associated with an HAC. The list of HACs has expanded to 14 categories. Under the HAC Reduction Program, HHS adjusts payments to hospitals that rank in the worst performing 25% with respect to HAC quality measures. In the fiscal year 2018 HAC Reduction Program, hospitals with a total HAC score of greater than 0.3687 may be subject to a payment reduction. While the University Hospitals currently have programs in place to monitor and prevent HACs, it is likely that University Hospitals, like almost all hospitals, will face reduced reimbursement at some point for costs associated with treating HACs.
Outpatient Services. Medicare payments for hospital outpatient services, including hospital operating and capital costs, also are established through a PPS methodology (“OPPS”). Under OPPS, procedures, evaluations, management services, drugs and devices in outpatient departments are classified into ambulatory payment classification (“APC”) groups. Services provided within an APC are similar clinically and in terms of the resources they require. Using hospital outpatient claims data from the most recently available hospital cost reports, CMS determines the median costs for the services and procedures in each APC group. For calendar year 2018, CMS has increased the payment rates under OPPS by an Outpatient Department fee schedule increase factor of 1.35%.
OPPS includes additional adjustments for transitional pass-through payments and outlier payments. Transitional pass-through payments are costs associated with new technology items (drugs, biologicals and medical devices) that were not reflected in the data that CMS used to calculate OPPS payment rates, and are intended to allow for adequate payment of new and innovative technology until there is enough data to incorporate the costs for these items into the base APC group.
Under OPPS, a hospital with costs exceeding the applicable payment rate would incur losses on such services provided to Medicare beneficiaries. There can be no assurance that the hospital OPPS rate, which bases payment on APC groups rather than individual services, will be sufficient to cover all of the University Hospitals’ actual costs of providing hospital outpatient services to Medicare patients.
Physician Payments. Payment for physician services is provided by Medicare Part B. Under Part B, physician services were reimbursed in an amount equal to the lesser of actual charges or the amount determined under a national fee schedule known as the resource-based relative value scale, which sets a relative value for each physician service that is then multiplied by a geographic adjustment factor and a nationally-uniform conversion factor, calculated utilizing the sustainable growth rate (“SGR”) system, to determine the amount Medicare will pay for each service. On April 16, 2015, President Barack Obama signed the Medicare Access and CHIP Reauthorization Act of 2015, which ended use of the SGR. The measure went into effect in July 2015.
51
The SGR formula was repealed and replaced with the following statutorily prescribed updates:
• Effective January 1, 2018, and carrying through 2019, Medicare physician payments will be updated 0.5 percent.
• Beginning January 1, 2020, and carrying through 2025, physician payments will not be updated.
• Beginning January 1, 2026, and effective January 1 of each subsequent calendar year, physician payments will be updated 0.75 percent for physicians who adequately participate in qualified alternative payment models, but only 0.25 percent for those who do not.
In addition to the annual updates described above, physician payments are being transitioned to pay-for-performance models beginning in 2019, where payment rates for physicians will depend on whether the physician chooses to participate in an Alternative Payment Model (“APM”) or Merit-based Incentive Payment System (“MIPS”). Physicians who participate in an APM program will receive a 5% lump sum incentive payment for each year beginning in 2019 and ending in 2024. Physicians who opt to participate in MIPS will receive payments subject to positive or negative performance adjustments equal to +/- 4% in 2019 and increasing gradually to +/- 9% for 2022 and subsequent years. There can be no assurances that reimbursement levels will remain at the present level after that date, potentially negatively impacting the reimbursement amounts received by the University for the cost of providing physician services.
Capital Costs. Hospitals are reimbursed on a fully prospective basis for capital costs (including depreciation and interest) related to the provision of inpatient services to Medicare beneficiaries. Payment for capital related costs for all hospitals are determined based on a multiplying the standardized amount (referred to as the federal rate), by the DRG weight for each discharge and by a geographical adjustment factor. The payments are subject to further adjustment by a DSH factor that contemplates the increased capital costs associated with providing care to low-income patients, and an indirect medical education (“IME”) factor that contemplates the increased capital costs associated with medical education programs. As noted above, the Affordable Care Act includes reductions over time to the DSH payments, though such reductions have been delayed through 2019.
There can be no assurance that the prospective payments for capital costs will be sufficient to cover the actual capital-related costs of the University Hospitals allocable to Medicare patient stays or to provide adequate flexibility in meeting the University Hospitals’ future capital needs.
Medical Education Costs. Under PPS, teaching hospitals receive additional payments from Medicare for certain direct and indirect costs related to their graduate medical education (“GME”) programs. Direct GME payments compensate teaching hospitals for the cost directly related to educating residents such as the residents’ stipends and benefits, the salaries and benefits of supervising faculty, and allocated overhead costs. IME payments compensate teaching hospitals for the higher patient care costs they incur relative to nonteaching hospitals. Those IME payments are issued as a percentage adjustment to the PPS payments.
52
The calculation for both the direct part and the indirect part of Medicare payments for GME include certain limitations on the number and classification of full-time equivalent residents reimbursed by Medicare. PPS hospitals with residents in an approved GME program receive an additional payment for each Medicare discharge to reflect the higher patient care costs incurred by teaching hospitals relative to non-teaching hospitals.
The formulae used to determine payments for medical education do not necessarily reflect the actual costs of such education, and the federal government will continue to evaluate its policy on graduate medical education and teaching hospital payments. There can be no assurance that payments to the University Hospitals under the Medicare program will be adequate to cover their direct and indirect costs of providing medical education to interns, residents, fellows and allied health professionals.
Inpatient Psychiatric Unit Reimbursement. Inpatient psychiatric units such as the unit at JUH are paid according to the inpatient psychiatric facility prospective payment system (“IPF PPS”). Patients who are treated for psychiatric conditions in specialty facilities are covered for 90 days of care per illness with a 60-day lifetime reserve and for 190 days of care in freestanding psychiatric hospitals.
Under the IPF PPS, federal per diem rates include inpatient operating and capital-related costs (including routine and ancillary services) and are determined based on geographic factors, patient characteristics, and facility characteristics. For fiscal year 2018, there is an estimated IPF payment rate of 1.25%. Under the Affordable Care Act, IPFs must report quality data and will be subject to a two percent reduction to the applicable rate for failure to do so. There is no guarantee that the Medicare per diem, as they may change from time to time, will be adequate to cover the actual cost of providing psychiatric services to Medicare patients.
Audits and Withholds. Medicare-participating hospitals are subject to audits and retroactive audit adjustments with respect to reimbursement claimed under the Medicare, Medicaid and commercial programs on an on-going basis. Such adjustments could be substantial and could exceed any reserves maintained for such purposes by the University Hospitals. Medicare regulations also provide for withholding Medicare payment in certain circumstances, and such withholds could have a material adverse effect on the financial condition of the University. See “CERTAIN INVESTMENT CONSIDERATIONS - The Fraud and Abuse Laws” for exposure to audits and withholds.
CMS is reviewing health care providers that are receiving large proportions of their Medicare revenues from outlier payments. Health care providers found to have obtained inappropriately high outlier payments will be subject to further investigations by the CMS Program Integrity Unit and potentially the Office of the Inspector General. Medicare-participating hospitals are also subject to Recovery Audit Contractor (“RAC”) audits. RAC auditors are authorized, in most cases, to look back three years from the date the claim was paid, and to review the appropriateness of each claim by applying the same standards and guidance as would a Medicare contractor. The Affordable Care Act expanded the scope of the RAC program to include Medicare Parts C and D and Medicaid. Medicaid RAC audit programs are overseen by states in accordance with federal guidelines. Medicare RAC recovery amounts have increased substantially over the last couple years. Although RACs are required to identify overpayments and underpayments,
53
RACs have in practice collected significantly more in overpayments from providers than paid out underpayments to providers. Furthermore, the federal and state governments have developed numerous other audit and fraud enforcement programs over the past decade increasing the likelihood that health care entities, like the University Hospitals, participating in Medicare and Medicaid may be subject to audits, retroactive audit adjustments and repayments with respect to reimbursement. Federal and state efforts to take monies back from providers as well as related investigations and, in some cases, criminal prosecutions for overbilling are expected to be prevalent for years to come. It is impossible to predict the effect of such efforts as any resulting future payment adjustments and/or re-payments could be material. Under certain circumstances, payments made may be determined to have been made as a consequence of improper claims subject to the federal False Claims Act or other federal statutes, subjecting the provider to civil or criminal sanctions. The University Hospitals received and responded to thousands of requests for charts in connection with past RAC audits. The RAC audits have been subject to criticism by the provider industry and CMS is making changes in response. In October, 2017, CMS expanded an alternative audit process, known as Targeted Probe and Educate (“TPE”) examinations to the RAC program. The University Hospitals expect to continue to receive TPE and other routine billing audits or examinations of some form from CMS in the future. There is no guarantee that the University Hospitals will not be subject to a RAC recovery in the future. Increased RAC recoupment efforts and other audit programs may have a material impact upon the revenue of the University.
Provider-Based Standards. Certain outpatient services of the University Hospitals are categorized as “provider-based” for reimbursement purposes. The Medicare program reimburses certain facilities and services (including, for example, physician offices and clinics) differently, depending upon whether they are “provider-based” or “freestanding.” A “provider-based” facility or service is an integral part of another provider, such as a hospital. Certain administrative costs and overhead of the provider organization must be allocated in part to the provider-based organization. “Freestanding” providers are not considered part of another provider for purposes of the Medicare program and stand on their own for reimbursement purposes. For any given facility or service, it is probable that one classification or the other will result in a higher aggregate reimbursement for the system as a whole. However, Section 603 of Bipartisan Budget Act of 2015 changed how CMS reimburses for such provider-based outpatient services that are established on or after November 2, 2015, by excluding new off-campus provider-based outpatient departments from the OPPS as of January 1, 2017. These sites are instead reimbursed under the applicable non-hospital payment system: the physician fee schedule. This may deter the University from establishing any new off-campus provider-based outpatient departments.
If CMS learns that a provider has treated a facility or organization as “provider-based” and the provider had not obtained a determination of that status from CMS, under strict provider-based regulations, the provider may be required to repay overpayments made by CMS due to such erroneous treatment by the provider. CMS may also review a past determination of “provider- based” status if it believes that the past determination was in error, in which case CMS will cease to treat the facility or organization as “provider-based.” In the event that the University Hospitals’ outpatient services billed on a provider-based basis are found to be out of compliance with the current provider-based regulations, the University could be liable for Medicare overpayments.
54
Exclusions from Medicare and Medicaid Participation. The Office of Inspector General for HHS (“OIG”) is required to exclude from federally funded governmental program participation, including Medicaid, for not less than five years, any individual or entity who has been convicted of a criminal offense relating to the delivery of any item or service reimbursed under Medicare and/or Medicaid; any criminal offense relating to patient neglect or abuse in connection with the delivery of health care; felony fraud against any federal, state or locally financed health care program; or an offense relating to the illegal manufacture, distribution, prescription or dispensing of a controlled substance. The OIG has the authority to exclude individuals and entities from participation in federal health care programs who are deemed “untrustworthy.” Additionally, there is a prohibition against employing providers and contracting with providers and vendors, including entities and individuals, who are on the OIG exclusion list. HHS also may exclude individuals or entities under certain other circumstances, such as for a conviction of fraud, theft, embezzlement, breach of fiduciary duty or other financial misconduct relating either to the delivery of health care in general or to participation in a federal, state or local government program. Exclusion means that no Medicare and/or Medicaid program payments may be made for any services rendered by an excluded party. On January 12, 2017, the OIG issued a final rule to expand and strengthen its authority to exclude individuals and entities from participation in federal health care programs, among other changes. Under the final rule, the OIG built on existing authority to impose penalties for a broader array of conduct by expanding the grounds for exclusion. The final rule’s effective date was temporarily postponed until March 21, 2017 due to a January 20, 2017 memorandum issued by President Trump, which delayed the implementation of pending regulations to allow for review by his administration.
Any action to exclude the University Hospitals from Medicare and/or Medicaid could have a significant adverse impact on the University because no program payments can be made to any provider who is excluded. Additionally, the University Hospitals regularly check the OIG exclusion list to ensure it is not contracting with or employing providers or vendors excluded from federally funded governmental program participation, including Medicaid. The University believes its efforts are in compliance with the requirement that it ensure it does not employ or contract with any individual or vendor who is excluded from federal funded program participation, but there can be no assurance that these efforts will not fail to detect an individual provider or vendor employed or contracted by the University who is excluded from federally funded governmental program participation. Such failure could have an adverse impact on the University.
Models for Care Under the Affordable Care Act. Among various other programs, the Affordable Care Act directed HHS to establish and implement various ACO programs, including the Medicare shared savings program (“MSSP”), which promotes accountability for the care of Medicare beneficiaries and encourages coordination of care and other efficiencies through ACOs. If an ACO realizes savings in Medicare expenditures above an expenditure benchmark established by CMS for the group, and meets or exceeds quality performance standards established by HHS, it will be paid a share of Medicare’s savings. Going forward, CMS has made it clear that ACOs will be expected to share in both the savings and losses generated. In 2015, HHS issued a final rule which included allowing eligible ACOs to continue participation for a second agreement period under a one-sided shared savings model where the ACO is not responsible for any portion of losses in the first three years, the addition of a new performance-based risk option that includes prospective beneficiary assignment and a higher sharing rate and a streamlined process for ACOs to access Medicare beneficiary claims data. In 2016, HHS issued a final rule which included an
55
option for ACOs to continue MSSP participation for a second agreement period under a two-sided shared savings model. In late 2016, CMS announced an additional ACO model designed to incorporate more limited downside risk than is present in certain other models under the MSSP.
In addition, although final rules for the MSSP published jointly by the OIG and CMS on October 29, 2015 provide for waivers of certain federal fraud and abuse laws, there may remain regulatory risks for participating hospitals, as well as financial and operational risks. The applicable regulating bodies have published guidance for MSSP ACOs to follow in order to comply with the law, but the published guidance is complex. In particular, since the federal MSSP ACO regulation does not preempt state law, Pennsylvania providers participating as a federal ACO must be organized and operated in compliance with any existing Pennsylvania statutes and regulations. Numerous organizations have formed ACOs and been selected by CMS to participate in the MSSP. In addition, private insurers are establishing similar incentives for providers, while requiring less infrastructural and organizational change. The potential long-term impacts of these initiatives and the regulation of ACOs are unknown, but introduce greater risk and complexity to health care finance and operations. There are currently 39 ACOs in Pennsylvania. Certain of the University Hospitals are a member of the Accountable Care Organization of Pennsylvania, LLC d/b/a Delaware Valley ACO (“ACO-PA”), which was formed in January 2011. See “HEALTHCARE ACTIVITIES - Delaware Valley ACO” in “APPENDIX A - DESCRIPTION OF THE UNIVERSITY” attached hereto.
The Affordable Care Act provides a number of programs designed to improve the quality of care while at the same time lowering costs. The “Bundled Payments for Care Improvement Initiative” (“BPCI”) program is one such program comprised of four models. Under the BPCI program, providers receive one payment for all services provided to a Medicare patient during an episode of care. The BPCI Model 2, for example, involves a retrospective bundled payment arrangement under which actual expenditures are reconciled against a target price for an episode of care. The bundled payment combines payment for physicians, hospitals and other services provided during the single episode of care. The entity receiving the payment is then responsible for distributing the payment to each provider. If the providers work together to provide higher quality care at a low cost, they will realize a profit. However, if providers are unsuccessful in reducing costs, they will lose money on the BPCI program. As of January 1, 2018, the Bundled Payments for Care Improvement Initiative Model 2 has 472 participants in Phase 2. AMH is currently the only University Hospital participating in the BPCI program. If other University Hospitals choose to participate in the future, along with AMH, there can be no guarantee that the bundled payments will be sufficient to cover all of AMH’s or the other participating University Hospitals’ actual costs of providing services to Medicare patients.
On January 9, 2018, CMS announced its plan to add a voluntary bundled payment model to the mix of pay for value and performance options available to providers in the Medicare fee- for-service program: Bundled Payments for Care Improvement Advanced (BPCI Advanced). Under BPCI Advanced, participants (providers and practitioners) will have the opportunity to earn additional payment for one or more of 32 different clinical episodes of care (e.g., inpatient, major joint replacement of the lower extremity), if Medicare fee-for-service expenditures during the applicable episodes of care (typically the admission date until 90 days post-discharge) remain under a spending target. A single retrospective bundled payment will be tied to performance on seven quality measures (e.g., all-cause hospital readmission measure). In addition to bearing
56
“down-side” financial risk, participants will be required to use certified electronic health records. The BPCI Advanced performance period will be from October 1, 2018 through December 31, 2023, and during this time, participants must commit to be held accountable for one or more of the 32 enumerated clinical episodes until January 1, 2020. After this first performance period, CMS will provide the opportunity for additional participation in January 2020. This model will have voluntary participation, unlike the mandatory hip fracture and cardiac bundled payment models, which CMS cancelled late last year. Following the recent announcement of this model addition, it is impossible to know the effect on the future operation of the University.
Medicare Advantage. Most individuals who are entitled to Medicare Part A benefits and enrolled in Medicare Part B may elect coverage under either the traditional Medicare fee-for- service program (Parts A and B) or a Medicare Advantage (“MA”) Plan. A MA plan may be offered by a coordinated care plan (such as an HMO or a PPO), a provider sponsored organization (“PSO”) (a network operated by health care providers rather than an insurance company), a private fee-for-service plan, or a combination of a medical saving account (“MSA”) and contributions to an MA plan. Each MA plan, except an MSA plan, is required to provide benefits approved by the Secretary of HHS. An MA plan will receive a monthly capitated payment from HHS for each Medicare beneficiary who has elected coverage under the plan. Health care providers, such as the University Hospitals, must contract with MA plans to treat MA enrollees at agreed upon rates or they may form a PSO to contract directly with HHS as a MA plan. Some or all of the University Hospitals may contract with various MA plans.
The shift of Medicare eligible beneficiaries from traditional fee-for-service to MA programs was intended to increase competitive pressure to improve benefits, reduce premiums and generate cost reductions. However, because the cost of the MA programs was on average 114% higher than traditional fee-for-service, the Affordable Care Act amended some of the MA payment methodologies.
Rate reductions and increased recoupment efforts in the MA program may have an impact on reimbursement from these insurance plans, which in turn may have a material negative impact upon the revenue of the University.
Medicaid Reimbursement
Medicaid is a partially-funded state program of medical care for the poor. States obtain federal matching funds for their Medicaid programs by obtaining the approval of CMS of a “state plan” which conforms to Title XIX of the Social Security Act and its implementing regulations. Under broad federal guidelines, each state establishes and administers its own Medicaid program, which includes determining its own eligibility standards, determining the types, amount, duration, and scope of services, and setting the rate of payment for services. After a state plan is approved, the federal government provides federal matching funds for Medicaid expenditures.
While the Affordable Care Act required each state to expand Medicaid coverage to include individuals with household income up to 138% of the FPL, beginning in January 2014, the United States Supreme Court rejected that mandate. As a result, each state has the option to expand Medicaid eligibility. The federal government funds a substantial portion of the coverage expansion costs. Under Governor Corbett, Pennsylvania adopted a modified form of Medicaid
57
expansion approved by CMS, the “Healthy Pennsylvania” plan, beginning in January 2015 that expanded coverage to include adults earning below 133% of the FPL subject to numerous eligibility and program requirements. Shortly after taking office in 2015, Pennsylvania Governor Wolf ended Healthy Pennsylvania in favor of a traditional expanded Medicaid program. In addition to individuals who qualified previously, Pennsylvanians ages 19 to 64 with incomes up to 138% of the Federal Poverty Level are eligible for coverage under Governor Wolf’s Medicaid expansion plan.
There can be no guarantee that Medicaid will continue to be funded at its current rate, especially given recent attempts by Congress to change the federal government's funding from a fee participation to a block grant methodology, shifting more of the financial risk to the states. Budgetary and financial constraints in Pennsylvania, as well as severe limitations on the method of acquiring increased federal financial participation through the use of provider taxes and donations have called into question the ability of DHS to make adequate and timely payments to providers. Further, there is no guarantee that rates paid for Medicaid patients will cover the costs of their care.
Medicaid Managed Care. In Pennsylvania, most Medicaid beneficiaries, including those in the University’s service area, are required to enroll in managed care plans known as “Health Choices,” that provide services on a prepaid basis. Medicaid recipients will receive physical health services through one managed care organization and behavioral health services through another managed care organization. The Community HealthChoices program addresses long-term care and nursing home costs for the elderly and physically disabled. The HealthChoices program has generally resulted in stricter utilization review of Medicaid-reimbursed hospital services and reduced lengths of stay and/or reimbursement compared with the previous fee-for-service system. The program also attempts to negotiate lower fee schedules with health care providers. There can be no assurance that the University Hospitals will be successful in contracting with the assigned managed care organizations or that the reimbursements from these managed care organizations will be sufficient to cover the costs of delivering care to Medicaid recipients.
CMS, under the administration of President Trump, has outlined its vision to reset the Medicaid federal-state partnership and give the states more control to design innovative programs through a new and expedited approach to Section 1115 demonstration programs, state plan amendments and 1915 waivers of the federal benefits requirements, CMS also intends to develop Scorecards to track and publish state and federal Medicaid improved health outcomes. These programs will take time to filter down to the hospital and outpatient provider level and their impact will also depend on whether Pennsylvania modifies its HealthChoices program in response. As a result, management cannot assess the impact that these new federal programs will have on the University.
Inpatient Services. Payment for inpatient services is made to hospitals in an amount determined in accordance with procedures and standards established by state law under federal guidelines. In addition to direct payments, the University Hospitals also receive reimbursement for services to Medicaid patients from certain HMOs that have contractual arrangements with DHS to provide coverage for such patients. Providers participating in Medicaid must accept Medicaid payment rates as payment in full.
58
Since 1984, Medicaid payment for operating and capital-related costs of acute care services has been based on a PPS similar to the federal Medicare DRG-based PPS. In 2010, when the State Plan was amended, Medicaid payment for inpatient hospital services was modernized by establishing a uniform base rate for all hospitals using the most current cost information, and making adjustments for differences in regional labor costs, teaching programs, and Medical Assistance volume. At the same time, hospital payments through the state’s Medicaid managed care program were enhanced, and additional matching Medicaid funds were obtained through the establishment of the Quality Care Assessment, a tax on hospital net inpatient revenues that allows the state to access additional federal dollars.
Through Pennsylvania’s Act 49 of 2010, DHS was authorized to impose a statewide hospital assessment on the net inpatient revenue of all Pennsylvania licensed acute care hospitals, with some exclusions, from July 1, 2010 through June 30, 2013. Act 49 itself modernized Pennsylvania’s inpatient hospital fee-for-service payment system, introduced enhanced hospital payments through Pennsylvania’s Medicaid managed care program, and secured additional matching Medicaid funds through the establishment of the Quality Care Assessment (“QCA”). Act 49 replaced the former clinical classification system with a new clinical classification system (“APR-DRG”) in which payments more accurately reflect the levels of service and patient needs unique to Medical Assistance patients. Next, Pennsylvania’s Act 55 of 2013 reauthorized the statewide hospital QCA for an additional three years: July 1, 2013 through June 30, 2016. More recently, Pennsylvania’s Act 92 of 2015 reauthorized the statewide hospital QCA through June 30, 2018. The Assessment is currently 3.71% of net inpatient revenues of the covered hospital. Through the significant amount of revenue that the assessment raises, Pennsylvania has been able to: maintain an updated inpatient payment system; to make changes to existing DSH payments and supplemental payments; and generate new payments where applicable. There can be no assurance that under Pennsylvania’s Hospital Assessment Initiative the enhanced payments received by the University Hospitals will equal or exceed the assessment amounts.
Disproportionate Share Payments (“DSH”), Medical Education Payments and Other Supplemental Payments. In addition, states must make DSH payments to qualified hospitals that provide services to a disproportionately large number of Medicaid, low income and/or uninsured patients. The Affordable Care Act provided for a gradual reduction in the federal funding for Medicaid DSH based on the assumption that the subsidized exchange premiums and expanded Medicaid eligibility would reduce the levels of uninsured care provided by hospitals. The effective date of those reductions, initially scheduled to begin in fiscal year 2014, has been delayed several times and had been scheduled for fiscal years 2018 through 2025. The Bipartisan Budget Act of 2018 removed the $5 billion DSH payment cuts scheduled for 2018 and 2019, but added additional DSH payment cuts of $4 billion in 2020 followed by incremental increases averaging $8 billion per year from 2021 through 2025.
Often DSH payments are insufficient to cover a hospital’s costs in providing care to such patients, and in light of the DSH payment reduction, there can be no assurance that any future DSH payments will cover University Hospitals’ costs. There can be no assurance that future Medicaid inpatient reimbursement rates will remain at current levels, or that such rates will cover University Hospitals’ costs of providing inpatient care to Medicaid patients.
59
Serious, Preventable Events. The Affordable Care Act required CMS to incorporate non- payment policies for certain HACs into the Medicaid regulations, including non-payment polices for provider preventable conditions. States have discretion to add additional HACs and provider preventable conditions to their non-payment policies. The University Hospitals currently have a program in place to monitor and prevent HACs, PPCs and OPPCs. Even with these programs in place, it is likely that the University Hospitals, like almost all hospitals, will face reduced reimbursement at some point for costs associated with treating HACs and provider preventable conditions.
The Pennsylvania Preventable Serious Adverse Events Act. Enacted in June 2009, this Act prohibits heath care providers from knowingly seeking payment for a “preventable serious adverse event” (“PSAE”) A PSAE is an event that occurs in a health care facility that is within the health care provider’s control to avoid, but that occurs because of an error or other system failure and results in a patient’s death, loss of body part, disfigurement, disability, or loss of bodily function lasting more than seven days or still present at the time of discharge from the health care facility. If a PSAE is discovered after payment has been made or a claim has been filed, the payment must be refunded within 30 days of the discovery or receipt of payment, whichever is later.
Outpatient Services. Fee-for-service Medicaid provides payment for hospital outpatient services rendered based on the lower of the usual charge to the general public for the same service or the Medicaid maximum allowable fee, or the upper limit established by Medicare or Medicaid. Pennsylvania's HealthChoices physical health managed care plans, the mandated coverage for all Medicaid recipients, reimburses for care provided to their enrollees based on the contract rates negotiated between the provider and the plan.
Inpatient Mental Health and Rehabilitation Services. Fee-for-service Medicaid provides payment for inpatient mental health and rehabilitation services rendered to eligible recipients by psychiatric hospitals and rehabilitation distinct part units at a per diem rate. Pennsylvania's HealthChoices behavioral health managed care plans, the mandated coverage for all Medicaid recipients, reimburses for care provided to their enrollees based on the contract rates negotiated between the provider and the plan.
Physician Payments. Under the Affordable Care Act, Medicaid reimbursement rates for primary care physicians were increased to Medicare levels in 2013 and 2014. However, that increase expired beginning January 2015. Thus, it appears that since January 2015, the University Hospitals faced reduced reimbursement for their Medicaid population. There is no guarantee that the reimbursement to physicians for treating the expanded Medicaid population will cover the costs of treating these patients.
Third Party Payers
In addition to government payors, the University Hospitals also receive reimbursement for services from commercial insurance companies and Blue Cross organizations under group and individual insured plans as well as self-funded employer group plans administered by the insurance companies.
60
Commercial Insurance (Indemnity). Most commercial insurance companies contract with hospitals on an “exclusive” or a “preferred” provider basis and pay for covered services based on prospectively established charges or negotiated rates, subject to various limitations, coinsurance provisions and deductibles depending on the coverage or plan involved. Certain agreements contain retrospective audit clauses allowing the payor to review and adjust claims subsequent to initial payment.
No assurance can be given as to whether commercial insurance revenues received by the University Hospitals under existing or future contractual arrangements, in addition to their other revenue sources, will be sufficient to cover the University Hospitals’ patient care costs in the future. Similarly, no assurance can be made that retrospective audits conducted by commercial insurers will not result in the recoupment of payments already made.
Managed Care Plans: HMO, PPO, EPO and High Deductible Plans. Most private insurers have introduced managed care plans, including HMOs, PPOs, exclusive provider organizations (EPOs), limited network plans and high deductible plans (HDP) for employees and individuals enrolling for coverage through their employer or from an exchange established under the Affordable Care Act. Under these plans, there may be financial incentives for subscribers to use hospitals that contract with those insurers (“network” providers). Commercial insurers, including but not limited to those insurers who contract with the federal government to cover Medicare Advantage beneficiaries are increasingly offering limited and tiered network plans and HDPs. HDPs reimburse for preventive care without cost-sharing but all other medical expenses are the responsibility of the subscriber until a high dollar threshold is reached. As HDPs proliferate, the University Hospitals will be responsible to collect a larger portion of their reimbursement from the individual patients and their families resulting in higher costs of collection and likely resulting in an increase of bad debt for the University.
Under an EPO, the payors limit coverage to those services provided by network hospitals and physicians, other than for emergency care. These types of plans may direct patients away from non-network hospitals by denying coverage for services provided by them. If the University Hospitals are excluded from EPOs, limited networks or top tiers of tiered networks they may experience reduced reimbursement from commercial insurers.
Exchange Plan Coverage. The Affordable Care Act requires states to either establish and operate a health insurance exchange or participate in a multi-state or federal exchange. Pennsylvania and New Jersey opted not to establish their own exchanges; federally facilitated exchanges are available for individuals in each state to buy coverage through the exchange. The health care plans offered on the federal exchange are operated by commercial payors and include various levels of coverage and provider access. The plans include traditional indemnity and managed care plans such as PPOs, EPOs, and high deductibles.
Under the Affordable Care Act, insurers offering exchange plans must make subsidies available to assist with paying the premiums and copayment of exchange plans for individuals living in households with earned income of less than 400% of the FPL. The availability of the subsidized coverage on the exchanges has resulted in a reduction in uninsured patients in the Commonwealth. However, in 2017 the Trump Administration announced that the federal government would no longer make cost-sharing reduction payments to reimburse such insurers for
61
reducing deductibles and copays for lower-income individuals. As a result, states, including Pennsylvania, instituted higher rate increases for plans sold on the Affordable Care Act exchanges, which could drive healthy individuals out of the exchanges.
Additionally, the Affordable Care Act exchanges are experiencing defections by private insurers due to the losses they have experienced in offering plans on such exchanges. For example, Aetna and UnitedHealthcare withdrew completely from the 2017 individual market under the Affordable Care Act exchanges in Pennsylvania. Exchanges may have originally contributed to the reduction in charity care for hospitals, but if defections by private insurers continue, hospitals nationwide, including the University Hospitals, may have to render more charity care. As a result, the University Hospitals may be required to provide services for which they receive payment below cost, or for which they may receive no payment at all, from the patient or third party payors.
Commercial Coverage Reimbursement. Most insurers and HMOs currently negotiate contracts that provide for reimbursement to hospitals on a discounted fee-for-service basis or on a discounted fixed rate per day of care. Some services are reimbursed on an “episode of care” or “capitation” payment methodology under which a hospital is paid a predetermined rate for a particular episode of care for a patient or a periodic rate for each enrollee who is “assigned” to, or otherwise directed to receive care at, a particular hospital. In a capitation payment system, the hospital assumes an insurance risk for the cost and scope of care given to such enrollees. These contracts generally are enforceable for a stated term regardless of provider losses. The Affordable Care Act reforms in the Medicare and Medicaid programs described above, including VBP, ACOs and population health management, are also beginning to be incorporated into the reimbursement methodologies of some commercial payors.
Blue Cross. The dominant third party payors in the University Hospitals’ markets are the Blue Cross entities, which pay for patient care pursuant to contractual arrangements and various formulas. The University Hospitals are currently reimbursed by Independence Blue Cross based on a per diem and per case arrangement for inpatient services and a fee schedule and percentage of charges for outpatient services (depending on the service). The current contract also includes a performance incentive plan. There can be no assurance that the payment rates and methodology employed under the contract(s) will reimburse the University Hospitals at adequate levels.
Failure to maintain contracts with Independence Blue Cross and other substantial insurance carriers could have the effect of reducing the University Hospitals’ patient base and/or revenues. Conversely, participation may maintain or increase the patient base, but may result in reduced payment and lower net income from operations.
Management of the University Hospitals expects these managed care plans to continue to account for a significant percentage of their patients under contracts requiring discounted charges. The high proportion of revenues from a single payer presents a significant risk in the event that services provided under the contract fail to yield the revenue anticipated at the time the contract was negotiated. No assurance can be given as to whether commercial insurance or other third party revenues received by the University Hospitals under existing or future contractual arrangements will be sufficient to cover patient care costs in the future. Similarly, no assurance can be made that retrospective audits conducted by commercial insurers or other third party payers will not result in the recoupment of payments already made.
62
Health Plan Financial Pressure and Insolvency. In cases where a managed care organization is a major purchaser of services from a particular hospital, contract rate reduction, contract cancellation, inability to pay, business failure or bankruptcy of the HMO may have a substantial negative effect on that hospital’s financial condition. It is not possible at this time to predict the future financial viability of the managed care industry in general or to predict what impact the insolvency and general financial state of such organizations might have on hospitals, including the University Hospitals.
Physician Contracting and Relations. The University Hospitals contract with physician organizations (“POs”) (e.g., independent physician practices or associations, physician-hospital organizations, faculty practice plans, etc.) to arrange for the provision of physician and ancillary services. POs are separate legal entities with their own goals, obligations to shareholders, financial status, and personnel, so there are risks involved in contracting with the POs.
The success of the University Hospitals will partially depend upon their ability to contract with POs to participate in the network, and upon the POs, including their employed physicians’, abilities to perform their obligations and deliver high quality patient care in a cost-effective manner. There can be no assurance that the University Hospitals will be able to contract with and retain the requisite number of POs, or that such POs will deliver high quality health care services. Without contracting with a sufficient number and type of POs, they could fail to be competitive, fail to keep or attract payor contracts, or be prohibited from operating until they has arranged for physician services necessary to provide adequate access for patients. Such occurrences could have a material adverse effect on the business or operations of the University Hospitals.
The Fraud and Abuse Laws
The Federal Anti-Kickback Act. The federal Anti-Kickback Law (“AKS”) is a criminal statute that prohibits the knowing and willful offer, payment or receipt of remuneration in exchange for or as an inducement to make or influence a referral of a patient for the provision of goods or services that may be reimbursed under any federal health care program. The scope of the AKS is very broad, and it potentially implicates many practices and arrangements common in the health care industry. Violation of the AKS is a felony, subject to a maximum fine of $100,000 for each criminal act, imprisonment for up to ten years, both a fine and imprisonment, civil monetary penalties of up to $100,000 per violation (adjusted for inflation annually) or damages equal to three times the amount of the prohibited remuneration, as well as exclusion from the federal health care programs. The Affordable Care Act clarified the intent requirement to provide that a person need not have actual knowledge of the AKS or specific intent to commit a kickback violation to violate the statute. The result of this change is that the government will have less of a burden to prove a violation under the AKS. In addition, a claim that includes items or services resulting from a violation of the AKS is a false claim for purposes of the federal civil False Claims Act (discussed below).
HHS has issued regulations from time to time setting forth safe harbors that protect limited types of arrangements from prosecution under the statute. Arrangements that do not comply with the strict requirements of the safe harbors, while not necessarily illegal, face an ongoing risk of investigation or prosecution due to the broad language of the statute. The safe harbors described in the regulations are narrow and do not cover many common economic relationships between and
63
among hospitals, including the University Hospitals, physicians and other health care providers. Some or all of the University Hospitals may have entered into arrangements with other health care providers that may not meet all of the requirements of the “safe harbor” regulations. Given the narrowness of the safe harbor regulations and the scarcity of the case law interpreting the AKS, there can be no assurances that the University Hospitals will not be found to have violated the AKS, and if such a violation were found, that any sanctions imposed would not have a material adverse effect upon the operations and financial conditions of the University.
Pennsylvania Anti-Kickback Law. Pennsylvania regulations contain provisions that prohibit a provider enrolled in the Medicaid program from directly or indirectly doing any of the following acts: solicitation or receipt or offer of a kickback, payment, gift, bribe or rebate for purchasing, leasing, ordering or arranging for, or recommending purchasing, leasing, ordering, or arranging for, a good, facility, service or item for which payment is made using Medicaid.
The University Hospitals make every effort to comply with the provisions of these regulations. Violations of Pennsylvania’s Anti-Kickback Law may lead to civil and criminal penalties, as well as exclusion from the Commonwealth’s Medicaid program.
Physician Payment Sunshine Act. To increase transparency regarding the financial relationships between hospitals, doctors, and healthcare manufacturing companies, the Physician Payment Sunshine Act requires that manufacturers of drugs, medical devices and biologicals that participate in federal health care programs must report certain payments and items of value given to physicians and teaching hospitals, such as the University Hospitals. This information is publicly available on the CMS website. It is impossible to predict the future impact of this reporting on the University Hospitals, whether companies will reduce payments to University Hospitals, or whether the federal government will pursue investigations as a result of such reporting.
Federal False Claims Act. The federal criminal False Claims Act (“criminal FCA”) makes it illegal to submit or present a false, fictitious or fraudulent claim to the federal government. Violation of the criminal FCA can result in imprisonment, fines and/or forfeiture of any property derived from proceeds traceable to the offense. The federal civil False Claims Act (“civil FCA”), one of the government’s primary weapons against health care fraud, allows the United States government to recover significant damages from persons or entities that submit false or fraudulent claims for payment to any federal agency through actions taken by the U.S. Attorney’s Office or the Department of Justice. The civil FCA also permits individuals to initiate actions on behalf of the government in lawsuits called qui tam actions. These qui tam plaintiffs, or “whistleblowers,” can share in the damages recovered by the government.
Under the civil FCA, health care providers may be liable if they take steps to obtain improper payments from the government by submitting false claims or failing to refund known overpayments. Civil FCA violations have been alleged solely on the existence of alleged kickback or self-referral arrangements. Even in the absence of evidence that false claims have been submitted, these cases argue that the improper business relationship tainted the subsequently submitted claims, thereby rendering the claims false under the civil FCA. In 2009, the scope of the civil FCA was expanded to include so-called “reverse false claims,” where a provider that knowingly retains a government overpayment is subject to FCA liability. The Affordable Care Act further requires that any overpayment be reported and repaid within 60 days after the date on
64
which overpayment was identified. Failure to do so will be considered a per se false claim under the civil FCA. The Affordable Care Act also modified the FCA by extending the FCA to AKS violations.
Violations of the civil FCA can result in penalties up to triple the actual damages incurred by the government and also monetary penalties ranging from $11,181 to $22,363 per claim (adjusted for inflation annually). Private individuals may also bring suit under the qui tam provisions of the civil FCA and may be eligible to share in the government’s recovery for providing information that leads to recoveries or sanctions that arise in a variety of contexts in which health care providers operate. The Affordable Care Act also eased the requirements for private individuals to bring suit under the civil FCA. In recent years there has been a significant increase in the number of whistleblower allegations filed under the civil FCA.
These statutes pose significant risks to all health care organizations. There can be no assurances that the University Hospitals will not be charged with, or found to have violated, the criminal FCA or civil FCA and, if so, that any fines or other penalties would not have a material adverse effect on its operations.
Civil Monetary Penalties Law. The Civil Monetary Penalties Law under the Social Security Act (“CMP Law”) provides for the imposition of civil monetary penalties against any person who submits a claim to Medicare, Medicaid or any other federal health care program that the person knows or should know is for items or services not provided as claimed; is false or fraudulent; is for services provided by an unlicensed or uncertified physician or by an excluded person; represents a pattern of claims that are based on a billing code higher than the level of service provided; or is for services that are not medically necessary. The CMP Law, among other things, also prohibits hospitals from paying physicians to limit medically necessary care. Penalties under the CMP Law include up to $100,000 for each item or service claimed (per a recent increase included in the Bipartisan Budget Act of 2018), and damages of up to three times the amount claimed for each item or service, and exclusion from participation in the federal health care programs.
Health care providers may be found liable under the CMP Law even when they did not have actual knowledge of the impropriety of their action. Knowingly undertaking the action is sufficient. The imposition of civil monetary penalties could have a material adverse impact on the University’s financial condition.
Self-Disclosures. Both CMS and DHS have protocols for providers to self-disclose possible overpayments and the University Hospitals have utilized and will continue to utilize those protocols to disclose overpayments identified by the University Hospitals.
Stark Self-Referral and Payment Prohibitions. The federal Ethics in Patient Referrals Act (known as the “Stark Law”) prohibits the referral of patients for certain “designated health services” (which include inpatient and outpatient hospital services) payable by Medicare to entities with which the referring physician (or an immediate family member of such physician) has a financial relationship, unless an exception applies. The statute also prohibits the entity furnishing the “designated health services” from billing the Medicare or Medicaid program for designated health services furnished pursuant to a prohibited referral. The law requires reporting of financial
65
relationships to CMS. The Stark Law is a strict liability statute. CMS has made several changes to existing Stark regulations in the final 2016 Physician Fee Schedule, affecting hospital-physician recruitment arrangements, timeshare arrangements, Stark’s writing and signature requirements, requirements concerning term of agreements and holdover leases, as well as changes in the regulatory definitions of “remuneration” and “stand in the shoes.” The Bipartisan Act of 2018 codified changes CMS made in the 2016 Physician Fee Schedule regarding the writing requirement, signature requirement, and indefinite holdover provisions for leases and personal services arrangements.
Violations of the Stark Law can result in refunds of the amounts collected for services rendered pursuant to a prohibited referral, 2017 civil monetary penalties of up to $24,253 (adjusted for inflation annually) for each claim arising out of such referral and exclusion from the Medicare and Medicaid programs. The Stark Law also provides for a 2017 civil penalty of up to $161,692 (adjusted for inflation annually) for entering into an arrangement with the intent of circumventing its provisions. In certain circumstances, knowing violations may also create liability under the FCA.
Due to the complexity of the Stark Law and similar laws at the state level, as well as related federal and state regulatory guidance, there can be no assurance that the University Hospitals will not be found to have violated the Stark Law or similar state-specific laws and if so, whether any sanction imposed would have a material adverse effect on the operations and/or financial condition of the University.
Pennsylvania Anti-Referral Law. While Pennsylvania does not have a state law similar to the Stark Law that prohibits self-referrals in all circumstances, it has laws and regulations prohibiting kickbacks in governmental programs. Additionally, Pennsylvania’s Workers’ Compensation Act and its Medicaid regulations have self-referral restrictions similar to the federal Stark Law. For example, under current Pennsylvania law, physicians are required to disclose to patients any referral to a facility where the physician has a financial interest, and must advise the patient that he or she retains the ability to choose any other recommended facility. Physicians are prohibited from establishing an automatic referral system or agreement with other providers or facilities. Providers participating in the Medicaid program may not refer a Medicaid recipient to an independent laboratory, pharmacy, radiology or other ancillary medical service in which the practitioner or professional corporation has an ownership interest.
Antitrust
Antitrust liability may arise in a variety of circumstances, including medical staff privilege disputes, payor contracting, joint ventures, merger, affiliation and acquisition activities, certain pricing or salary setting activities and anticompetitive business conduct or practices. The application of federal and state antitrust laws to heath care entities is constantly evolving, therefore the University cannot make assurances that federal or state enforcement authorities or private parties will not assert that the University is in violation of antitrust laws.
Violation of antitrust laws may result in criminal and/or civil enforcement proceedings by federal and state agencies, as well as give rise to private actions. In certain actions, private litigants may be entitled to treble damages, and the government may be able to assess substantial monetary
66
fines. Additionally, successful private or governmental litigants may be able to obtain injunctive relief which may impact the University’s ability to conduct or continue certain business practices or activities.
Exposure to Liability
Due to the nature of their business, the University Hospitals from time to time become involved as defendants in medical malpractice lawsuits, and are subject to the attendant risk of substantial damage awards. The most significant source of potential liability in this regard is the negligence of physicians employed or contracted by the University Hospitals. To the extent such physicians are employed by the University Hospitals or regarded as agents of the University Hospitals in the practice of medicine, the University Hospitals could be held liable for their negligence. In addition, the University Hospitals could be found in certain instances to have been negligent in performing their management services under contractual arrangements even if no agency relationship with the physicians were found to exist. The University Hospitals’ contracts with third party payors generally require the University Hospitals to indemnify such other parties for losses resulting from the negligence of physicians who were employed or managed by or affiliated with University Hospitals. See “INSURANCE” in “APPENDIX A - DESCRIPTION OF THE UNIVERSITY” for a description of the professional liability insurance maintained by the University.
There can be no assurance, however, that any insurer will remain solvent and able to meet its obligations to provide coverage for any such claim or claims, or that such coverage will continue to be available or available with sufficient limits and at a reasonable cost to adequately and economically insure the University Hospitals’ operations in the future. A judgment against the University Hospitals in excess of such coverage could have a material adverse effect on the University.
Medical Professional Liability Insurance Market
Professional liability costs for Pennsylvania’s physicians and other health care providers have been among the highest in the nation. Rapidly deteriorating underwriting results have in recent years generated substantial premium increases and coverage reductions in the medical professional liability insurance marketplace. A dramatic and sustained rise in claim severity nationwide coupled with lower investment returns available to insurers due to the economic slowdown have caused substantial reductions in medical professional liability insurance capacity. Health care entities that have self-funded programs are also experiencing similar difficulties with respect to reinsurance on their captive insurance companies and/or with respect to insurance placements in excess of the primary coverage layers.
The Pennsylvania General Assembly has enacted laws to address these issues, including the Medical Care Availability and Reduction of Error (“MCARE”) and the Fair Share Act. MCARE brought reform to the area of professional liability and created the MCARE fund which, in exchange for premiums from physicians, serves as a source of recovery for claims in excess of the provider’s base insurance limits. The Fair Share Act provides that, with some exceptions, a defendant will only be responsible to pay a portion of any judgment equal to the percentage of
67
liability found against that defendant. See “CERTAIN INVESTMENT CONSIDERATIONS - Other Legislative and Regulatory Actions” herein.
The effect of these developments has been to increase the operating costs of hospitals, including those of the University Hospitals. In addition, the increase in the cost of professional liability insurance may cause established physicians to leave the most heavily affected geographical regions, including Pennsylvania, and prevent new physicians from establishing their practices in the University Hospitals’ region. See “INSURANCE” in “APPENDIX A - DESCRIPTION OF THE UNIVERSITY” attached hereto. There can be no assurance that the unpredictability of jury awards and claims payouts, the reduction of coverage availability, and/or the rising cost of professional liability insurance coverage will not ultimately adversely affect the operations or financial condition of the University.
Charity Care
Hospitals are permitted to have tax-exempt status under the Code because the provision of health care historically has been treated as a “charitable” enterprise. This treatment arose before most Americans had health insurance, and when charitable donations were required to fund the health care provided to the sick and disabled. Some have posited that, with the onset of employer- sponsored health insurance and government reimbursement programs, there is no longer any justification for special tax treatment for the not-for-profit health care sector, and the availability of tax-exempt status should be eliminated. Management of the University Hospitals cannot predict the likelihood for such a dramatic change in the law, and the cost of charity care provided by the University Hospitals over the past several years has been significant. Federal and state tax authorities are beginning to demand that tax-exempt hospitals justify their tax-exempt status by documenting their charitable care and other community benefits. The Affordable Care Act requires hospitals to conduct a community needs assessment every three years in order to maintain its tax-exempt status.
The Affordable Care Act is designed to reduce uncompensated care by expanding health care coverage to a larger portion of the population, but one component of this expanded coverage, the health care exchanges, is experiencing defections by private insurers due to the losses they have experienced in offering plans on such exchanges. Exchanges may have originally contributed to the reduction in charity care for hospitals, but if defections by private insurers continue, hospitals nationwide, including the University Hospitals, may have to render more charity care. As a result, the University Hospitals may be required to continue to provide services for which they receive payment below cost, or for which they may receive no payment, from the patients or third party payors. While the University Hospitals attempt to provide care to the poor and indigent in a prudent manner, the continuation or expansion of such policy, or the inability to properly document their indigent care, could have an adverse financial effect on the University.
Tax Law Changes that May Impact Charitable Giving (Tax Cuts and Jobs Act)
Tax law changes not directly related to the deductibility of charitable contributions (including certain changes enacted in late 2017 as part of the federal Tax Cuts and Jobs Act) may lead to reduced incentives for charitable giving. Limitations on the deductibility of state and local income and property taxes in higher-tax states will lead to residents in such states having less
68
income available for charitable donations. Increases to the estate tax exemption which lower the tax burden on heirs may reduce incentives to leave charitable bequests.
Other Legislative and Regulatory Actions
The University and its operations are subject to regulation, certification and accreditation by various federal, state and local government agencies and by certain non-governmental agencies such as The Joint Commission, the Liaison Committee on Medical Education and the Middle States Commission on Higher Education. Various health and safety laws and regulations enforced by state and local agencies apply to the University. Violations of certain of these standards could result in closure of the University Hospitals or portions thereof, or requirements that compliance with such standards be immediately achieved. Such standards are subject to change, and there can be no assurances that in the future, their facilities will meet any changed standards or that the University Hospitals will not be required to expend significant sums to comply with changed standards. No assurance can be given as to the effect on the University Hospitals’ future operations or on the University’s educational or other activities in the future of existing laws, regulations and standards for certification or accreditation or of any future changes in such laws, regulations and standards.
Other possible federal or state legislation which could have an adverse effect on the University would include: (i) limitations on the amount of charitable contributions which are deductible for income tax purposes; (ii) limitations on the amount or availability of tax-exempt financing for Section 501(c)(3) corporations; (iii) amendments to tax law provisions that could adversely affect the marketability or market value of the Series 2018D Bonds or otherwise prevent holders of the Series 2018D Bonds from realizing the full benefit of the tax exemption of interest on the Series 2018D Bonds; and (iv) regulatory limitations affecting the University’s ability to undertake capital projects or develop new services.
Other regulatory programs which may significantly affect the University Hospitals are changes in governmental requirements regarding patient treatment. These regulations are embodied in patients’ bills of rights and similar programs being promulgated with greater frequency and changes in licensure requirements. All of these could increase the cost of doing business and consequently adversely affect the financial condition of the University.
Environmental Laws and Regulations. The University’s health care operations generate medical waste that must be disposed of in compliance with federal, state and local environmental laws, rules and regulations. The operation of and the purchase or sale of facilities, are also subject to compliance with various environmental laws, rules and regulations. Any violations may subject the University and its entities to sanctions, fines, forfeiture of collateral bonds, suspension and or revocation of the University’s medical waste license.
Emergency Medical Treatment and Active Labor Act
In response to concerns regarding inappropriate hospital transfers of emergency room patients due to a patient’s inability to pay for services, Congress enacted the Emergency Medical Treatment and Active Labor Act (“EMTALA”) or the federal “anti-dumping” statute. This law imposes certain requirements on hospitals prior to discharging an emergency patient or transferring
69
such a patient to another facility. Failure to comply with the law can result in exclusion from the Medicare and/or Medicaid programs as well as civil penalties. The failure of the University Hospitals to meet their responsibilities under EMTALA could adversely affect the financial condition of the University. EMTALA and its implementing regulations are complex, and the University Hospitals’ compliance is dependent, in part, upon the compliance of independent medical staff members. Accordingly, there can be no assurance that no violation of EMTALA will be found or, if found, that any sanction imposed would not have a material adverse effect on the operations or financial conditions of the University.
Health Insurance Portability and Accountability Act
Providers of health care, such as the University Hospitals, have been impacted by certain health information requirements contained in the Health Insurance Portability and Accountability Act of 1996 and its implementing regulations (“HIPAA”), as amended in 2009 by the Health Information Technology for Economic and Clinical Health Act (“HITECH”). HIPAA mandates the adoption of detailed standards for maintaining the privacy and security of protected health information (“PHI”). HITECH made significant modifications to HIPAA including subjecting business associates to direct regulation and enforcement by the Office of Civil Rights of HHS (“OCR”), instituting a breach notification requirement for breaches of unsecured PHI, including a breach of PHI held by a business associate, and strengthening the enforcement tools available to OCR. Additionally, under HIPAA covered entities or business associates must perform risk assessments.
The financial costs of continuing compliance with HIPAA regulations are substantial and will increase as a result of increased enforcement, and well-publicized breaches. Enforcement of HIPAA compliance has heightened in recent years and this trend is expected to continue. This includes, but is not limited to, a steady increase in the number of substantial settlements with governmental authorities as a result of breaches. The Obligated Group Members and their Affiliates are actively engaged in continuing compliance efforts with HIPAA and HITECH. Enforcement of HIPAA compliance has heightened in recent years and this trend is expected to continue. This includes, but is not limited to, a steady increase in the number of substantial settlements with governmental authorities as a result of data breaches. If OCR conducts an investigation (whether as a result of an audit or reporting of such a breach), OCR could impose certain fines and penalties and could also require University Hospitals to enter into corrective action plans. The University Hospitals are actively engaged in continuing compliance efforts with HIPAA and HITECH. There are also costs and risks associated with vendors and contractors as it is possible that the University Hospitals could be responsible for HIPAA violations or breaches of its vendors and contractors. To date, the University Hospitals have reported a number of breaches to HHS, including misdirects, missing/disappearing records and unauthorized access. No guarantee can be made that the various Obligated Group Members and their Affiliates will remain HIPAA/HITECH Act compliant in the future, or that OCR will not conduct an audit or investigation in connection with a reported breach. If OCR conducts an investigation (whether as a result of an audit or reporting of such a breach), OCR could impose significant fines and penalties and could also require the Obligated Group Members and their Affiliates to enter into a corrective action plan.
70
In addition, as data breaches continue to have greater exposure both inside and outside of the health care industry, and awareness of such breaches continues, private litigation is expected to increase. As a result, no assurances can be given that the Obligated Group Members and their Affiliates will not be faced with potential private litigation in the event of a data breach.
Breach of Personal Information Notification Act. The Breach of Personal Information Notification Act (the “Notification Act”) was enacted in 2006. Under the Notification Act any state agency, political subdivision, individual or business that operates in Pennsylvania and maintains, stores, or manages computerized data that includes personal consumer information must provide notice of any security system breach to state residents whose personal information was or may have been compromised by the breach.
A violation of the Notification Act is deemed an unfair or deceptive act or practice violation of the Pennsylvania Unfair Trade Practices and Consumer Protection Law. Pennsylvania’s Attorney General has authority to bring an action for a violation of the Notification Act under the Unfair Trade Practices and Consumer Protection Law. Civil penalties may be imposed.
Electronic Health Record Incentive Program. HITECH provided funding for various activities intended to promote the adoption and meaningful use of certified electronic health record (“EHR”) technology. Eligible Medicare and Medicaid providers, including acute care hospitals and other health care professionals may be eligible to receive EHR payment incentives if they demonstrate the meaningful use of certified EHR technology and meet other program requirements. University Hospitals participated in the EHR Incentive Programs for Medicare and Medicaid as a “meaningful user,” and it received incentive payments from CMS in 2012-2014. The University did not seek reimbursement in 2015-2017. CMS has begun an audit program to assure the veracity of certifications.
Under the new Medicare physician reimbursement provisions described in the Physician Payments section above, the incentive to use EHR effectively is now integrated into the physician reimbursement formula. There can be no guarantee that the University Hospitals will continue to be able to recover reimbursement for their EHR and may be subject to reduced Medicare and/or Medicaid reimbursement.
Corporate Compliance
The University has implemented internal policies and procedures along with a compliance program that the University believes reduces exposure due to violation of state and federal laws. However, because the Government’s enforcement efforts are widespread throughout the industry, and may vary from region to region, the University cannot assure that the compliance program will reduce or eliminate its exposure to civil or criminal sanctions or any adverse administrative determinations.
The sentencing of organizations for federal health care crimes is governed by the U.S. Sentencing Guidelines (the “Guidelines”), which permit the imposition of extremely large fines in many instances. The Guidelines permit the fine to be reduced significantly if the provider had in place at the time of the crime an effective corporate compliance program and/or accepts responsibility for its actions. As a result of the current environment of increased enforcement
71
against health care fraud and abuse, the University Hospitals have established compliance programs to prevent or detect violations of federal law.
The University maintains a comprehensive compliance program, including oversight of the University Hospitals’ and physician billing activities and reporting to the Audit Committee of TJU. The University believes that its compliance program is in overall compliance with the OIG Compliance Guidance for Hospitals, but there is no guarantee that the University’s comprehensive compliance program will always remain in compliance with the Guidelines or OIG’s Compliance Guidance for Hospitals in the future.
Cyber-Security Risks
Despite the implementation of network security measures by the University Hospitals, its information technology may be vulnerable to breaches, attacks by hackers, computer viruses, ransomware, physical or electronic break-ins and other similar events or issues. Health care systems may be a target for cyber-attacks due to the mandatory transition from paper records to EHRs. Such events or issues could lead to the inadvertent disclosure of protected health information or other confidential information or could have an adverse effect on the ability of the University Hospitals to provide health care services.
Increased Enforcement Affecting Academic Research
The conduct of research at the University Hospitals and its clinical affiliates is subject to increasing federal regulation. The Department of Health and Human Services Office of Human Research Protection, the Food and Drug Administration and National Institutes of Health have increased their enforcement efforts in relation to their oversight of federally funded research, including research on human subjects. These laws regulate both the methods and requirements for submitting transfers for reimbursements of costs associated with performing the research and claims for services rendered to human subjects. These agencies’ enforcement powers range from substantial fines and penalties to exclusion of researchers and suspension or termination of entire research programs, and repayment for errors in billing of the Medicare Program for care provided to patients enrolled in clinical trials that is not eligible for Medicare reimbursement. These enforcement activities could subject the University Hospitals to sanctions as well as repayment obligations, which could have a material and adverse effect on the financial condition and operations of the University.
Fluctuations in Market Value of Investments
General. Earnings on investments have historically provided the University an important source of cash flow and capital appreciation to support their programs and services, to finance capital expenditure investments and to build cash reserves. Historically the value of both debt and equity securities has fluctuated and, in some instances, the fluctuations have been quite significant. Diversification of securities holdings may diminish the impact of these fluctuations. However, no assurances can be given that the market value of the investments of TJU or other Members of the Obligated Group will grow, or even remain at current levels and there is no assurance that such market value will not decline. Further, no assurances can be given that there will not be a significant decrease in the value of the University’s investments caused by market or other external
72
factors. See “CASH AND INVESTMENTS” in “APPENDIX A - DESCRIPTION OF THE UNIVERSITY” attached hereto for a discussion of the University’s investments.
Pension Funding Impact. Changes in market interest rates and debt and equity market fluctuations also have an impact on the pension fund liabilities of the Members of the Obligated Group who have defined benefit pension liabilities and the requirements for funding their related pension expenses. Like other entities with pension fund liabilities, certain of the Members of the Obligated Group find that increases or decreases in interest rates have an impact on the assumed earnings rates on pension assets needed to match pension fund liabilities, which accordingly affects the levels of actuarial pension investment assets required to meet future pension obligations. Consequently, any substantial and sustained decline in long-term interest rates could have the effect of increasing the current pension funding requirements of the applicable Members of the Obligated Group. No assurance can be given that such Members will not be required to make increased pension funding payments in this or other circumstances. See “BENEFITS” in “APPENDIX A - DESCRIPTION OF THE UNIVERSITY” attached hereto.
Interest Rate Swaps. There are a number of risks associated with interest rate swaps that could affect the value of the University’s swaps, the ability of the University to accomplish its objectives in entering into the swaps and the ability of the University to meet its obligations under the swaps. These risks include, among others, the following: counterparty risk - the failure of the counterparty to make required payments; credit risk - the occurrence of an event modifying the credit rating of the University or its counterparty; termination risk - the need to terminate the transaction in a market that dictates a termination payment by the University; tax risk - the risk created by potential tax events that could affect swap payments; and basis risk - the mismatch between actual variable rate debt service and variable rate indices used to determine swap payments. The University actively monitors the degree of risk and exposure associated with the swaps to which it is a party but can offer no assurances that it will not suffer adverse financial consequences as a result of these transactions.
Other Potential Transactions
TJU has entered into the Letter of Intent with EHN with respect to the Transaction, whereby TJU and EHN would combine assets and operations. For a further discussion with respect to the Letter of Intent, the Transaction and related matters, see “MANAGEMENT DISCUSSION AND ANALYSIS – Einstein Health Letter of Intent” and “Other Potential Transactions” within Appendix A to this Official Statement.
As part of its ongoing strategic planning process, from time to time the University considers potential joint ventures, affiliations, acquisitions, divestitures and similar transactions. Such transactions and the Transaction may result in additional entities becoming part of the Obligated Group or affiliates of Members of the Obligated Group in the future, or in certain entities no longer being part of the Obligated Group. There can be no assurance as to the impact that any such transaction or the Transaction would have on the financial results of the University.
Given the general complexity of these types of transactions, including the Transaction, the ongoing negotiations concerning their terms and conditions and the necessity for requisite government approvals in certain instances, there is no assurance that any particular transaction,
73
including the Transaction, will close, that the terms of the Transaction or any other particular transaction will not change materially from those which may be initially proposed, or that the University will not incur additional operating or capital costs in connection with any such transactions, including the Transaction. There also are no assurances that the failure to close the Transaction or any particular proposed transaction in the future will not have an adverse impact on the ability of the University to achieve its strategic goals.
Other Risk Factors Relating to the Finances and Operations of the University
In the future, the following factors, among others, may adversely affect the operations of the University to an extent that cannot be determined at this time.
A. Increases in the costs and decreases in the availability of public liability insurance. See “INSURANCE” in “APPENDIX A - DESCRIPTION OF THE UNIVERSITY” attached hereto.
B. Changes in the demand for higher education in general or for programs offered by the University in particular.
C. Reduced demand for higher education in Pennsylvania due to demographic factors including the current decline in the population of high school graduating seniors within Pennsylvania which may particularly impact the undergraduate programs of the University.
D. Cost and availability of energy.
E. Future interest rates, which could strain cash flow given the University’s variable rate debt or prevent borrowing for needed capital expenditures.
F. A decrease in student loan funds or other aid that provides many students with the opportunity to pursue higher education. See “EDUCATIONAL ACTIVITIES - Financial Aid” in “APPENDIX A - DESCRIPTION OF THE UNIVERSITY” attached hereto.
G. The continued ability and willingness of current and future undergraduate and graduate students of the University, and their families, to be able to afford the tuition and costs of attending the University.
H. Increased competition from for-profit universities and on-line programs offered by such universities or traditional universities.
I. An increase in the costs of health care benefits, retirement plan, or other benefit packages offered by the University to its employees and retirees. See “BENEFITS” in “APPENDIX A - DESCRIPTION OF THE UNIVERSITY” attached hereto for a discussion of the costs of the pension plans of certain Members of the Obligated Group.
74
J. Changes in reimbursement procedures or in contracts under public or private insurance programs.
K. Suspension or revocation of or a failure to renew any certificate of authority or license to operate one or more healthcare facilities, or any portion thereof, or any restriction on new admissions to licensed beds, or a failure to obtain a renewal of any applicable regulatory approval.
L. Unknown litigation, regulatory actions or other similar claims regarding the University or any of its affiliates. See “LITIGATION - The University” herein.
M. A reduction in charitable pledges and other fundraising support of the University. See “FUNDRAISING AND CONTRIBUTIONS” in “APPENDIX A - DESCRIPTION OF THE UNIVERSITY” attached hereto for a description of fundraising activities at the University.
N. The failure of the Pennsylvania General Assembly to meet the annual enactment deadline for the fiscal year’s state budget.
O. Strikes and other related work actions, contract disputes, discrimination claims, personal tort actions, work-related injuries, exposure to hazardous materials, interpersonal torts and other risks that may flow from various relationships involving students, faculty, employees, physicians and/or patients.
P. Increase in capital expenditures needed to maintain or upgrade University academic, research and healthcare facilities to remain competitive with other academic medical and research institutions, colleges and universities, and healthcare systems, which expenditures may limit debt capacity or reduce unrestricted net assets.
Q. The ability of the University to offer certain sophisticated and costly equipment for diagnosis and treatment.
R. Reduced demand for the health care services of the University that might result from decreases in population in its service area.
S. Increased unemployment or other adverse economic conditions in the service areas of the University which would increase the proportion of patients who are unable to pay fully for the cost of their care or reduce the proportion of patients who have insurance coverage for health care services.
T. Limitations on availability of, and increased compensation necessary to secure and retain, faculty, physicians, nursing, technical, executive and other professional personnel.
U. Any increase in the quantity or cost of indigent care provided which is mandated by law or required due to increased needs of the community in order to maintain the charitable status of the applicable entities comprising the University.
75
V. Data breaches which may adversely affect the University’s financial results, operations and reputation.
W. Epidemics or other public health issues that may strain the University’s resources or disrupt its normal operations.
X. Extreme weather or climate events that may damage the University’s facilities or disrupt its normal operations.
Y. Terrorism.
LITIGATION
The Authority
There is no litigation of any nature pending or, to the Authority’s knowledge, threatened against the Authority at the date of this Official Statement to restrain or enjoin the issuance, sale, execution or delivery of the Series 2018D Bonds, or in any way contesting or affecting the validity of the Series 2018D Bonds or any proceedings of the Authority taken with respect to the issuance or sale thereof, or the pledge or application of any moneys or the security provided for the payment of the Series 2018D Bonds or the existence or powers of the Authority.
The University
There are various claims, legal actions and audits pending against the University, which have arisen in the ordinary course of the University’s business, some of which include demands for punitive damages as well as other types of damages, which are outside the scope of insurance coverage or for which the University would itself be responsible, if its liability would be established. In the opinion of management of the University, none of such pending claims, legal actions or audits would materially adversely affect the business, financial condition or properties of the University.
TAX MATTERS
Federal Tax Matters Applicable to the Series 2018D Bonds
In the opinion of Ballard Spahr LLP, Bond Counsel, interest on the Series 2018D Bonds is excludable from gross income for purposes of federal income tax under existing laws as enacted and construed on the date of initial delivery of the Series 2018D Bonds, assuming the accuracy of the certifications of the Authority and the University and continuing compliance by the Authority and the University with the requirements of the Code. Interest on the Series 2018D Bonds is not an item of tax preference for purposes of the individual federal alternative minimum tax. The corporate alternative minimum tax was repealed by legislation enacted on December 22, 2017 (known as the "Tax Cuts and Jobs Act"), effective for tax years beginning after December 31, 2017. For tax years beginning on or before December 31, 2017 interest on the Series 2018D Bonds is not an item of tax preference for purposes of the corporate alternate minimum tax in effect prior to enactment of the Tax Cuts and Jobs Act; however, interest on the Series 2018D Bonds held by a corporation (other than an S Corporation, regulated investment company, or real estate
76
investment trust) indirectly may be subject to federal alternative minimum tax because of its inclusion in the adjusted current earnings of a corporate holder. Bond Counsel expresses no opinion regarding other federal tax consequences relating to ownership or disposition of, or the accrual or receipt of interest on, the Series 2018D Bonds.
Commonwealth of Pennsylvania Tax Matters
Bond Counsel is also of the opinion that, under the laws of the Commonwealth of Pennsylvania as presently enacted and construed, the Series 2018D Bonds are exempt from personal property taxes in Pennsylvania, and interest on the Series 2018D Bonds is exempt from Pennsylvania personal income tax and Pennsylvania corporate net income tax.
LEGAL MATTERS
Certain legal matters incident to the authorization, issuance, validity, sale and delivery of the Series 2018D Bonds are subject to the unqualified approving legal opinion of Ballard Spahr LLP, Philadelphia, Pennsylvania, in its capacity as Bond Counsel. The legal opinion of Bond Counsel will speak only as of its date and subsequent distribution of it by recirculation of this Official Statement or otherwise shall not create any implication that subsequent to the date of the legal opinion bond counsel has affirmed its opinion. The proposed text of the legal opinion of Bond Counsel is attached hereto as “APPENDIX E - PROPOSED FORM OF OPINION OF BOND COUNSEL.”
Certain legal matters will be passed upon for the Authority by Douglas B. Breidenbach, Jr., Esquire, Pottstown, Pennsylvania, and for the University by the Office of University Counsel and Ballard Spahr LLP, Philadelphia, Pennsylvania, in its capacity as counsel to the University, including Disclosure Counsel. Certain legal matters will be passed upon for the Underwriter by its counsel Cozen O’Connor, Philadelphia, Pennsylvania.
CONTINUING DISCLOSURE
To assist the Underwriter in complying with the Rule, simultaneously with the issuance of the Series 2018D Bonds, TJU will execute the Disclosure Agreement substantially in the form attached hereto as “APPENDIX F - FORM OF CONTINUING DISCLOSURE AGREEMENT.” TJU, as an “obligated person” under the Rule, has covenanted in the Disclosure Agreement to provide certain financial information and operating data relating to the Obligated Group and the Series 2018D Bonds in each year (the “Annual Report”), and to provide notices of the occurrence of certain events described in the Disclosure Agreement. The annual financial information and notices of certain events (as described in the Disclosure Agreement) will be filed by the dissemination agent, on behalf of the Obligated Group, with the repository designated by the SEC, presently the Municipal Securities Rulemaking Board (the “MSRB”) through the Electronic Municipal Market Access (“EMMA”) system in an electronic format prescribed by the MSRB. The specific nature of the financial information, operating data, the type of events which trigger a disclosure obligation, the timing of the Annual Report and event filings and other details of the University’s undertakings are more fully described in “APPENDIX F- FORM OF CONTINUING DISCLOSURE AGREEMENT” attached hereto. TJU also has, by separate agreement, retained
77
DAC as dissemination agent to assist TJU in connection with certain of its obligations under the Disclosure Agreement.
During the previous five years, in connection with TJU’s continuing disclosure undertakings executed in connection with certain prior bond issues, TJU filed an event notice with EMMA on July 28, 2014 regarding TJU becoming the sole corporate member of TJUH System on June 30, 2014, which filing date was more than the required 10 business days after the underlying event.
TJU has established and implemented policies and procedures for purposes of complying with its continuing disclosure undertakings.
RATINGS
S&P Global Ratings (“S&P”), and Moody’s Investors Service, Inc. (“Moody’s” and together with S&P, the “Rating Agencies”) have assigned ratings of “A+” (stable outlook) and “A2” (negative outlook), respectively, to the Series 2018D Bonds.
Such ratings reflect only the respective views of the Rating Agencies, and an explanation of the significance of such ratings may only be obtained from the Rating Agencies furnishing the ratings. Generally, a rating agency bases its rating on the information and materials furnished to it and on investigations, studies, and assumptions of its own. There is no assurance that such ratings will remain unchanged for any given period of time or that they will not be revised downward or withdrawn entirely by the rating agency furnishing the same, if, in its judgment, circumstances so warrant. Any such downward revision or withdrawal of such ratings or other actions by the Rating Agencies, or either of them, may have an adverse effect on the liquidity and/or market price of the affected Series 2018D Bonds. Neither the Authority, TJU, nor the Underwriter has undertaken any responsibility to oppose any such revision, suspension or withdrawal.
UNDERWRITING
The Series 2018D Bonds are being purchased by Merrill Lynch, Pierce, Fenner & Smith Incorporated (the “Underwriter”). The Underwriter has agreed to purchase from the Authority the Series 2018D Bonds at a purchase price of $______(representing the aggregate principal amount of the Series 2018D Bonds, less an underwriter’s discount of $______). The Underwriter will be obligated to purchase all Series 2018D Bonds if any are purchased. The initial public offering prices of the Series 2018D Bonds set forth on the inside front cover page of this Official Statement may be changed from time to time by the Underwriter without any requirement of prior notice. The Underwriter reserves the right to join with other dealers in offering the Series 2018D Bonds to the public. The Series 2018D Bonds may be offered and sold to other dealers (including Series 2018D Bonds for deposit into investment trusts, certain of which may be sponsored or managed by the Underwriter) at prices other than the public offering prices stated on the inside front cover page of this Official Statement. The Series 2018D Bonds are being sold simultaneously with the Series 2018A Bonds, Series 2018B Bonds, and Series 2018C Bonds (which are being offered under a separate official statement), all as part of a common plan of finance to accomplish the 2018 Project.
78
The Underwriter and its affiliates are full service financial institutions engaged in various activities, which may include securities trading, commercial and investment banking, financial advisory, investment management, principal investment, hedging, financing and/or brokerage services. The Underwriter and its affiliates may, from time to time, perform various investment banking services for the Authority or the University, for which they received or will receive customary fees and expenses.
In the ordinary course of their various business activities, the Underwriter and its affiliates may make or hold a broad array of investments and actively trade debt and equity securities (or related derivative securities, which may include credit default swaps) and financial instruments (including bank loans) for their own account and for the accounts of their customers and may at any time hold long and short positions in such securities and instruments. Such investment and securities activities may involve securities and instruments of the Authority.
The Underwriter and its affiliates may also communicate independent investment recommendations, market color or trading ideas and/or publish or express independent research views in respect of such assets, securities or instruments and may at any time hold, or recommend to clients that they should acquire, long and/or short positions in such assets, securities and instruments.
TJU intends to use a portion of the proceeds from the offering of the Series 2018D Bonds to refund the Refunded Obligations. To the extent the Underwriter or any affiliate thereof is an owner or holder of any of the Refunded Obligations, the Underwriter, or its affiliate, as applicable, would receive a portion of the proceeds from the issuance of the Series 2018D Bonds contemplated herein in connection with such transactions.
REMARKETING
General
The initial Remarketing Agent (as defined under the 2018D Indenture) for the Series 2018D Bonds will be Merrill Lynch, Pierce, Fenner & Smith Incorporated. The Remarketing Agent has agreed to remarket the Series 2018D Bonds on a best efforts basis, subject to the provisions of a remarketing agreement by and between TJU and the Remarketing Agent (the “Remarketing Agreement”). TJU has agreed to indemnify the Remarketing Agent against certain liabilities, including certain liabilities arising under federal and state securities laws.
The Remarketing Agent will set the interest rates on the Series 2018D Bonds during the Variable Rate Mode or for other interest rate modes and perform the other duties and remarket the Series 2018D Bonds as provided for in the 2018D Indenture, subject to the provisions of the Remarketing Agreement. The Remarketing Agent may deal in Series 2018D Bonds for its own account or as broker or agent for others and may do anything any other Bondholder may do to the same extent as if the Remarketing Agent were not serving as such.
The Remarketing Agent and its affiliates are full service financial institutions engaged in various activities, which may include securities trading, commercial and investment banking, financial advisory, investment management, principal investment, hedging, financing and brokerage activities. The Remarketing Agent and its affiliates have, from time to time, performed
79
and may in the future perform, various investment banking services for the University, for which they received or will receive customary fees and expenses. In the ordinary course of their various business activities, the Remarketing Agent and its affiliates may make or hold a broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (which may include bank loans and/or credit default swaps) for their own account and for the accounts of their customers and may at any time hold long and short positions in such securities and instruments. Such investment and securities activities may involve securities and instruments of the University.
Certain Considerations Concerning the Remarketing of the Series 2018D Bonds
The Remarketing Agent is Paid by TJU. The Remarketing Agent’s responsibilities include determining the interest rate from time to time and remarketing Series 2018D Bonds that are optionally or mandatorily tendered by the owners thereof (subject, in each ease, to the terms of the Remarketing Agreement), all as further described in this Official Statement. The Remarketing Agent is appointed by TJU and is paid by TJU for its services. As a result, the interests of the Remarketing Agent may differ from those of existing holders and potential purchasers of Series 2018D Bonds.
The Remarketing Agent May Purchase Series 2018D Bonds for its Own Account. The Remarketing Agent is permitted, but not obligated, to purchase tendered Series 2018D Bonds for its own account. The Remarketing Agent, in its sole discretion, routinely acquires tendered bonds for its own inventory in order to achieve a successful remarketing of such bonds (i.e., because there are otherwise not enough buyers to purchase the bonds) or for other reasons. However, the Remarketing Agent is not obligated to purchase tendered Series 2018D Bonds and may cease doing so at any time without notice. The Remarketing Agent also may make a market in the Series 2018D Bonds by routinely purchasing and selling Series 2018D Bonds other than in connection with an optional or mandatory tender and remarketing. Such purchases and sales may be at or below par. However, the Remarketing Agent is not required to make a market in the Series 2018D Bonds. The Remarketing Agent also may sell any Series 2018D Bonds it has purchased to one or more affiliated investment vehicles for collective ownership or enter into derivative arrangements with affiliates or others in order to reduce its exposure to the Series 2018D Bonds. The purchase of Series 2018D Bonds by the Remarketing Agent may create the appearance that there is greater third party demand for the Series 2018D Bonds in the market than is actually the case. The practices described above also may reduce the supply of Series 2018D Bonds that may be tendered in a remarketing.
Series 2018D Bonds May be Offered at Different Prices on Any Date Including a Rate Determination Date. Pursuant to the 2018D Indenture, the Remarketing Agent is required to determine the applicable rate of interest that, in its judgment, is the lowest rate that would permit the sale of the Series 2018D Bonds at par plus accrued interest, if any, on and as of the applicable Rate Determination Date. The interest rate will reflect, among other factors, the level of market demand for the Series 2018D Bonds (including whether the Remarketing Agent is willing to purchase Series 2018D Bonds for its own account). There may or may not be Series 2018D Bonds tendered and remarketed on a Rate Determination Date, the Remarketing Agent may or may not be able to remarket any Series 2018D Bonds tendered for purchase on such date at par and the
80
Remarketing Agent may sell Series 2018D Bonds at varying prices to different investors on such date or any other date.
The Remarketing Agent is not obligated to advise purchasers in a remarketing if it does not have third party buyers for all of the Series 2018D Bonds at the remarketing price. In the event the Remarketing Agent owns any Series 2018D Bonds for its own account, it may, in its sole discretion in a secondary market transaction outside the tender process, offer such Series 2018D Bonds on any date, including the Rate Determination Date, at a discount to par to some investors.
The Ability to Sell the Series 2018D Bonds May Be Limited. While the Remarketing Agent may buy and sell Series 2018D Bonds, it is not obligated to do so and may cease doing so at any time without notice. Thus, investors who purchase the Series 2018D Bonds, whether in a remarketing or otherwise, should not assume that they will be able to sell their Series 2018D Bonds.
Under Certain Circumstances, the Remarketing Agent May Be Removed, Resign or Cease Remarketing the Series 2018D Bonds. Under certain circumstances the Remarketing Agent may be removed or have the ability to resign or cease its remarketing efforts, subject to the terms of the Remarketing Agreement and the 2018D Indenture.
The 2018D Indenture provides that in the event that TJU shall fail to appoint a successor Remarketing Agent within the notice periods provided therein, the resigning party may petition any court of competent jurisdiction to appoint a successor or the Trustee may either appoint a Remarketing Agent or itself act as Remarketing Agent until the appointment of a successor Remarketing Agent in accordance with the 2018D Indenture. The Trustee, in its capacity as Remarketing Agent, is not required to sell Series 2018D Bonds or establish interest rates (unless it is appointed Calculation Agent) and is only required to purchase Series 2018D Bonds with funds held by it as Trustee. The resignation or removal of the Remarketing Agent shall not be effective until a successor Remarketing Agent shall have been appointed and such Remarketing Agent shall have accepted such appointment.
INDEPENDENT ACCOUNTANTS
The financial statements as of June 30, 2017 and 2016, and for each of the two years in the period ended June 30, 2017, included in this Official Statement, have been audited by PricewaterhouseCoopers LLP, independent accountants, as stated in their report appearing therein.
FINANCIAL ADVISOR
In connection with the authorization, sale and issuance of the Series 2018D Bonds, TJU has retained Echo Financial Products, LLC, King of Prussia, Pennsylvania, as its financial advisor (for purposes of this paragraph only, the “Financial Advisor”). The Financial Advisor is not obligated to undertake, and has not undertaken, either to make an independent verification of or to assume responsibility for the accuracy, completeness, or fairness, of the information contained in this Official Statement and the Appendices hereto. The Financial Advisor is an independent financial advisory firm and is not engaged in the business of underwriting, trading or distributing municipal securities or other public securities.
81
CERTAIN RELATIONSHIPS
Five attorneys or officers of Cozen O’Connor, which is acting as Underwriter’s counsel in connection with the Series 2018D Bonds, serve on the Board of Trustees of TJU or certain of its affiliates. See “GOVERNANCE AND MANAGEMENT - Board of Trustees” in “APPENDIX A - DESCRIPTION OF THE UNIVERSITY” attached hereto. Ballard Spahr LLP and Cozen O’Connor also represent TJU and various affiliates, from time to time, in certain matters unrelated to this transaction.
Bank of America, National Association, an affiliate of the Underwriter, is the holder of all the Refunded 2017E Bonds which are being redeemed from a portion of the proceeds of the 2018 Bonds.
FORWARD-LOOKING STATEMENTS
Any statements made in this Official Statement, including in the appendices attached hereto, involving estimates or matters of opinion, whether or not so expressly stated, are set forth as such and not as representations of fact, and no representation is made that any of the estimates or matters of opinion will be realized.
This Official Statement, including the appendices attached hereto, contains certain “forward-looking statements” concerning the University’s operations, performance and financial condition, including its future economic performance, plans and objectives and the likelihood of success in developing and expanding. Any statements that express, or involve discussions as to expectations, beliefs, plans, objectives, assumptions, future events or performance (often, but not always, through the “may,” “would,” “could,” “will,” “expect,” “anticipate,” “believe,” “intend,” “plan,” “estimate,” “will result,” “expects to,” “will continue” and similar expressions are meant to identify these forward-looking statements), are not historical and may be forward-looking. Forward-looking statements are subject to known and unknown risks, uncertainties and other factors, including, but not limited to, the risks described under the heading “CERTAIN INVESTMENT CONSIDERATIONS” which may cause actual results to be materially different from those expressed or implied by such forward-looking statements. Although the University believes that the expectations reflected in the forward-looking statements are reasonable, the University cannot guarantee future resolutions, levels of activity, performance or achievements. Readers should not place undue reliance on forward-looking statements. All forward-looking statements included or incorporated by reference in this Official Statement are based on information available on the date hereof and the University assumes no obligation to update any such forward-looking statements.
The forward looking statements herein are necessarily based on various assumptions and estimates and are inherently subject to various risks and uncertainties, including risks and uncertainties relating to the possible invalidity of the underlying assumptions and estimates and possible changes or developments in social, economic, business, industry, market, legal and regulatory circumstances and conditions and actions taken or omitted to be taken by third parties, including customers, suppliers, business partners and competitors, and legislative, judicial and other governmental authorities and officials. Assumptions related to the foregoing involve judgments with respect to, among other things, future economic, competitive, and market
82
conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the control of the University. Any of such assumptions could be inaccurate and, therefore, there can be no assurance that the forward-looking statements included in this Official Statement, including in the appendices attached hereto, will prove to be accurate.
MISCELLANEOUS
All of the summaries of the provisions of the Act, the 2018D Indenture, the 2018D Loan Agreement, the Master Indenture, the Master Note, the Series 2018D Bonds, the Disclosure Agreement and other documents set forth herein are only brief outlines of certain provisions thereof, are made subject to all of the detailed provisions thereof, and do not purport to be complete statements of the provisions of such documents. Reference is directed to all such documents for full and complete statements of all matters of fact relating to the Series 2018D Bonds, the source for repayment for the Series 2018D Bonds and the rights and obligations of the Holders. Copies of such documents may be obtained as specified under the caption “INTRODUCTION - Other Information” herein.
Information concerning the University, the Obligated Group and the anticipated use of the proceeds of the Series 2018D Bonds has been provided by TJU. The information contained in this Official Statement, including in the appendices, has been obtained from official and other sources deemed by TJU to be reliable, and, while not guaranteed as to completeness or accuracy, is believed by the University to be correct as of the date of this Official Statement.
Neither this Official Statement nor any statement which may have been made orally or in writing is to be construed as a contract with the owners of the Series 2018D Bonds.
[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]
83
AUTHORIZATION OF AND CERTIFICATION OF OFFICIAL STATEMENT
This Official Statement and its distribution and use by the Underwriter have been duly authorized by the Authority and the Obligated Group and the execution and delivery thereof have been duly authorized and approved by the Authority and the Obligated Group.
MONTGOMERY COUNTY HIGHER EDUCATION AND HEALTH AUTHORITY
By: James A. Konnick, Chairman Approved:
THOMAS JEFFERSON UNIVERSITY, as Obligated Group Agent
By: Alfred C. Salvato, Senior Vice President, Corporate Finance & Chief Investment Officer
84
APPENDIX A
DESCRIPTION OF THE UNIVERSITY
Table of Contents Page
INTRODUCTION ...... A-1 General ...... A-1 Education and Research ...... A-1 Clinical ...... A-2 History of the University ...... A-2 University Organizational Structure/Obligated Group Members ...... A-5
FACULTY, STAFF AND EMPLOYEES ...... A-9 Faculty ...... A-9 Staff and Employees ...... A-9
GOVERNANCE AND MANAGEMENT ...... A-9 Board of Trustees ...... A-9 Senior Administrative Officers ...... A-12
EDUCATIONAL ACTIVITIES ...... A-15 Sidney Kimmel Medical College ...... A-15 Jefferson College of Biomedical Sciences ...... A-16 Jefferson College of Nursing ...... A-16 Jefferson College of Health Professions ...... A-16 Jefferson College of Pharmacy ...... A-17 Jefferson College of Population Health ...... A-17 College of Architecture and the Built Environment ...... A-17 College of Sciences, Health and the Liberal Arts ...... A-17 Kanbar College of Design, Engineering and Commerce ...... A-18 Other Educational Activities ...... A-18 Locations ...... A-19 Enrollment ...... A-19 Tuition and Fees ...... A-22 Financial Aid ...... A-23 Accreditation ...... A-24 Future University Educational Plans ...... A-25
RESEARCH ACTIVITIES ...... A-25
HEALTHCARE ACTIVITIES ...... A-26 TJUH System ...... A-27 Jefferson/Abington ...... A-27 Jefferson/Aria ...... A-28 Jefferson/New Jersey ...... A-29 Jefferson/Magee ...... A-29 Jefferson Health Physicians ...... A-30 Utilization and Operating Statistics ...... A-30 Sources of Patient Revenue ...... A-31 Delaware Valley ACO ...... A-31
HEALTHCARE SERVICE AREA, DEMOGRAPHICS AND COMPETITION ...... A-32
A-i
Healthcare Service Area ...... A-32 Jefferson Health Clinical Assets ...... A-34 Current and Projected Population ...... A-34 Patient Origin ...... A-35 Other Healthcare Facilities ...... A-35 Future Jefferson Health Healthcare Plans ...... A-38
FINANCIAL INFORMATION AND DISCUSSION ...... A-38 Unaudited Consolidated Balance Sheet ...... A-38 Unaudited Pro Forma Consolidated Statement of Operations ...... A-40
MANAGEMENT DISCUSSION AND ANALYSIS ...... A-41 Unaudited Operating Results as of February 28, 2018 and 2017 ...... A-41 Organizational Structure ...... A-43 Integrated Strategic Financial Planning Process ...... A-43 Notable Activities ...... A-44 Einstein Health Letter of Intent ...... A-45 Other Potential Transactions ...... A-46
INDEBTEDNESS ...... A-46 Outstanding Debt ...... A-46 Interest Rate Derivatives ...... A-46
CASH AND INVESTMENTS ...... A-47 Asset Allocation ...... A-47 Liquidity ...... A-48 Investment Policy, Management and Oversight ...... A-48 Endowment Spending ...... A-49
BENEFITS ...... A-49 Defined Contribution Plans ...... A-49 Defined Benefit Plans ...... A-49 Participation in Multiemployer Defined Benefit Pension Plan ...... A-50
FUNDRAISING AND CONTRIBUTIONS ...... A-50
CAPITAL PROGRAM AND PLANNING ...... A-50
INSURANCE ...... A-51
LITIGATION ...... A-51
A-ii
In addition to the information provided in the Official Statement, including each of the appendices attached thereto, with respect to the Montgomery County Higher Education and Health Authority Thomas Jefferson University Variable Rate Revenue Bonds, Series 2018D (R-Floats) (the “Series 2018D Bonds”), Thomas Jefferson University, a Pennsylvania nonprofit corporation (“TJU”) has provided the following description of TJU and its various affiliates and subsidiaries. A complete review of this Appendix A, together with the body of the Official Statement and all other appendices attached thereto, is essential to the making of an informed investment decision by any purchaser of the Series 2018D Bonds. In the making of an informed investment decision relating to the Series 2018D Bonds, a potential purchaser should not conclude that the presentation of information in this Appendix A, versus presentation of information in the body of the Official Statement, denotes that the information so provided in this Appendix A is of less relevance or importance than the information set forth in the body of the Official Statement.
TJU has not authorized anyone to give any information or to make any representations not contained herein or supplemental hereto, and if given or made, such other information or representations must not be relied upon as having been authorized. The delivery by TJU of the information contained herein shall not, under any circumstances, create any implication that there has been no material change in the affairs of TJU since the date of the Official Statement. All capitalized terms used herein and not otherwise expressly defined herein shall have the respective meanings set forth in the Official Statement.
Information included in this Appendix A includes forward-looking statements about the future that are necessarily subject to various risks and uncertainties (the “Forward-Looking Statements”). These Forward-Looking Statements are (i) based on the beliefs and assumptions of management of the University and on information currently available to such management; and (ii) often identifiable by words such as “estimates,” “expects,” “expected,” “plans,” “believes” and similar expressions.
Events that could cause future results to differ materially from those expressed in or implied by Forward-Looking Statements or historical experience include the impact or outcome of many factors that are described throughout this Appendix A and the rest of the Official Statement. Although the ultimate impact of such factors is uncertain, they may cause future performance to differ materially from results or outcomes that are currently sought or expected by TJU. See also, “CERTAIN INVESTMENT CONSIDERATIONS” in the front part of the Official Statement.
Unless otherwise noted, all information provided in this Appendix A, including the information in the tables, has been provided by the University.
A-iii
INTRODUCTION
General
Thomas Jefferson University (“TJU”) is a nonprofit corporation formed exclusively for charitable, scientific and educational purposes within the meaning of Section 501(c)(3) of the Internal Revenue Code of 1986, as amended (the “Code”). TJU’s mission is “reimagining health, education and discovery to create unparalleled value.” Clinically, TJU is committed to improving lives and providing for, facilitating and enabling patient access to high quality health care in an evolving healthcare delivery system; and integrating care delivery and payment systems to provide comprehensive solutions to patients and the communities served by TJU and its affiliates and subsidiaries, which together are referred to in this Appendix A as the “University.”
AS FURTHER DESCRIBED HEREIN, TJU, TJUH SYSTEM (“TJUH SYSTEM”), THOMAS JEFFERSON UNIVERSITY HOSPITALS, INC. (“TJU HOSPITALS”), JEFFERSON UNIVERSITY PHYSICIANS (“JUP”), ABINGTON HEALTH (“ABINGTON HEALTH”), ABINGTON MEMORIAL HOSPITAL (“AMH”), ABINGTON HEALTH FOUNDATION (“AHF”), LANSDALE HOSPITAL (“LH”), ARIA HEALTH SYSTEM (“ARIA HEALTH SYSTEM”), ARIA HEALTH (“ARIA HEALTH”), PHILADELPHIA UNIVERSITY (“PHILADELPHIA UNIVERSITY”), KENNEDY HEALTH SYSTEM, INC. (“KENNEDY HEALTH SYSTEM”), KENNEDY HEALTH FACILITIES, INC. (“KHF”), KENNEDY UNIVERSITY HOSPITAL, INC. (“KUH”), KENNEDY MEDICAL GROUP PRACTICE, P.C. (“KMGP”) AND THE MAGEE MEMORIAL HOSPITAL FOR CONVALESCENTS (“MAGEE”), AT THE TIME OF ISSUANCE OF THE SERIES 2018D BONDS, WILL BE THE MEMBERS OF THE OBLIGATED GROUP (THE “OBLIGATED GROUP”), WHICH WAS CREATED UNDER THE MASTER INDENTURE REFERRED TO IN THE FOREPART OF THIS OFFICIAL STATEMENT. THESE ENTITIES, AND ONLY THESE ENTITIES, ARE JOINTLY AND SEVERALLY LIABLE FOR ALL OBLIGATIONS ISSUED OR TO BE ISSUED UNDER THE MASTER INDENTURE.
Education and Research
TJU includes nine colleges, two schools and one institute divided primarily among two campuses in Philadelphia (individually, the “Center City Campus” and the “East Falls Campus.” The East Falls Campus was formerly Philadelphia University). The University’s nine colleges are: the Sidney Kimmel Medical College (“Sidney Kimmel Medical College”), one of the oldest and largest private medical colleges in the United States; Jefferson College of Biomedical Sciences (“JCBS” or the “College of Biomedical Sciences”); Jefferson College of Health Professions (“JCHP” or the “College of Health Professions”); Jefferson College of Nursing (“JCN” or the “College of Nursing”); Jefferson College of Pharmacy (“JCP” or the “College of Pharmacy”); Jefferson College of Population Health (“JCPH” or the “College of Population Health”); Kanbar College of Design Engineering and Commerce (“Kanbar College”); College of Architecture and the Built Environment (“CABE”); and the College of Science, Health and the Liberal Arts (“CSHLA”). The nine colleges had a total enrollment of approximately 7,800 (headcount) students for the 2017-2018 academic year, including 1,074 students enrolled in Sidney Kimmel Medical College.
The University’s academic activities are supported by endowments, tuition and fee revenues, gifts, and other sources. As a major scientific and medical research center, the University also receives revenues from research and other grants and contracts with federal, state and local governments, and private industry.
A-1
See “EDUCATIONAL ACTIVITIES” and “RESEARCH ACTIVITIES” herein for a more detailed discussion of the University’s educational and research activities.
Clinical
TJU is the sole corporate member of TJUH System, Abington Health, Aria Health System, Kennedy Health System and Magee, each of which is a non-profit corporation and an organization described in Section 501(c)(3) of the Code. TJUH System, Abington Health, Aria Health System, Kennedy Health System and Magee and each of their operating subsidiaries, and other companies and ventures operated by such corporate entities, are collectively referred to herein as “Jefferson Health.” Jefferson Health, the largest provider of health care services in the greater metropolitan area of Philadelphia, in 2017 had a combined 19.2% market share. See the table titled “SELECT OPERATING STATISTICS OF MAJOR HOSPITALS/SYSTEMS IN JEFFERSON HEALTH 9-COUNTY PSA FOR CALENDAR YEAR 2017” set forth herein in “HEALTHCARE SERVICE AREA, DEMOGRAPHICS AND COMPETITIONS - Other Healthcare Facilities.” Jefferson Health’s healthcare activities include the provision of inpatient and outpatient services at 14 hospitals and a comprehensive outpatient network in two states.
See “HEALTHCARE ACTIVITIES” herein for a more detailed discussion of the University’s healthcare activities.
History of the University
TJU was founded as a medical college in 1824 and opened its first free-standing hospital, called Thomas Jefferson University Hospital, in 1887. Between 1887 and 1995, Thomas Jefferson University Hospital was an unincorporated division of TJU and its budgets, staffing, capital plans and other activities were developed and implemented as part of TJU. Likewise, the clinical practices of the full time faculty of the Sidney Kimmel Medical College practiced under numerous departments that were owned and controlled by TJU. In 1995, TJU formed Jefferson Faculty Foundation to consolidate the departmental practices of its employed faculty into a single, separately incorporated, nonprofit, tax-exempt entity. In 1998, Jefferson Faculty Foundation changed its name to Jefferson University Physicians.
In 1995, TJU Hospitals was established as a controlled affiliate of TJU. In March of 1996, through a transfer of the corporate membership interest, TJU Hospitals became a founding member and controlled affiliate of Jefferson Health System (“JHS”). JHS was a regional non-profit healthcare system not corporately affiliated with TJU that included other controlled hospitals and health care affiliates in southeastern Pennsylvania. In connection with the transfer of corporate membership from TJU to JHS, TJU transferred its hospital-related assets to TJU Hospitals for an amount sufficient to enable TJU to pay off all of its debt allocable to the transferred hospital facilities. Thereafter, TJU and TJU Hospitals operated as separate entities: the hospital’s budgeting, finance, staffing and other transactions were undertaken under the auspices of JHS, while TJU continued to own and operate its educational facilities, research facilities and clinical practice activities. Despite not being corporate affiliates, TJU and TJU Hospitals maintained a close working relationship, with common facilities and shared services. TJU provided certain management and other services to TJU Hospitals.
In 2013, TJU, TJU Hospitals and JHS concluded that it would be advantageous to re-examine the nature and scope of their relationships and that TJU and TJU Hospitals should consider working together under a commonly controlled entity. By then, TJU Hospitals owned and operated three separate hospital divisions – Thomas Jefferson University Hospital, Jefferson Hospital for Neuroscience and Methodist Hospital Division – and was a controlled affiliate of TJUH System, a nonprofit corporation controlled by JHS.
A-2
In 2014, in a series of related transactions among TJU, TJUH System, JUP, JHS and the remaining controlled affiliates of JHS, TJU became the sole corporate member of TJUH System, and TJUH System became the sole corporate member of TJU Hospitals and JUP, thereby aggregating all clinical operations of TJUH System under the control of TJU and effectively unwinding JHS.
On June 30, 2015, TJU and Abington Health, entered into an Enterprise Formation Agreement in which, among other things, TJU became the sole corporate member of Abington Health and the TJU Board (as defined below) was reconstituted to include trustees from TJU and trustees from Abington Health. Abington Health, directly and through its controlled affiliates, including AMH, AHF and LH, owns and operates a major teaching hospital, a community hospital and other healthcare facilities in Montgomery County and Bucks County, Pennsylvania.
On January 19, 2016, TJU entered into a System Integration Agreement with Aria Health System in which, among other things, TJU became the sole corporate member of Aria Health System and the TJU Board was reconstituted to include designees from Aria Health System. Aria Health System, directly and through its controlled affiliates, including Aria Health (“Aria Health”), owns and operates a licensed acute care hospital at three locations and a network of outpatient centers and physicians with facilities in Philadelphia and Bucks County, Pennsylvania. The Aria Health System transaction was accounted for as an acquisition.
On July 1, 2017, Philadelphia University became a controlled affiliate of TJU pursuant to the terms of a university combination agreement dated as of September 9, 2016. TJU became the sole corporate member of Philadelphia University and the TJU Board was reconstituted to include designees from Philadelphia University. The combination created a comprehensive university centered on the delivery of professional education that leverages the strengths of both TJU and Philadelphia University to deliver high-impact education and value for students in health, science, architecture, design, fashion, business and engineering.
On September 1, 2017, Kennedy Health System became a controlled affiliate of TJU pursuant to the terms of a system integration agreement dated as of August 9, 2016. TJU became the sole corporate member of Kennedy Health System and the TJU Board was reconstituted to include designees from Kennedy Health System. Kennedy Health System, directly and through its controlled affiliates, including KHF, KUH and KMGP, owns and operates three licensed acute care hospitals, a long-term care facility, and a network of outpatient centers and physicians with facilities in southern New Jersey.
On January 5, 2018, Magee became a controlled affiliate of TJU pursuant to the terms of a definitive agreement dated as of December 18, 2017. TJU became the sole corporate member of Magee and the TJU Board was reconstituted to include designees from Magee. Magee, founded in 1958, is a 96- bed specialty medical rehabilitation hospital providing physical and cognitive rehabilitation services. It is the 13th ranked rehabilitation hospital in the country according to the 2017-2018 rankings of U.S. News & World Report. Magee’s flagship facility is located in Center City Philadelphia.
The transactions with Abington Health, Aria Health System, Kennedy Health System, Philadelphia University and Magee include provisions for the filling by Abington Health, Aria Health System, Kennedy Health System, Philadelphia University and Magee, respectively, of any vacancies occurring with respect to their designees to the TJU Board during transition/integration periods immediately following the closing of each of those transactions. The transition/integration periods are specific to each transaction and range from two to three years in duration. Following such transition/integration periods, such vacancies will be filled by the TJU Board. During such transition/integration periods, TJU is also required to seek the formal advice and input or, in very limited cases that do not include the incurrence of debt, the approval, of the legacy boards of Abington Health,
A-3
Aria Health System, Kennedy Health System, Philadelphia University and Magee, as applicable, to certain actions that specifically relate to the operation or assets of those entities.
As further described in the front part of the Official Statement, each of TJU, TJUH System, TJU Hospitals, JUP, Abington Health, AMH, AHF, LH, Aria Health System, Aria Health, Philadelphia University, Kennedy Health System, KHF, KUH, KMGP and Magee will comprise, at the time of issuance of the Series 2018D Bonds, and are collectively referred to as, the “Obligated Group.”
[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]
A-4
University Organizational Structure/Obligated Group Members
Thomas Jefferson University
Jefferson Academic Jefferson Health
Philadelphia Magee Rehabilitation TJUH System Kennedy Health Center City Abington Health Aria Health System University Hospital (Jefferson University System, Inc. Campus (Jefferson/Abington) (Jefferson/Aria) (East Falls Campus) (Jefferson/Magee) Hospitals) (Jefferson/New Jersey)
Kennedy Abington Abington Thomas Jefferson Jefferson Kennedy Kennedy Medical Lansdale Aria Health Memorial Health University University University Group Practice, Hospital Health Facilities, Hospital Foundation Hospitals, Inc. Physicians Hospital, Inc. P.C. Inc.
Note: - Orange boxes denote operating groups or divisions and are not actual legal entities. - Blue boxes denote legal entities that comprise the Obligated Group. As further detailed in the first paragraph on the next page, the Obligated Group Members together constitute approximately 93% of the consolidated University revenues and approximately 95% of the consolidated University assets.
* Thomas Jefferson University is the parent entity and also the corporation in which the “Center City Campus” business entity is actually located.
A-5
The following is a brief description of the activities and operations of the Obligated Group (excluding TJU, which is described above). The members of the Obligated Group are the only entities obligated to make payments on the Series 2018D Bonds. TJU currently has approximately 64 controlled Affiliates that comprise the University, all of which, except Magee, are included in TJU’s unaudited interim financial statements as of December 31, 2017 filed on the Electronic Municipal Market Access (“EMMA”) website of the Municipal Securities Rulemaking Board (the “MSRB”) but such unaudited interim financial statements are not incorporated into this Official Statement by such reference. TJU is the borrower under the Loan Agreement and pursuant thereto has promised to repay the Series 2018D Bonds. The other Obligated Group Members are the largest (by revenues, assets and/or visibility) of TJU’s controlled Affiliates. TJU and the other Obligated Group Members together currently constitute approximately 93% of the consolidated University revenues and approximately 95% of the consolidated University assets. As described in the Master Indenture, all of the Obligated Group Members are jointly and severally liable on the obligations issued and outstanding under the Master Indenture, including the Series 2018D Bonds, together with TJU, and have pledged their Gross Revenues to secure such obligations. None of TJU’s controlled Affiliates is currently designated as an Excluded Affiliate and therefore the credit currently available to repay the Series 2018D Bonds is the University (i.e., TJU, the other Obligated Group Members, and each of their controlled Affiliates). For information on the terms by which a controlled Affiliate of TJU could become an Excluded Affiliate in the future, see “SECURITY AND SOURCES OF PAYMENT FOR THE SERIES 2018D BONDS – Addition, Exclusion and Release of Entities with Respect to the Requirements of the Master Indenture” in the front part of this Official Statement. Throughout this Appendix A, the term “University” is used to refer collectively to TJU, the other Obligated Group Members and all of their controlled Affiliates.
TJUH System. TJUH System is a Pennsylvania nonprofit corporation and an organization described in Section 501(c)(3) of the Code whose sole corporate member is TJU. TJUH System is the sole corporate member of TJU Hospitals and JUP and serves as a holding company for the entities and operations that comprise Jefferson University Hospitals (as defined below).
Thomas Jefferson University Hospitals, Inc. TJU Hospitals is a Pennsylvania nonprofit corporation and an organization described in Section 501(c)(3) of the Code whose sole corporate member is TJUH System. TJU Hospitals was founded in 1825 and is the University’s flagship teaching hospital located on the Center City Campus. TJU Hospitals is licensed for 937 acute care beds and is nationally recognized for its programs in Cancer treatment; Cardiology and Heart Surgery; Diabetes and Endocrinology; Ear, Nose and Throat; Gastroenterology and GI Surgery; Geriatrics; Nephrology; Neurology and Neurosurgery; Ophthalmology; Orthopedics; and Urology. TJU Hospitals has a Level I Regional Resource Trauma Center designation and has been designated by the national Institute of Handicapped Research as a Regional Spinal Cord Injury Center. TJU Hospitals operates three acute care hospital locations – Thomas Jefferson University Hospital in Center City, Jefferson Hospital for Neuroscience also in Center City and the Methodist Hospital Division, which is located in South Philadelphia. These facilities are sometimes collectively referred to herein as “Jefferson University Hospitals.”
Jefferson University Physicians. JUP is a Pennsylvania nonprofit corporation and an organization described in Section 501(c)(3) of the Code whose sole corporate member is TJUH System. JUP is a multi-specialty physician practice comprised of the University’s salaried faculty members and was formed to consolidate the clinical activities of the full time faculty of the Sidney Kimmel Medical College into a single nonprofit, tax-exempt entity. JUP is comprised of approximately 708 physicians and operates at approximately 70 locations.
Abington Health. Abington Health is a Pennsylvania nonprofit corporation and an organization described in Section 501(c)(3) of the Code. Abington Health is the sole corporate member of AMH, LH
A-6
and AHF and serves as a holding company for the entities and operations that comprise Jefferson/Abington (defined below).
Abington Memorial Hospital. AMH is a Pennsylvania nonprofit corporation and an organization described in Section 501(c)(3) of the Code whose sole corporate member is Abington Health. Founded in 1913, AMH is a 660-bed acute care hospital located in Abington, Pennsylvania. AMH provides healthcare services primarily to the residents of Abington Township and surrounding communities in Montgomery and Bucks counties, Pennsylvania, as well as other parts of the Philadelphia metropolitan area.
Abington Health Foundation. AHF is a Pennsylvania nonprofit corporation and an organization described in Section 501(c)(3) of the Code whose sole corporate member is Abington Health. AHF’s sole corporate purpose is to support the charitable tax-exempt purposes, programs, and services of AMH and LH.
Lansdale Hospital. LH is a Pennsylvania nonprofit corporation and an organization described in Section 501(c)(3) of the Code whose sole corporate member is Abington Health. Founded in 1934, LH is a 135-bed acute-care facility located in Lansdale, Pennsylvania. LH provides healthcare services primarily to the residents of Lansdale and surrounding communities in Montgomery and Bucks counties, Pennsylvania, as well as other parts of the Philadelphia metropolitan area. LH, together with AHF and AMH, are collectively referred to as “Jefferson/Abington.”
Aria Health System. Aria Health System is a Pennsylvania nonprofit corporation and an organization described in Section 501(c)(3) of the Code. Aria Health System is the sole corporate member of Aria Health, and serves as a holding company for the entities and operations that comprise Jefferson/Aria (defined below).
Aria Health. AH is a Pennsylvania nonprofit corporation and an organization described in Section 501(c)(3) of the Code whose sole corporate member is Aria Health System. Founded in 1903, AH is a 480-bed acute care hospital with three locations in the northeast section of Philadelphia and Lower Bucks County. AH provides healthcare services primarily to residents of northeast Philadelphia and Bucks County. AH and Aria Health System are collectively referred to herein as “Jefferson/Aria.”
Kennedy Health System, Inc. Kennedy Health System is a New Jersey nonprofit corporation and an organization described in Section 501(c)(3) of the Code. Kennedy Health System is the sole corporate member of KHF and KUH, and serves as a holding company for the entities and operations that comprise Jefferson/New Jersey (defined below).
Kennedy Health Facilities, Inc. KHF is a New Jersey nonprofit corporation and an organization described in Section 501(c)(3) of the Code whose sole corporate member is Kennedy Health System. KHF operates Jefferson Health Care Center, a 190 bed extended care facility in Washington Township, New Jersey, with 60 beds devoted to short-term rehabilitation services (“Jefferson Health Care Center”).
Kennedy University Hospital, Inc. KUH is a New Jersey nonprofit corporation and an organization described in Section 501(c)(3) of the Code whose sole corporate member is Kennedy Health System. Founded in 1962, KUH operates three acute-care hospitals in Cherry Hill, Stratford, and Washington Township, New Jersey. KUH provides healthcare services primarily to residents of Camden, Gloucester, Burlington, Atlantic and Cumberland Counties, New Jersey.
Kennedy Medical Group Practice, P.C. KMGP (also known as Kennedy Health Alliance) is a New Jersey captive professional corporation that employs a network of primary care physicians and
A-7
specialists with offices located throughout southern New Jersey. KMGP employs approximately 210 physicians and provides services at more than 20 locations. Kennedy Health System, KHF, KUH and KMGP are collectively referred to herein as “Jefferson/New Jersey.”
Philadelphia University. Philadelphia University is a Pennsylvania nonprofit corporation and an organization described in Section 501(c)(3) of the Code. Philadelphia University was a stand-alone, fully accredited university founded in 1884. Since its combination with TJU in 2017, Philadelphia University’s three main colleges, the Kanbar College, CABE and CSHLA, are now operated as a part of the educational activities of the University principally at the East Falls Campus. See “EDUCATIONAL ACTIVITIES” and “RESEARCH ACTIVITIES” in this Appendix A.
The Magee Memorial Hospital for Convalescents. Magee (doing business as Magee Rehabilitation Hospital) is a Pennsylvania nonprofit corporation and an organization described in Section 501(c)(3) of the Code. Founded in 1958, Magee is a 96-bed specialty medical rehabilitation hospital providing physical and cognitive rehabilitation services. Magee has three locations in Philadelphia and one in Langhorne, Pennsylvania and is collectively referred to herein as “Jefferson/Magee.”
The following map illustrates the nature and location of many of the University’s facilities.
A-8
FACULTY, STAFF AND EMPLOYEES
Faculty
The University has approximately 4,400 faculty members, 3,326 University faculty and/or College of Biological Sciences (“JCBS”) faculty, of whom 2,344 are non-salaried appointed faculty. All full-time, salaried members of the Sidney Kimmel Medical College and JCBS faculty who are engaged in clinical activities are members of JUP. The volunteer faculty is primarily in clinical departments and participates in the clinical instruction of medical students and residents at Jefferson Health’s hospitals and at other clinical sites. Medical staff at hospitals participating in student and resident education must meet the same criteria for faculty status as the full-time faculty and must hold an appointment in the Sidney Kimmel Medical College.
There are approximately 1,171 faculty members at the University’s other colleges and schools, of which approximately 291 are full-time and 37 are tenured.
Staff and Employees
The University is one of the largest employers in the Philadelphia metropolitan area. The University has approximately 30,000 employees (including the salaried faculty employees described above).
Approximately 1,056 University employees are represented by unions and are under collectively bargained contracts. The hospital and healthcare service workers are represented by District Council 1199C (National Union of Hospital and Healthcare Employees) (“1199C”). They are currently covered by a 5-year collective bargaining agreement that was signed on July 1, 2013 and is effective through June 30, 2018. Discussions are currently underway with 1199C leadership regarding this contract. Certain security personnel are covered by a collective bargaining agreement with the International Union, Security, Police and Fire Professionals of America, Local Union 511. A 5-year agreement was signed by union membership on July 1, 2014 and is effective through June 30, 2019. The maintenance and plant operations employees are covered by a collective bargaining agreement with the Teamsters Local No. 830 of Philadelphia, Pennsylvania union. A 3-year agreement was signed by union membership on February 1, 2018 and is effective through January 31, 2021.
Management of the University considers its relations with its employees to be good.
GOVERNANCE AND MANAGEMENT
Board of Trustees
The business and affairs of the University are managed or controlled by the Board of Trustees of TJU (the “TJU Board”), which has all of the powers, authority, responsibilities, and obligations given the board of directors of a nonprofit corporation under the laws of the Commonwealth of Pennsylvania. TJU’s bylaws specify that the number of trustees (other than Trustees Emeriti) may be no greater than 45. Trustees Emeriti are not limited in number. As sole member of the Jefferson Health entities and Philadelphia University, TJU has control over all of the entities comprising the University.
The TJU Board has various standing committees. The Executive Committee has general charge of the affairs of the University and broad powers, including the power to carry out any directions or resolutions of the TJU Board, to transact any business that is committed to it by the TJU Board, as well as other business which may require action between meetings of the TJU Board, and to authorize the
A-9
borrowing of money. The Executive Committee includes: (i) the Chair of the TJU Board; (ii) the Chair- elect or Vice-Chair of the TJU Board; (iii) the Secretary of the TJU Board; (iv) the Treasurer of the TJU Board; (v) the chair of each of the following standing committees: Audit, Compliance and Risk, Academic Affairs (currently known as the “Jefferson Academic Board”), Clinical Affairs and Finance; and (vi) the President and Chief Executive Officer (“CEO”), along with additional appointed Trustees representing enterprise pillars and divisions.
The current membership of the TJU Board is as follows:
Robert S. Adelson1, Merion, PA ...... President, Osage Investments, Inc. David Archibald, EdD, Langhorne,PA ...... Former Superintendent, Lower Moreland Township School District, Retired Robert Barsky, DO, Cherry Hill, NJ ...... President & Medical Director, Mid-Atlantic Kidney Stone Center David R. Binswanger, Philadelphia, PA ...... President and CEO, Binswanger Companies Jay W. Blumenthal, Elkins Park, PA...... Treasurer and Tax Collector, Abington Township Ira Brind, Philadelphia, PA...... President, Brind Investments, Inc. Thomas S. Brown, Esq., Strafford, PA ...... Attorney, Butler Pappas Weihmuller Katz Craig, LLP Ronald L. Caputo, Delran, NJ ...... Vice President and Senior Fiduciary Advisor, Wilmington Trust Stephen P. Crane2, 3, Fort Washington, PA ...... Ernst & Young, LLP, Retired Partner Alfred J. D’Angelo, Jr., Esq., Berwyn, PA ...... Attorney, Cozen O’Connor4 Robert DiStanislao, Haddonfield, NJ ...... Owner and President, RDS Enterprises John F. Durante, Sewell, NJ ...... Independent Owner, McDonald’s Bruce K. Entwisle5, Lower Gwynedd, PA ...... President, Harry Miller Corporation William A. Finn, Mt. Pleasant, SC ...... Chairman, Asten Johnson H. Richard Haverstick, Jr.6, 7, Medford, NJ ...... Managing Partner, Ernst & Young LLP, Retired Richard W. Hevner8 Malvern, PA ...... Managing Director, Wells Fargo Advisors Stephen K. Klasko, MD, MBA*, Philadelphia, PA ...... President and CEO, Thomas Jefferson University & Jefferson Health William A. Landman, Haverford, PA ...... Principal and Chief Executive Officer, MainLine Investment Partners Joseph A. Maressa, Jr., Esq., Waterford, NJ ...... President, Title America Agency Corp. Eileen Martinson910, Philadelphia, PA ...... Chief Executive Officer, Sparta Systems Marvin Mashner11, 12, Ambler, PA ...... Former President and CEO of ACTS Retirement-Life Communities, Retired
1 Member, Executive Committee 2 Chair, TJU Board 3 Chair, Executive Committee 4 Alfred J. D’Angelo, Jr., a member of the TJU Board, is an attorney with Cozen O’Connor, which is serving as underwriter’s counsel for the Series 2018D Bonds. 5 Member, Executive Committee 6 Chair, Finance Committee 7 Member, Executive Committee 8 Member, Executive Committee 9 Member, Executive Committee 10 Co-Chair, Jefferson Academic Board (formerly known as the Academic Committee) 11 Chair, Audit, Risk and Compliance Committee 12 Member, Executive Committee
A-10
Edward F. McKenna, III, Glenside, PA ...... Vice President for Operations, Performance Development Group Leslie J. McNamara, Wilmington, DE ...... Managing Director, Citigroup Austin A. Meehan, III, PE, Yardley, PA ...... President, General Asphalt Paving Company Ronald J. Naples, Wynnewood, PA ...... Chairman Emeritus, Quaker Chemical Corporation John S. Oyler, Esq., Huntingdon Valley, PA ...... Senior Advisor, Faulkner Organization Bruce J. Paparone, Haddonfield, NJ ...... President, Bruce Paparone, Inc., New Homes Vivian W. Pinn, MD, Washington, DC ...... Senior Scientist Emerita, Former Director, Office of Research on Women’s Health, National Institute of Health, Retired Duncan B. Pitcairn, Bryn Athyn, PA ...... Principal and Treasurer, Cairnwood Cooperative Corporation Daniel J. Ragone, CPA, Haddonfield, NJ ...... Retired Principal, Daniel J. Ragone & Company Richard T. Riley, West Chester, PA ...... Former Chairman and CEO, LoJack Corp. Caro U. Rock, Gladwyne, PA ...... Publisher, Family Business Magazine Richard H. Rothman, MD, PhD1, Philadelphia, PA ...... Founder, Rothman Institute Benjamin V. Sanchez, Esq., CPA, Jenkintown, PA ...... Independent Accountant, Attorney Philip J. Sasso, MD, Lower Gwynedd, PA ...... Physician, Chair, Department of Anesthesiology, Abington Memorial Hospital John P. Silvestri2, Haddonfield, NJ ...... President, Interstate Commercial Real Estate Albert E. Smith3, Haddonfield, NJ ...... Retired President, Canon Financial Services Joseph A. Smith, CPA, Philadelphia, PA ...... Vice President, Marketing & Corporate Communications, Philadelphia Gas Works Michael Sneed, Newtown, PA ...... Worldwide Vice President, Global Corporate Affairs, Johnson & Johnson Meryle Twersky, Esq., Huntingdon Valley, PA ...... Former Business Associate and Attorney, Retired Trista M. Walker, New Hope, PA ...... President, Baldwin & Obenauf, Inc. John D. Walp, New Britain, PA ...... President, Converje, LLC Patricia D. Wellenbach, Philadelphia, PA ...... Strategy Advisor to the CEO, Please Touch Museum Craig E. White, Philadelphia, PA ...... President and CEO, Philadelphia Gas Works
Emeritus Trustees
Lennox K. Black, Limerick, PA ...... Former CEO, Teleflex Incorporated, Retired Richard C. Gozon, Naples, FL ...... Chairman of the Board, Amerisource- Bergen Brian G. Harrison, Key West, FL ...... President and CEO, Granville Company James E. Ksansnak, Jupiter, FL ...... Former Vice Chairman, ARAMARK Corporation, Retired Douglas J. MacMaster, Jr., Esq., Ambler, PA ...... Former Senior Vice President, Merck & Co., Inc., Retired Thomas B. Morris, Jr., Esq., Philadelphia, PA ...... Director, Berwind Corporation
1 Member, Executive Committee 2 Member, Executive Committee 3 Member, Executive Committee
A-11
Britton H. Murdoch, Newtown Square, PA ...... Managing Director, Strattech Partners R. Richard Williams, Radnor, PA ...... Principal, Seaboard Advisors, Ltd
Senior Administrative Officers
The President/CEO of the University is elected by and serves at the pleasure of the TJU Board. The day-to-day governance of the University is delegated to the President and, through the President, to his assisting officers and the provost, deans and faculty in each of the colleges and to officers in the University’s other controlled affiliates. The President nominates for approval by the TJU Board all executive vice presidents and certain senior vice presidents, along with all faculty members who are recommended for tenure. The following is a summary of selected biographical information pertaining to the executive cabinet members of the University.
Stephen K. Klasko, MD, MBA, serves as President and Chief Executive Officer TJU and Jefferson Health (2013-present). Dr. Klasko was previously: Chief Executive Officer, USF Health (University of South Florida) and Dean, Morsani College of Medicine; Dean, College of Medicine and Chief Executive Officer of Drexel University Physicians; President and Chief Executive Officer of the Lehigh Valley Physician Group. Additionally, Dr. Klasko serves or has served in various roles with the following organizations: Corporate Director, Teleflex, Inc.; Board Co-Chair, Delaware Valley–ACO; Trustee, Friedrich’s Ataxia Research Alliance; Trustee, Lehigh Valley Health Network; Trustee, Resurrection Health System; Trustee, Certification Commission for Healthcare Information Technology; Board Chair, Health Professions Conferencing Corporation; Dean Liaison, AAMC Group On Institutional Affairs; Trustee, Tampa General Hospital; Health Care Consultant, Governance Institute; Principal, Health Visions LLC; Founding President, Spirit of Women Inc.; and Principal, North Group, Inc.
Anne Boland Docimo, MD, MBA, serves as Executive Vice President and Chief Clinical Transformation Officer (2015-present). Dr. Docimo previously served as Chief Medical Officer, University of Pittsburgh Medical Center (“UPMC”) Health Plan and as Senior Medical Director for the Hospital Division of UPMC. Prior to her roles at UPMC, she was Director of Urgent Care and Community Medicine at Johns Hopkins Health System.
Cristina G. Cavalieri, Esq., serves as Executive Vice President and Chief Legal Officer, TJU General Counsel and Assistant Secretary, JUP Secretary (2015-present). Previous University positions include; Senior Vice President, Chief Legal Officer, Secretary TJU; Vice President for Institutional and External Affairs, TJU General Counsel and Assistant Secretary; General Counsel and Secretary, JUP. Ms. Cavalieri was Senior Partner and Chairperson of the Health Care Department in the law firm of Pelino and Lentz (which merged with Archer & Greiner, P.C.).
Elizabeth A. Dale, EdD, serves as Executive Vice President for Institutional Advancement (2014-present). Dr. Dale was previously Senior Vice President for Institutional Advancement, Drexel University. Prior to Drexel, Dr. Dale was the Vice Chancellor for Advancement and founding Executive Director of the University of Massachusetts’ Amherst Foundation.
Peter L. DeAngelis, Jr., CPA, MBA, FHFMA, serves as Executive Vice President for Financial Affairs and Chief Financial Officer (2016-present). Previously, Mr. DeAngelis served as a partner of the Strategic Execution practice of IMA Consulting, a leading national healthcare provider consulting firm. Mr. DeAngelis was the Executive Vice President and Chief Financial Officer, and then Chief Operating Officer, of Catholic Health East (“CHE”), one of the nation’s largest multi-institutional, Catholic healthcare delivery systems. CHE later merged with Trinity Health. Most recently, Mr. DeAngelis held the position of President of the East Group of the CHE Division, and Executive Vice President of Trinity Health.
A-12
Joseph W. Devine, FACHE, serves as Executive Vice President, Hospital and Health Services, Jefferson Health (2017-present) President and Chief Executive Officer, Jefferson Health-New Jersey Division (2013-present). Mr. Devine is a 30-year Kennedy veteran holding the positions of Senior Vice President for Administration, Vice President for Hospital Services, and Vice President for Business Development. He serves on numerous boards including the Southern New Jersey Chamber of Commerce, is the Executive Club Chairman of the Gloucester County Chamber of Commerce; Commissioner of the South Jersey Transportation Authority; and, Treasurer of the New Jersey Hospital Association (NJHA) Board of Trustees.
John C. Ekarius serves as Executive Vice President and Chief of Staff (2013-present). Mr. Ekarius was previously Chief Operating Officer at University of South Florida Health and the Morsani College of Medicine, as well as Associate Dean for External Relations and Strategic Development at Drexel University. He also was Vice President of Public and Government Affairs at the University of Medicine and Dentistry of New Jersey.
Kathleen Gallagher, MSN, BS, serves as Executive Vice President and Chief Operating Officer (2013-present) and was previously Managing Director at Huron Consulting Group, Inc. Prior to her role at Huron, Ms. Gallagher was Vice Dean for Administration at NYU School of Medicine and served as Senior Associate Dean at the Drexel University College of Medicine.
Joseph B. Hill, serves as Senior Vice President and Chief Diversity and Inclusion Officer (2015- present). Previously, he served as Vice President and Chief Diversity Officer for Froedtert and the Medical College of Wisconsin in Milwaukee. He was Managing Director of Diversity and Inclusion for the American Cancer Society’s national home office in Atlanta, Ga. Prior to the American Cancer Society, Mr. Hill served as Senior Diversity Manager of Cingular Wireless, which became AT&T Mobility.
Kathleen Kinslow, CRNA, EdD, MBA, serves as Chief Executive Officer, Aria Health, Executive Vice President & Chief Integration Officer (2016-present). Dr. Kinslow was previously President and Chief Executive Officer of Aria Health and served as CEO and Executive Director of Pennsylvania Hospital, part of the University of Pennsylvania Health System.
Karen E. Knudsen, PhD, serves as Director of the Sidney Kimmel Cancer Center, and the Hilary Koprowski Professor and Chair of Cancer Biology at TJU (2015-present), with joint appointments in the departments of Medical Oncology, Urology, and Radiation Oncology. Notably, Dr. Knudsen served as the first Vice Provost for TJU, overseeing and integrating basic and clinical research across all six colleges at TJU.
Stephen Littleson, FACHE serves as President, Aria-Jefferson Health (2018-present). Mr. Littleson was most recently President of the Hospital Service Division and Chief Operating Officer at Hackensack Meridian Health. His previous positions were that of Executive Vice President and Chief Operating Officer of Meridian Health, as well as President of Jersey Shore University Medical Center.
Charles G. Lewis serves as Executive Vice President, Chief Growth and Marketing Officer (2016-present). Mr. Lewis was most recently Senior Vice President for the Catholic Leadership Institute. He was Senior Vice President of External Affairs for Lehigh Valley Health Network in Allentown, Pennsylvania. Mr. Lewis also directed his own consulting business, Charles G. Lewis & Associates, serving a number of healthcare and non-profit clients throughout the United States. He is also the former Secretary for External Affairs for the Archdiocese of Philadelphia. Mr. Lewis began his professional career as a congressional aide and speechwriter in Washington, D.C.
A-13
Margaret McGoldrick serves as President, Abington-Jefferson Health (2015-present). Ms. McGoldrick previously served as Executive Vice President and Chief Operating Officer at Abington Health since January 1999. Her previous positions were that of President and Chief Executive Officer of Hahnemann University Hospital and Medical College of PA Hospital.
Laurence M. Merlis serves as Executive Vice President and Chief Operating Officer, Jefferson Health (2015-present). Mr. Merlis was previously President and Chief Executive Officer of Abington Health, after having served as Chief Executive Officer for over twenty years at three healthcare organizations: GBMC Healthcare in Maryland, and Riverview Medical Center and East Orange General Hospital in New Jersey, as well as Executive Vice President for the Clinical Enterprise for the Meridian Health System in New Jersey.
Bruce A. Meyer, MD, MBA, serves as Senior Executive Vice President and Chief Physician Executive (2017-current) for TJU and Jefferson Health. Mr. Meyer previously served as Executive Vice President for Health System Affairs at the University of Texas Southwestern Medical Center (“UTSW”), Chief Executive Officer for its Accountable Care Network and the Senior Executive Officer leading the Population Health Services Company of Southwestern Health Resources. Prior to joining UTSW in 2007, Dr. Meyer served as Chair, Department of Obstetrics and Gynecology at the University of Massachusetts Medical School and President of UMass Memorial Medical Group, a 750-member physician faculty practice.
Rose Ritts, MS, PhD, serves as Executive Vice President and Chief Innovation Officer (2015- present). Dr. Ritts was previously Executive Director for the Office of Licensing and Ventures, Duke University. In addition to her previous role at Duke University, Dr. Ritts managed emerging venture- capital funded NewCos and served as the Director of Biotechnology and Materials at Sarnoff Corporation and Program Manager at the Defense Advanced Research Projects Agency of the United States Department of Defense.
Stephen Spinelli, Jr., PhD, serves as Executive Vice President and Chancellor of TJU (2017- present) and President, Jefferson-East Falls Division (2007-present). He has many years of leadership experience in academia, business and philanthropy. Dr. Spinelli serves on the Board of Advisors for the Berwind Corporation and the Board of Directors for Planet Fitness. Prior to Philadelphia University, Dr. Spinelli held a variety of leadership positions at Babson College in Wellesley, Massachusetts, including vice provost for entrepreneurship and global management, chair of the entrepreneurship division and director of the Arthur M. Blank Center for Entrepreneurship. He was co-founder of Jiffy Lube International and Chairman and CEO of the American Oil Change Corporation.
Alfred C. Salvato serves as Senior Vice President for Corporate Finance & Chief Investment Officer (2011-present). Mr. Salvato was previously Vice President for Finance & Chief Investment Officer and served as Treasurer. He sits on the Client Advisory Boards of BNY Mellon, TIAA/CREF and JP Morgan and participates on the valuation committees of several private capital limited partnerships.
Jeffrey Stevens, serves as Executive Vice President and Chief Human Resources Officer (2016- present). Previously, Mr. Stevens was Chief Human Resources Officer at the University of Rochester Medical Center, a system of three hospitals employing more than 18,000 people. He also held leadership roles at University of Massachusetts Memorial Healthcare and Northern Berkshire Healthcare, also located in Massachusetts.
Mark L. Tykocinski, MD, serves as Executive Vice President for Academic Affairs & Provost, TJU and Dean of Sidney Kimmel Medical College (2008-present). Dr. Tykocinski was professor and Chair of the Department of Pathology and Laboratory Medicine at the University of Pennsylvania School
A-14
Of Medicine. Prior to Penn, Dr. Tykocinski held prominent university and medical school appointments at Case Western Reserve University.
Richard J. Webster, RN, MSN, NEA-BC serves as President, TJU Hospitals (2015-present). Mr. Webster has had a variety of clinical and administrative positions within healthcare, starting as a staff nurse and progressively advancing in management positions to his current role. He has worked in several Philadelphia hospitals, including Pennsylvania Hospital and Penn Presbyterian.
Jack Carroll, Ph.D., M.H.A. serves as President and Chief Executive Officer of Magee (2016- present). Mr. Carroll has served in a variety of clinical and administrative positions during his forty year career. Prior positions in Grand Forks, North Dakota included Chief Executive Officer for the Medical Center Rehabilitation Hospital; Chief Operating Officer for the Rehab, a division of United Hospital; and Administrative Director for Altru Health System (a 3,200 FTE integrated delivery network). Mr. Carroll also previously served as the Vice-Chairman of the Medical Advisory Board for the North Dakota Workers Compensation Board.
EDUCATIONAL ACTIVITIES
The University offers educational degree programs primarily on the Center City Campus and the East Falls Campus through its nine Colleges described below.
Sidney Kimmel Medical College
The Sidney Kimmel Medical College, founded in 1824 as Jefferson Medical College, offers a four-year educational program leading to a degree of doctor of medicine and is also engaged in biomedical, health services and educational research, as well as patient care related to its programs. It is one of the oldest and largest private medical schools in the United States. Sidney Kimmel Medical College, in coordination with Jefferson Health, provides a wide variety of consulting and educational services to healthcare professionals in the Delaware Valley region. Sidney Kimmel Medical College has awarded more than 31,000 medical degrees and has more living graduates than any other private medical school in the nation. Sidney Kimmel Medical College has approximately 13,000 members in its Alumni Association.
The JeffMD curriculum, launched in July 2017, is a patient-centered curriculum that integrates clinical experience, science instruction, and development of a professional persona - how you will interact with clients and peers - throughout the four years of medical school. JeffMD students can customize their studies and declare a specialty interest before the last phase of the curriculum to complete work on the given student’s core competencies in the context of that specialty.
In November 2016, Sidney Kimmel Medical College received approval from its accrediting body, the Liaison Committee for Medical Education, to establish a branch campus at one of its clinical sites, Atlantic Health System in Morristown, New Jersey. Beginning in July 2018, select third- and fourth-year medical students will participate in a longitudinal integrated curriculum, a unique program in which students follow a panel of patients throughout their clinical training – an approach that differs from traditional rotations and reinforces continuity of care and patient-centered treatment. The branch campus is an extension of the affiliation that Sidney Kimmel Medical College and Atlantic Health System have had in place since July 2015.
In addition to the branch campus, the Sidney Kimmel Medical College has established a number of international partnerships with European and Asian educational institutions. One agreement allows up to eight students from Sichuan/West China University to complete two years of clinical training at the
A-15
University, provided they meet certain academic requirements. In addition, a partnership with St. George’s University of London (“SGUL”) offers fourth-year student exchanges, and a pathway for 12 SGUL students to complete their final clinical years at Jefferson Health affiliates. This program also offers an optional Master’s of Public Health from the University’s College of Population Health.
Jefferson College of Biomedical Sciences
Jefferson College of Biomedical Sciences, founded in 1949 as the Board for the Regulation of Graduate Studies, offers PhD programs, Masters of Science programs, and a post-baccalaureate pre- professional program for candidates interested in completing their prerequisite course work for medical and professional schools. In conjunction with Sidney Kimmel Medical College, JCBS also offers a combined MD/PhD program. The PhD degree programs offer leading-edge interdisciplinary education and research training under the mentorship of nationally and internationally recognized faculty. The PhD programs include biochemistry and molecular pharmacology, genetics, cell biology and regenerative medicine, immunology and microbial pathogenesis, and neuroscience. Masters of Science programs are offered in biomedical science, cell and developmental biology, clinical research, forensic toxicology, human genetics and genetic counseling, microbiology and immunology, and pharmacology.
Jefferson College of Nursing
Jefferson College of Nursing, founded in 1891 as the Jefferson Hospital Training School for Nurses, offers a continuum of fully-accredited nursing degree programs, from baccalaureate through doctoral levels and including eight Master of Science in Nursing specialties and an entry-level Doctor of Nursing Practice in nurse anesthesia. The pre-licensure Bachelor of Science in Nursing (“BSN”) program is upper-division, which requires students to have 59 specific undergraduate credits prior to entering the program.
On August 28, 2017, Jefferson College of Nursing opened a satellite campus at AMH in Willow Grove, Pennsylvania. This campus offers three BSN programs: an accelerated program (12 months), upper division pre-licensure BSN program (2 years) and an upper division evening/weekend program (two years including summers).
Jefferson College of Health Professions
The Jefferson College of Health Professions offers undergraduate and graduate degree programs, and is comprised of seven academic departments: Medical Laboratory Sciences and Biotechnology, Couple and Family Therapy, Occupational Therapy - Center City Campus, Physician Assistant Studies - Center City Campus, Physical Therapy, Radiologic Sciences and Professional and Continuing Studies.
Specialty tracks are offered in the Department of Medical Laboratory Sciences and Biotechnology (bachelor’s and master’s programs in biotechnology, cytotechnology, medical laboratory sciences) and the Department of Radiologic Sciences (bachelor’s programs in radiography, general sonography, cardiac sonography, invasive cardiovascular technology, computed tomography, magnetic resonance imaging, medical dosimetry, nuclear medicine, radiation therapy and vascular sonography). A Master of Science in Medical Physics, an executive master’s program in Radiologic and Imaging Sciences, and PET/CT and CT certificate programs are also offered in the Department of Radiologic Sciences. In the Department of Occupational Therapy - Center City Campus, a bachelor’s to master’s program is offered, as well as entry-level masters, entry level doctorate, and post professional doctoral programs. The Department of Physical Therapy offers a clinical doctorate. The Master’s in Family Therapy is offered through the Department of Couple and Family Therapy, as well as a certificate in Medical Family Therapy. The Department of Physician Assistant Studies - Center City Campus, offers a
A-16
Master of Science in Physician Assistant Studies. The Department of Professional and Continuing Studies offers a variety of certificate programs, including medical coding and data quality, medical practice management, and healthcare management information systems, as well as a bachelor’s degree program with majors in health services management, health professions management and health services management information systems.
Jefferson College of Pharmacy
Jefferson College of Pharmacy, founded in 2008, prepares students for careers in the profession of pharmacy. Students earn a Doctor of Pharmacy degree. The PharmD program is structured to provide an understanding of the basic sciences, clinical information, pharmaceutical sciences, administrative and social sciences, and the importance of each component of pharmacy practice. In addition, students have the opportunity to apply the skills learned in the classrooms and labs across a variety of pharmacy practice settings during the experiential portions of the program – working side by side with practicing pharmacists and caring for patients.
Jefferson College of Population Health
Jefferson College of Population Health, founded in 2008, was the first designated School of Population Health in the United States. JCPH offers a certificate and Master of Science programs in health policy, healthcare quality and safety, applied health economics and outcomes research and public health. At the doctoral level, JCPH offers a PhD in population health sciences as well as a certificate program in healthcare operational excellence. JCPH also offers a certificate and Master’s Degree program in Population Health, and Population Health Intelligence. These are two distinct programs, each with a certificate and Master’s Degree.
College of Architecture and the Built Environment
CABE, located at the East Falls Campus, is dedicated to educating future leaders in the architecture, interior design, landscape architecture, construction management, geodesign, sustainable design and real estate development fields. The curricula emphasize specialized knowledge unique to each discipline, paired with inter-professional collaboration that prepares students for practice in the global market. The school’s dynamic approach to education and emphasis on transdisciplinary learning, sustainability, and innovation train the graduates to become successful design professionals and leaders in sustainable practice.
CABE offers the following undergraduate degrees: Architecture, Architectural Studies, Construction Management, Interior Design, Landscape Architecture. CABE offers the following graduate degrees: Architecture, Construction Management, Geospatial Technology for Geodesign, Interior Architecture, Real Estate Development, Sustainable Design.
College of Sciences, Health and the Liberal Arts
CSHLA is located at the East Falls Campus and its students tackle real-world issues through study abroad opportunities, environmental and conservation fieldwork, clinical experiences and mock trial competitions. With attentive advising, and opportunities for community engagement and participation in faculty research, its students are prepared to succeed in the professional realm or to continue their academic studies at a higher level. An interdisciplinary approach to learning is at the heart of CSHLA, where the liberal arts convene with social, health, and behavioral sciences to form a truly innovative curriculum.
A-17
CSHLA offers the following undergraduate degrees in Biochemistry, Biology, Biopsychology, Chemistry, Communication, Health Sciences, Law and Society, Pre-Medical Studies, and Psychology. Graduate students in CSHLA can earn the following degrees: Athletic Training, Disaster Medicine and Management, Midwifery, Occupational Therapy, Physician Assistant Studies, Community and Trauma Counseling, Art Therapy, Community and Trauma Counseling.
Kanbar College of Design, Engineering and Commerce
The Kanbar College, located at the East Falls Campus, is comprised of two schools: the School of Business and the School of Design and Engineering. The two schools offer the following undergraduate degrees: Accounting, Finance, Animation and Digital Media, Engineering, Fashion Design, Fashion Merchandising and Management, Graphic Design Communication, Industrial Design, International Business, Management, Marketing, Mechanical Engineering, Textile Design, Web Design and Development. Graduate degree offerings include: Master of Science Fashion Design Management, Master of Science Global Fashion Enterprise, Master of Science Industrial Engineering, Innovation MBA, Master of Science Surface Imaging, Master of Science Taxation, Master of Science Textile Design, Master of Science Textile Engineering, Ph.D in Textile Engineering and Sciences, Master of Science User Experience and Interaction Design.
Other Educational Activities
Aria Health School of Nursing (“AHSON”) was founded in 1904 as the Frankford Hospital School of Nursing and currently has 243 students enrolled. The program, leading to a diploma in nursing, is 2 years and 10 months in length. Completion of the diploma leads to eligibility to sit for the National Council Licensure Examination-Registered Nurse for licensure as a registered nurse. The program offers a strong theory and clinical foundation for nursing practice. Additionally, graduates may complete the Bachelor of Science in Nursing at Penn State University in as little as one term, or other colleges and universities based on their requirements. AHSON is accredited by the Accreditation Commission for Education in Nursing and approved by the Pennsylvania State Board of Nursing. AHSON enrolled its last new students in January 2017. It is currently anticipated that AHSON will close after the Fall 2019 semester.
The School of Continuing and Professional Studies offers specialized short courses and certificate programs to give up-to-date training, hands-on experience and tools that will keep students at the forefront of their field, or help in the exploration of a new interest. Students in the School of Continuing and Professional Studies can earn an Associate’s Degree in the following disciplines: Occupational Therapy, Health and Human Services: Radiologic Technology. Undergraduate degree offerings include: Accounting, Behavioral and Health Services, Business Management, Health Sciences, Health Services Management, Human Resources Management, Information Technology, Law enforcement Leadership, Leadership in Emergency Services, Leadership in Homeland Security, and Organizational Leadership. The School also offers one graduate degree in Strategic Leadership. In addition, the School offers specialized non-recurring seminars and corporate partnerships to meet the demand for particularized educational services.
The Institute of Emerging Health Professionals (“IEHP”), founded in 2015, has a mission to provide innovative and unique education and training that will be needed to fill future career, training, and certification gaps in healthcare practice and delivery. IEHP is a first-of-its-kind educational think-tank and incubator aimed at providing today the training that workers in healthcare and related disciplines will need tomorrow. IEHP’s programming is organized under six healthcare related areas – Aging, Clinical, Community Engagement, Integrative Medicine, Data Management and Business of Healthcare. IEHP focuses on educating clinicians to be better healthcare providers, anticipating and then practicing on the
A-18
cutting edge of clinical and education horizons, while also educating consumers and other health professionals to be more prepared, more engaged, and more participatory partners in healthcare delivery. While it does not have a degree program of its own, IEHP offers advanced adult education techniques, unique and contemporary distance learning technology, and an engaged multi-disciplinary, international faculty to deliver curricula designed for clinicians, non-clinicians, and combined groups who learn from each other, side by side.
AMH sponsors five residency programs: family medicine; internal medicine; OB/GYN; general surgery; and dental surgery. AMH has fellowships in Geriatric Medicine, Bariatric Surgery and Interventional Neurology. As of August 31, 2017, 118 residents and two fellows, each of which are students at colleges or universities other than the University, were enrolled in these training programs. AMH also has a pharmacy residency training program which trains three PGY1 residents and one PGY2 ID pharmacy resident.
AMH also provides postgraduate physician training: in affiliation with Temple University Hospital for orthopedics, urology, plastic surgery, physical medicine and rehabilitation, and otolaryngology; in affiliation with Hahnemann University Hospital for orthopedic surgery, internal medicine, infectious disease, cardiology, interventional cardiology, anesthesia, rheumatology, psychiatry, vascular surgery, and interventional neurology; and in affiliation with The Philadelphia College of Osteopathic Medicine in neurosurgery and otolaryngology. Students from Drexel University College of Medicine, The Lewis Katz School of Medicine at Temple University and Sidney Kimmel Medical College receive training in various clinical departments at AMH. The Physician Assistant Programs at TJU have clinical training affiliations with AMH. LH provides post-graduate training to hand surgery fellows from the Philadelphia Hand to Shoulder Center.
Locations
Sidney Kimmel Medical College, JCBS, JCN, JCHP, JCP and JCPH currently operate primarily out of the Center City Campus. CABE, CSHLA and Kanbar College currently operate out of the East Falls Campus.
Enrollment
The following table shows fall full-time-equivalent student enrollment at the University’s nine Colleges, one Institute, AHSON and the School of Continuing and Professional Studies, in the current and the previous four academic years on a pro forma basis (assuming the University, as currently constituted, existed during such periods).
[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]
A-19
PRO FORMA FALL FULL-TIME-EQUIVALENT ENROLLMENT
Fall 2017 Fall 2016 Fall 2015 Fall 2014 Fall 2013 Sidney Kimmel Medical College1 1,086 1,070 1,056 1,072 1,061 Jefferson College of Biomedical Sciences 271 245 213 200 213 Jefferson College of Health Professions 754 756 726 684 676 Jefferson College of Nursing2 794 792 864 874 829 Jefferson College of Pharmacy 261 275 273 281 290 Jefferson College of Population Health 137 117 104 88 78 College of Architecture and the Built Environment 583 576 607 640 615 Kanbar College of Design, Engineering and Commerce 1,364 1,478 1,522 1,574 1,550 College of Sciences, Health and the Liberal Arts 912 854 812 773 776 School of Continuing & Professional Studies 465 401 360 332 271 Institute of Emerging Health Professions 16 5 n/a n/a n/a Aria Health School of Nursing 165 243 239 217 202 Totals 6,808 6,812 6,776 6,735 6,561
The following tables provide information on applications, acceptances and matriculations for first-year students at the indicated University colleges for the current and the previous four academic years.
SIDNEY KIMMEL MEDICAL COLLEGE
Academic Year 2017-18 2016-17 2015-16 2014-15 2013-14 Total National Applications 51,954 52,735 51,102 49,372 47,855 Applications 10,052 10,726 10,540 10,204 10,118 Applications as % of National Applications 19% 20% 21% 21% 21% Acceptances Offered 459 461 446 423 452 Acceptances as % of Applications 5% 4% 4% 4% 5% First Year Matriculants 274 266 266 259 260 First Year Matriculants as % of Acceptances 60% 58% 60% 62% 58% Total Headcount 1,086 1,070 1,056 1,072 1,061
Source: National application statistics provided by the American Association of Medical Colleges.
1 All Sidney Kimmel Medical College and JCP students are full-time. 2 Includes students formerly enrolled in the Abington Memorial Hospital Dixon School of Nursing which was consolidated into the JCN in October 2017.
A-20
JEFFERSON COLLEGE OF BIOMEDICAL SCIENCES
Academic Year 2017-18 2016-17 2015-16 2014-15 2013-14 Applications 551 416 428 300 619 Acceptances Offered 292 220 212 134 154 Acceptances as % of Applications 53% 53% 50% 45% 25% First Year Matriculants 161 159 122 98 112 First Year Matriculants as % of Acceptances 55% 73% 58% 65% 73% Total Headcount 364 3371 287 277 290
JCHP, JCN, JCP AND JCPH – UNDERGRADUATE
Academic Year 2017-18 2016-17 2015-16 2014-15 2013-14 Applications 1,718 1,667 1,324 1,308 1,381 Acceptances Offered 817 600 616 675 585 Acceptances as % of Applications 45% 36% 47% 52% 42% First Year Matriculants 591 477 533 575 568 First Year Matriculants as % of Acceptances 73% 80% 87% 86% 97% Total Headcount 1,080 1,0522 1,077 1,188 1,232
PRO FORMA EAST FALLS CAMPUS – UNDERGRADUATE3
Academic Year 2017-18 2016-17 2015-16 2014-15 2013-14 Applications 4,987 5,238 5,336 5,883 5,801 Acceptances Offered 2,936 3,161 3,354 3,709 3,692 Acceptances as % of Applications 59% 60% 63% 63% 64% First Year Matriculants 1,068 1,166 1,002 1,118 1,026 First Year Matriculants as % of Acceptances 36% 37% 30% 30% 28% Total Headcount 2,763 2,753 2,814 2,911 2,834
1 Increase in enrollment from Academic Year 2015-16 due to increased marketing efforts, including use of webinars and emphasizing the ability to choose both a part-time or accelerated option for completing coursework. 2 Decrease in enrollment from Academic Year 2015-16 due to Occupational Therapy and Physical Therapy programs shifting to Masters and Doctorate level Graduate programs. 3 Comprises the colleges formerly constituting Philadelphia University.
A-21
JCHP, JCN, JCP AND JCPH – GRADUATE
Academic Year 2017-18 2016-17 2015-16 2014-151 2013-14 Applications 5,697 6,111 5,019 6,333 3,484 Acceptances Offered 1,162 1,244 978 866 691 Acceptances as % of Applications 20% 20% 20% 14% 20% First Year Matriculants 685 740 727 632 589 First Year Matriculants as % of Acceptances 59% 60% 74% 71% 85% Total Headcount 1,7382 1,405 1,272 1,114 1,068
PRO FORMA EAST FALLS CAMPUS – GRADUATE3
Academic Year 2017-18 2016-17 2015-16 2014-15 2013-14 Applications 4,297 3,409 3,526 3,543 3,177 Acceptances Offered 1,259 1,351 1,334 1,140 884 Acceptances as % of Applications 29% 40% 38% 32% 28% First Year Matriculants 584 610 601 490 438 First Year Matriculants as % of Acceptances 46% 45% 45% 43% 50% Total Headcount 803 781 701 620 526
Tuition and Fees
The following table provides average tuition and fee information for the various University academic divisions.
TUITION AND FEES FOR SELECTED FULL-TIME PROGRAMS
Academic Year 2017-18 Sidney Kimmel Medical College $55,464 JCBS 28,261 JCHP 36,796 JCN 42,363 JCP 39,023 JCPH 43,912 East Falls Campus Undergraduate Program 38,160 AHSON 18,585
1 Academic Year 2014-15 was the first year for the Physician Assistant Program which received approximately 1,300 applications for 30 positions. 2 Year-over-year increase in enrollment due to the addition of nursing students from the Abington Campus and a larger enrollment in JCPH’s Master of Public Health program. 3 Comprises the colleges formerly constituting Philadelphia University.
A-22
The following table provides average tuition and fees information for Sidney Kimmel Medical College and selected competitor schools for the current academic year.
COMPARATIVE TUITION AND FEE INFORMATION
Medical School 2017-18 University of Pennsylvania $60,947 Drexel University 56,126 Sidney Kimmel Medical College 55,464 University of Pittsburgh 55,548 Pennsylvania State University 49,800 Temple University 54,000
Source: Compiled by TJU from various publically available records.
The following table provides average tuition and fees information for East Falls Campus Undergraduate Programs and selected competitor schools for the current academic year.
EAST FALLS CAMPUS UNDERGRADUATE COMPARATIVE TUITION AND FEE INFORMATION
Private Institution 2017-18 Villanova University $50,554 Drexel University 49,632 Pratt Institute 47,986 Syracuse University 45,150 St. Joseph’s University 43,700 Widener University 43,296 Arcadia University 41,630 Rochester Institute of Technology 39,506 East Falls Campus Undergraduate 38,160 Marist College 36,120 LaSalle University 28,800
Financial Aid
The University’s admissions and financial aid policies are designed to assist the most qualified students to attend its schools, regardless of their financial circumstances. Approximately 67% of the University’s total student population receive some form of financial aid. Financial aid is received through a combination of grants and loans from governmental, private and institutional sources.
The following table sets forth the amounts of student financial aid provided from governmental, private and institutional sources during the past five academic years, on a pro forma basis (assuming the University, as currently constituted, existed during such periods).
A-23
PRO FORMA STUDENT FINANCIAL AID
Fiscal Year Ended June 30, 2017 2016 2015 2014 2013 Sidney Kimmel Medical College Grants $ 8,700,502 $ 8,625,025 $ 8,654,685 $ 8,585,230 $ 7,952,189 Loans 32,011,829 36,279,843 36,256,121 35,089,028 35,876,378 JCBS Grants 128,137 3,020,135 2,735,770 3,449,900 3,677,151 Loans 2,388,962 1,920,630 1,630,992 1,653,663 1,354,980 Other Center City Campus Colleges Grants 6,273,827 5,841,298 5,370,529 5,639,666 5,402,509 Loans 53,388,719 48,205,532 46,560,635 45,296,906 46,011,911 East Falls Campus Undergraduate Program Grants/Scholarship Aid 47,474,486 46,632,217 45,950,217 42,517,824 41,790,478 Loans 14,712,073 15,262,489 16,629,746 16,286,022 16,434,437
Accreditation
TJU is fully accredited by the Middle States Commission on Higher Education (the “MSCHE”). The MSCHE acted to reaffirm TJU’s accreditation in June 2014 for 10 years and accepted the required process report in June 2016, again reaffirming full accreditation through 2024. Philadelphia University held continuous accreditation from MSCHE since 1955, which was reaffirmed in 2016. MSCHE approved the combination of TJU and Philadelphia University in 2017.
Sidney Kimmel Medical College is fully accredited by all appropriate accrediting bodies. In 2016, the Liaison Committee on Medical Education of the Council on Medical Education of the American Medical Association and the Executive Council of the Association of American Medical Colleges granted the Sidney Kimmel Medical College a full accreditation through Academic Year 2022-23.
Programs for the education of residents are all fully accredited by the various specialty boards under the aegis of the Accreditation Council on Graduate Medical Education.
The University’s professional programs are approved by the following accrediting agencies:
• Commission on Accreditation of Allied Health Education Programs • Cytotechnology Programs Review Committee, American Society of Cytopathology • Joint Review Committee on Education in Diagnostic Medical Sonography • National Accrediting Agency for Clinical Laboratory Sciences • Joint Review Committee on Education in Radiologic Technology • Commission on Collegiate Nursing Education • Council on Accreditation of Nurse Anesthesia Educational Programs • Accreditation Council for Occupational Therapy Education (American Occupational Therapy Association) • Commission on Accreditation of Physical Therapy Education (American Physical Therapy Association)
A-24
• Committee on Education of the American Association of Marital and Family Therapy • Accreditation Review Commission on Education for the Physician Assistant • Joint Review Committee on Cardiovascular Technology • Joint Review Committee on Education in Radiologic Technology • Accreditation Council for Pharmacy Education • Accreditation Commission for Midwifery Education (ACME) • National Association of Schools of Art and Design, Commission on Accreditation • National Architectural Accrediting Board • Council for Interior Design Accreditation • Accreditation Board for Engineering and Technology • Landscape Architecture Accreditation Board • American Chemical Society • Accreditation Council for Business Schools and Programs
The Master’s Program in Public Health is accredited by the Council for Education in Public Health.
Future University Educational Plans
The University’s strategic vision is to expand from the current nine colleges to 11 colleges as of July 1, 2018 and 14 colleges by 2024. The University’s current enrollment goal is to grow to 10,000 students by 2024, while during the same period increasing overall student selectivity. Any expansion of the University’s current academic framework and enrollment is subject to a variety of factors and no assurances can be given as to the occurrence and the timing of such expansion.
RESEARCH ACTIVITIES
The University’s research efforts are focused on investment in areas of science and programmatic initiatives, such as Mitochondrial Pathogenesis, Fibrotic Diseases, Nuerodegeneration/ALS, and Airway Disease. The University’s management believes that investment in the recruitment of strategically funded faculty members, as well as promising junior faculty members, has enhanced the University’s ability to stabilize and promote growth of research within those targeted areas.
The University receives revenues from grants and contracts awarded to support costs of sponsored research and certain other efforts. Revenues are provided by both federal and non-federal sponsors and generally consist of two components: direct costs (including salary and benefits of faculty members and other employees, supplies and expenses related to research efforts); and indirect costs (representing the allocation of overhead costs such as physical plant maintenance, utilities, administrative expenses and depreciation and interest on equipment and facilities related to research efforts). Indirect cost recovery is based on a negotiated indirect cost recovery rate for sponsored research which is applied to direct costs. For federal purposes, the University generally negotiates an indirect cost recovery rate that is applied to all of its federal awards. Recovery rates for non-federal awards vary by award.
Applied research at the East Falls Campus is funded through a variety of external sponsors ranging from federal research agencies, mission-driven agencies, a host of industry sponsors and other for-profit and not-for-profit entities. The work is typically performed by faculty teams, and by undergraduate and graduate students (under the supervision of faculty) and often involves external partnerships with for-profit and not-for-profit clients, independent contractors, and other academic institutions. There will be opportunities to capture the value of new knowledge developed during applied
A-25
research projects through the execution and licensing of patents and copyrights. Applied research, incorporated into East Falls curricula, introduces active, collaborative, real-world experiences through client-driven problem-solving in a transdisciplinary team-based environment.
The following table sets forth the University’s operating revenues from grants and contracts for the past two fiscal years on a pro forma basis (assuming the University, as currently constituted, existed during such periods):
PRO FORMA GRANTS AND CONTRACTS REVENUE ($000s)
Fiscal Year Ended June 30, 2017 2016 Organized Research: Federal Direct $40,941 $37,658 Federal Indirect 19,579 18,525 Non-Federal Direct 19,369 15,733 Non-Federal Indirect 4,049 4,730 Total Organized Research $83,938 $76,646
Teaching, Training, Multipurpose 17,560 16,618 Meaningful Use/EH 0 Subtotal $99,763 $93,264
Less: Amounts Reflected as Tuition Revenue (525) (2,079) Totals $99,238 $91,185
The University’s management expects that level of grants and contracts revenue will continue to be under pressure due to the competitive environment created by reduced funding levels from the National Institute of Health. The University’s management expects to continue to diligently monitor faculty funded status and will identify opportunities that will maintain and grow the University’s grant portfolio via linkages to existing clinical programs, recruitment of well-funded faculty, and increased collaborations with regional and multi-disciplinary institutes and centers.
HEALTHCARE ACTIVITIES
Jefferson Health is a nationally ranked academic medical system. Jefferson Health has experienced significant growth in recent years. Jefferson Health’s healthcare activities include the provision of primary, secondary and tertiary care, inpatient and outpatient services in five separately licensed acute care hospitals operating at eleven acute care hospital locations, two specialty hospitals, one rehabilitation hospital, one long-term care facility, multiple physician practice groups with approximately 1,680 physicians, sub-acute care facilities, and other related endeavors.
Jefferson Health is committed to caring for its patients and their families, educating healthcare professionals for the future, pursuing discovery research and clinical innovation, and serving its community. Jefferson Health’s strategic vision is to be recognized as a leading academic healthcare system differentiated by its ability to deploy new models for physician recruitment and engagement,
A-26
embrace a shared governance structure to build strategic combinations, and use technology to transform how healthcare is delivered to patients in meaningful, convenient and cost-effective ways. Jefferson Health’s commitment to discovery, innovation, and compassionate, patient-focused care is core to its mission.
TJUH System
TJUH System currently includes Thomas Jefferson University Hospital and Jefferson Hospital for Neuroscience on the University’s main campus in Center City, Philadelphia; and Methodist Hospital Division in South Philadelphia; Jefferson at the Philadelphia Navy Yard, in South Philadelphia; JUP, ROSH (as defined below) in Bensalem, Bucks County, Pennsylvania; and Jefferson at Voorhees, in southern New Jersey. Jefferson at the Philadelphia Navy Yard and Jefferson at Voorhees provide multi- specialty outpatient and community-based services. Outpatient and community-based services are also delivered through an extensive network of owned and affiliated physician practices, satellite medical and surgical centers, outpatient laboratories and radiology centers, and retail pharmacies.
According to the 2017-2018 rankings of U.S. News & World Report, Thomas Jefferson University Hospital ranks among the top hospital facilities in the Philadelphia metro area (2nd), in Pennsylvania (3rd), and nationally (16th). Thomas Jefferson University Hospital had three specialties in the top 10 in the country (ophthalmology, ear nose and throat, and orthopedic surgery) and eleven specialties in the top 50 nationally, including the Sidney Kimmel Cancer Center, ranked 20th nationally.
Jefferson University Hospitals have 937 licensed acute care beds and provides the full range of clinical care delivery – from primary through complex quaternary – both in inpatient and ambulatory settings and in all specialties and subspecialties.
JUP is a multi-specialty physician practice group of approximately 838 physicians comprised of the full-time salaried faculty physicians of the Sidney Kimmel Medical College and is the entity through which those physicians provide their clinical services to patients. JUP operates at approximately 70 locations throughout the region and JUP physicians are the attending physicians for most of the patients admitted to TJUH System.
Rothman Orthopaedic Specialty Hospital, LLC (“ROSH”), a Pennsylvania limited liability company, owns and operates a licensed specialty acute care hospital located in Bensalem, Bucks County, Pennsylvania. ROSH focuses on patients with orthopaedic medical issues and offers services for joint replacement, spinal surgery, and sports medicine management, among others. The hospital, which opened in 2010, has 24 beds and six operating rooms and is accredited by The Joint Commission. In 2016, TJUH System obtained a controlling interest in ROSH. The remaining ownership interests are held by Rothman Specialty Hospital Investment, LLC, Nueterra Holdings, LLC and Holy Redeemer Health System.
Jefferson/Abington
Jefferson/Abington provides a wide range of inpatient and outpatient acute care services for medical, surgical, pediatric and obstetrical/gynecological patients, as well as tertiary care services in the areas of cardiology, orthopedics, neurology, neurosurgery, neonatology and oncology primarily to residents of Bucks, Montgomery and Philadelphia counties. Jefferson/Abington has one of only two trauma centers in Montgomery County and has a Level III Neonatal Intensive Care Unit (NICU). According to the 2017-2018 rankings of U.S. News & World Report, AMH is rated as high performing regionally in heart bypass surgery, chronic obstructive pulmonary disease and colon cancer surgery.
A-27
Founded in 1913, Jefferson/Abington’s main campus contains 660 licensed acute care beds and is located on approximately 18 acres in Abington Township, Pennsylvania. Jefferson/Abington also includes a 50-acre ambulatory care complex five miles north of AMH’s main campus in Willow Grove, Pennsylvania. The Willow Grove complex provides a full range of outpatient and physician services and houses the Abington branch of the JCN and the Asplundh Cancer Pavilion. The Asplundh Cancer Pavilion is a new 86,000 square foot ambulatory location that will provide high-quality and comprehensive cancer care in a single location. Asplundh is scheduled to open in the summer of 2018. AMH also owns the former Warminster Hospital, located approximately five miles north from AMH and now known as Abington Health Center-Warminster. The Warminster campus provides ambulatory care services with physician offices, a sleep center, a Bariatric Surgery program, inpatient hospice and outpatient services in laboratory, radiology, neuroscience and rehabilitation.
Jefferson/Abington also includes LH a 135 licensed bed acute care facility located about 12 miles north of AMH’s main campus. LH provides a full range of medical and surgical services, employing 630 people and maintaining a medical staff of 300.
Jefferson/Aria
Jefferson/Aria is a leading healthcare provider serving Northeast Philadelphia and Bucks County. Jefferson/Aria has three inpatient facilities with 485 licensed beds and a network of outpatient sites and physician practices. Jefferson/Aria employs approximately 4,000 workers with a medical staff membership exceeding 850.
Jefferson/Aria’s Torresdale campus has served the residents of Northeast Philadelphia and surrounding suburban communities since 1977. The 258-bed licensed facility offers an array of inpatient and outpatient medical, emergent and surgical services. The Torresdale campus is a state-accredited Level II Trauma Center, one of the original nine trauma sites designated by the Commonwealth of Pennsylvania. This campus delivers a wide range of primary, specialty and emergency care services.
Jefferson/Aria’s Frankford campus has served the residents of Lower Northeast Philadelphia and the surrounding community since 1903. The 115-bed licensed facility offers an array of emergency, inpatient, outpatient, medical and surgical services.
Jefferson/Aria’s Bucks County campus, a 112-bed licensed facility, has served the residents of Lower Bucks County and the surrounding community since 1999. The Bucks County campus offers an array of in-patient and outpatient medical, surgical and emergency services.
In 2004, AHSON, under its former name The Frankford Hospital School of Nursing, celebrated its 100-year anniversary. The School continues to carry on the long tradition of educating caring and responsible nurses who will become a vital part of the healthcare community and the community in which they live. AHSON currently has 243 students.
Health Partners of Philadelphia, Inc., is a hospital-owned, non-profit Health Maintenance Organization providing access to healthcare services on a prepaid basis. Health Partners is licensed to operate in Philadelphia and the surrounding counties with both Medicare and Medicaid lines of business, serving more than 190,000 members in Philadelphia, Chester, Delaware, Bucks and Montgomery counties. Jefferson/Aria is one of six hospitals in the Philadelphia market with an ownership interest in Health Partners.
A-28
Jefferson/New Jersey
Jefferson/New Jersey (formerly Kennedy Health System) delivers a broad range of inpatient and outpatient services at its three acute care hospital locations in southern New Jersey with 607 licensed beds and a network of outpatient sites and physician practices. Jefferson/New Jersey employs approximately 4,700 workers with a medical staff membership exceeding 1,000.
Jefferson/New Jersey’s Cherry Hill campus includes a 196 licensed bed facility on a sixteen acre campus providing primary and secondary care clinical services and limited tertiary care services. This campus includes a 51 bed psychiatric services unit, including acute child and adolescent care services, and outpatient psychiatric and drug rehabilitation services. The Cherry Hill campus is designated as a Children’s Crisis intervention service by the New Jersey Division of Children’s Behavioral Health Services and as a Short-Term Care Facility by the New Jersey Division of Mental Health & Addiction Services. In June 2017, the Jefferson/New Jersey opened a new 100,000 square foot medical office building at the Cherry Hill campus connected to the hospital, that includes various outpatient services, a 22,000 square foot ambulatory surgical center in partnership with ROSH and physician office space. The former medical office building will be replaced by the new patient care tower being financed as a part of the New Money Project described in the forepart of this Official Statement.
Jefferson/New Jersey’s Stratford facility is a 181 licensed bed facility on a ten acre site, providing primary, secondary, tertiary care and clinical services, and serves as the main facility for KUH’s graduate medical education programs. This facility focuses on general medical/surgical services and also has an ACE (Acute Care for Elders) unit, a distinct medical/surgical unit designed to meet the unique needs of hospitalized older adults and a Bariatric Surgery Program accredited as a Level 1 facility by the Bariatric Surgery Center Network of the American College of Surgeons.
Jefferson/New Jersey’s Washington Township campus includes a 230 licensed bed facility on a fourteen acre campus providing services to the citizens of the greater Gloucester County, New Jersey area. This campus has recently initiated a significant breast cancer surgery program with the employment of three surgeons and the engagement of an oncological radiologist. Adjoining the Washington Township campus is a hospital-owned outpatient surgical center and a select surgical center.
Jefferson/New Jersey also operates Jefferson Health Care Center, a 190 bed extended care facility in Washington Township, New Jersey. The facility includes a 130-bed skilled nursing facility with private and semi-private rooms for residents as well as a 60-beds sub-acute rehabilitation center for patients who have experienced an acute medical event (e.g., stroke, head trauma, etc.) and need a bridge between a hospital stay and a return to home, usually lasting less than a month.
Jefferson/Magee
Jefferson/Magee is a 96-bed licensed acute rehabilitation specialty hospital located in Philadelphia and sees more than 940 inpatients and 32,000 outpatients annually. As further described in the forepart of this Official Statement a portion of the New Money Project includes the construction, development, renovation, improvement and equipping of approximately 92,000 gross square feet of patient rooms, therapy gyms and the relocation of an existing pharmacy at Jefferson/Magee’s Center City location.
Jefferson/Magee is accredited by The Joint Commission and has had a long tradition of excellence by being the first acute inpatient rehab hospital in Philadelphia and the first CARF-accredited (Commission on Accreditation of Rehabilitation Facilities) brain injury program in the United States. Jefferson/Magee is also the co-founder of the Christopher & Dana Reeve Foundation NeuroRecovery
A-29
network and the preeminent provider of complex physical and cognitive rehabilitation in the region. According to U.S. News & World Report, Magee ranks 13th among the top rehabilitation hospitals in the nation.
Jefferson Health Physicians
Jefferson Health has approximately 1,680 employed physicians (including JUP physicians). Jefferson Health follows a “pluralistic” physician alignment model that includes employed physicians, affiliated physicians and aligned physicians depending on the specific strategic circumstances of Jefferson Health and the physician.
JeffCare Alliance (the “Alliance”) is Jefferson Health’s Clinically Integrated Network, a vehicle coordinating care across affiliated providers including independent and employed primary care physicians, specialist, hospitals and ambulatory sites. The Alliance’s mission is to achieve efficiencies in the delivery of care, to implement evidence-based clinical protocols to enhance patient outcomes and to partner with payers to develop contracts that drive definable clinical improvement and add value to patients and participating physicians.
JeffCare PHO is Jefferson Health's Physician Hospital Organization, a vehicle enabling Jefferson Health and independent physician partners to work cooperatively to improve payer negotiations. JeffCare PHO currently supports more than 1,100 member practices, offering convenient, single-source, messenger model managed care services.
Utilization and Operating Statistics
The following tables provide a historical summary of pro forma utilization and other operating statistics for Jefferson Health for the past five fiscal years (assuming Jefferson Health, as currently constituted, existed during such periods).
JEFFERSON HEALTH SELECTED PRO FORMA UTILIZATION STATISTICS
Fiscal Year Ended June 30, 2017 2016 2015 2014 2013 Bed Capacity: Licensed Beds 2,904 2,911 2,925 2,918 2,936 Available Beds 2,605 2,561 2,567 2,618 2,705 Total Patient Days 641,417 643,135 636,249 643,934 659,562 Occupancy Rate 67.5% 68.6% 67.9% 67.4% 66.8% Total Admissions 128,800 129,835 128,587 128,347 133,788 Avg. Length of Stay (Days) 4.98 4.95 4.95 5.02 4.93 OR Procedures 89,450 88,304 86,789 86,579 84,795 ER Visits 517,321 520,417 511,508 501,805 509,319 Total Outpatient Visits 1,564,339 1,612,059 1,592,005 1,583,167 1,572,421
A-30
JEFFERSON HEALTH PHYSICIANS SELECTED PRO FORMA OPERATING DATA1
Fiscal Year Ended June 30, 2017 2016 2015 2014 2013 Physician Headcount 1,378 1,289 1,150 1,091 1,052 Gross Charges ($000s)2 $1,466,137 $1,368,791 $1,204,627 $1,144,999 $1,080,136 Collections ($000s) $546,837 $529,210 $471,167 $460,538 $440,472 New Patients3 243,165 248,619 219,179 203,328 192,669 Outpatient Office Visits 1,913,087 1,753,491 1,592,641 1,546,751 1,553,736 O/P Office Procedures 224,020 214,282 199,654 190,904 191,452
Sources of Patient Revenue
Patient revenues are received by Jefferson Health from patients, various insuring organizations (including self-insured employers) and federal and state governments under Medicare, Medicaid and other programs. Jefferson Health’s total net patient revenues for Fiscal Years 2017 and 2016 were approximately $3.91 billion and $3.76 billion, respectively (pro forma). The approximate percentages of net patient revenues derived from various payment sources for Fiscal Years 2014-2017 were as set forth below on a pro forma basis (assuming Jefferson Health, as currently constituted, existed during those periods):
JEFFERSON HEALTH PRO FORMA PAYER MIX (NET PATIENT REVENUES)
Fiscal Year Ended June 30, 2017 2016 2015 2014 Medicare 24.3% 25.6% 25.6% 24.9% Medicare Managed Care 13.6 11.0 10.4 10.2 Blue Cross (Indemnity) 3.8 3.4 3.7 3.6 Medicaid 2.6 2.3 2.7 3.0 M/A Managed Care 7.9 7.3 6.8 6.3 Managed Care 42.3 42.5 42.9 43.8 Self-Pay and Other 5.5 7.9 7.9 8.2 Totals 100.0% 100.0% 100.0% 100.0%
Delaware Valley ACO
TJU holds a 50% interest in Accountable Care Organization of Pennsylvania, LLC d/b/a Delaware Valley ACO (“DVACO”), a Pennsylvania limited liability company that operates a Medicare Accountable Care Organization. The remaining ownership interest of DVACO is held by Main Line Health (“MLH”) (50%). DVACO was formed on December 22, 2010. DVACO’s programs are coordinated and aligned closely with its members’ local programs, both hospital and clinically integrated
1 Includes JUP and other Jefferson Health-owned physician practices, except for Fiscal Year 2013, which does not include Jefferson/TJUH’s Jefferson Medical Care physician practice (approximately 20 physicians). Includes Urgent Care centers. 2 Represents gross charges unadjusted for any payer discounts. 3 Represents initial visits by patients during Fiscal Year. Fiscal Years 2013 through 2016 were adjusted.
A-31
network-based. The DVACO seeks to be a convener and accelerator of capabilities needed to move into value-based payment models, and offer a differentiated care model to the regional market.
The Centers for Medicare & Medicaid Services (“CMS”) defines accountable care organizations as groups of doctors, hospitals and other health care providers who come together voluntarily to give coordinated high quality care to their Medicare patients. On January 1, 2013, DVACO commenced participation in an “upside-only” accountable care organization in the Medicare Shared Savings Program (“MSSP”) offered by CMS. DVACO’s initial term in MSSP concluded on December 31, 2016, and DVACO plans to continue participation in the upside-only model of the MSSP for a second three-year term which commenced on January 1, 2017.
In addition to participating in MSSP, DVACO contracts with several commercial payers on behalf of its participating providers for certain shared shavings agreements, including Aetna, United, and Humana. The University and MLH also include health insurance options for their respective employees based on the providers that participate in the DVACO network.
Across all of its value-based programs, DVACO has in excess of approximately 250,000 attributed beneficiaries.
HEALTHCARE SERVICE AREA, DEMOGRAPHICS AND COMPETITION
Healthcare Service Area
The Jefferson Health Primary Service Area (“PSA”) consists of the five southeastern Pennsylvania counties (Bucks, Chester, Delaware, Montgomery, and Philadelphia) as well as four southern New Jersey counties on the border of Pennsylvania (Burlington, Camden, Gloucester and Salem).
Jefferson Health’s PSA was developed by establishing traditional PSAs for Jefferson University Hospitals, Jefferson/Abington, Jefferson/Aria, Jefferson/Magee and Jefferson/New Jersey separately. Contiguous zip codes were identified from which each entity drew 80% of its inpatient discharges in the most recent year. The combined service areas encompass the nine counties surrounding Philadelphia.
[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]
A-32
JEFFERSON HEALTH PRIMARY SERVICE AREA
[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]
A-33
Jefferson Health Clinical Assets
Current and Projected Population
Jefferson Health’s PSA, straddling the Delaware River between Pennsylvania and New Jersey, is home to approximately 4.2 million adults. The adult population of Jefferson Health’s service area is expected to continue growing over the next five years, albeit at a slower rate than that of the U.S. as a whole. By 2022, the PSA is expected to be home to more than 4.3 million residents over age 18.
The following table depicts the projected adult population data for Jefferson Health’s PSA, as well as for the states of Pennsylvania and New Jersey and the United States.
[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]
A-34
PROJECTED ADULT POPULATION
Jefferson Health PSA PA NJ US
2017 (18+) 4,229,668 10,154,866 7,013,717 251,100,493 2022 (18+ Projected) 4,320,143 10,304,321 7,208,716 262,507,417 % Projected Growth (18+ 2017-2022) +2.1% +1.5% +2.8% +4.5%
Source: Truven Health Analytics, Demographics Expert.
Patient Origin
The following table depicts the proportion of Jefferson Health’s total adult discharges by county in calendar year 2016 on a pro forma basis (assuming Jefferson Health, as currently constituted, existed during such time period).
PRO FORMA PATIENT ORIGIN
% Total Discharges Calendar Year 2016 Philadelphia (PA) 36.8% Montgomery (PA) 18.6 Camden (NJ) 12.7 Bucks (PA) 10.9 Gloucester (NJ) 8.1 Burlington (NJ) 3.0 Delaware (PA) 2.0 Chester (PA) 1.1 Salem (NJ) 0.2 Other 6.6 Total 100.0%
Source: Truven Health Analytics, all ages, excludes normal newborns.
Other Healthcare Facilities
There are numerous healthcare providers in the Jefferson Health service area offering both routine and specialized medical services. The following graphics and table highlight major health systems and selected comparative operating statistics.
A-35
o 0 System III Jefferson Health • CHS Community Health Systems o 0 Cooper Health System 0 Crozer-Keystone Health System • Einstein Healthcare Network Independent 15mi • 0 0 Inspira Health Network 0 Main Line Health System 0 Paladin Healthcare 0 Penn Med ici ne o 0 Prime Healthcare Services • Temple University Health System 0 Trinity/CHE 0 Virtua Health
III
System • 0 • 0 • l:::l Jefferson Health 00.. 6' 0 0 • Atlantic Health System • • • 0 0 • • Bayhealth • 0 0 • 0 • CHS Community Health Systems • 0 • • Capital Health o Care Point Health • '" • Christiana Care Health System • • • a Cooper Health System 0 • • a Crozer-Keystone Health System 160mi • 0 III o Department of Veterans Affairs • 'b a • • Einstein Healthcare Network III o III • • • Geisinger Health System 0 •• Ill . a • Hackensack Meridian Health III 0 a • • • • • Independent 0 0 • [I o Inspira Health Network 0 :0 0 • 0 15mil 0 a OQl!W 0 • o Lehigh Va lley Networ1< 0 o 0 III o Ma in Li ne Health System 0 00 0 • 0 III a Nemours Childrens Health System 0 • Paladin Healthcare 0 "" • o Penn Medicine • • Penn Slate a Pr im e Healthcare Services 0 • • Princeton HealthCare System a RWJ Barnabas Health
0 • a Reading Health System • St Luke's University Health Network • o St Peler's Healthcare System • • Temple University Health System • TrinitylCHE o Virtua Health • • We tlSpan Health •
A-36
The following table illustrates on a pro forma basis (assuming Jefferson Health, as currently constituted, existing during such period) that in 2017, Jefferson Health had a combined 19.2% share of the nine county market’s inpatient discharges (18+) and ranked first in the market.
SELECT OPERATING STATISTICS OF MAJOR HOSPITALS/SYSTEMS IN JEFFERSON HEALTH 9-COUNTY PSA FOR CALENDAR YEAR 2017
Hospital/System % Share Discharges Total Licensed % (# of Hospitals) within 9-County PSA Discharges Beds Occupancy1 Jefferson Health Pro Forma (10) 19.2% 134,338 2,924 62.3% Penn Medicine (5) 12.1 134,789 2,975 65.9 Main Line Health (4) 8.3 61,180 1,240 61.8 Virtua (3) 7.5 57,978 983 68.3 Einstein Health Network (4) 5.4 35,449 965 59.7 Temple Health (3) 5.7 40,456 978 68.8 Mercy Health System (3) 3.8 24,322 564 53.1 Crozer-Keystone Health System (4) 3.7 23,246 617 53.9
Source: Truven Health Analytics, Market Expert, Calendar Year 2017; Licensed Bed counts from Philadelphia Business Journal, Nov 2017.
The following table sets forth admission and other indicators for Fiscal Year 2017 for selected healthcare systems located in the Philadelphia area. The Jefferson Health information is presented on a pro forma basis (assuming Jefferson Health, as currently constituted, existed during such period).
SELECTED PRO FORMA OPERATING STATISTICS FOR JEFFERSON HEALTH AND SELECTED PHILADELPHIA AREA COMPETITORS FOR FISCAL YEAR 2017
Available (Staffed) % Avg. Length ER Beds Occupancy Admissions of Stay (Days) Visits Births Jefferson Health2 2,099 68.4% 103,529 5.1 376,201 6,440 Penn Medicine3 1,739 79.4% 85,149 5.9 188,156 12,100 Main Line Health4 1,195 61.6% 56,780 4.7 177,463 7,572 Temple Health5 799 79.1% 32,445 7.1 135,400 2,650
Source: Delaware Valley Healthcare Council for Fiscal Year 2017 (July 2016 – June 2017).
1 Includes licensed beds, all ages, excluding newborns. 2 Does not include Jefferson/New Jersey. 3 Does not include Lancaster General Hospital and University of Princeton Medical Center for Penn Medicine, which do not report DVHC data. 4 The University has an academic affiliation agreement with MLH. 5 Temple Health includes Temple University Hospital and Fox Chase Cancer Center. Jeanes Hospital excluded due to non- reporting of data to DVHC.
A-37
Future Jefferson Health Healthcare Plans
Jefferson Health has expanded significantly over the last three years and is currently actively engaged in the process of integration of its newly combined healthcare assets. As part of this integration process, Jefferson Health has developed a service line and geographic prioritization strategic framework for Jefferson Health hospitals that is being used to inform network configuration and service distribution. As part of this integration effort, Jefferson Health plans to support a single academic medical center (TJUH and JHN); two regional referral centers (AMH and Jefferson/New Jersey – Washington Township); two community hospital centers, four “connected” community hospitals, three specialty hospitals and micro hospitals. Healthcare services and location of services will be aligned with the planned network configuration to achieve Jefferson Health’s goals of a “world class, integrated, essential patient, staff, student and clinician centric, entrepreneurial, academic medical, consumer-driven, health network.” As part of the plan, Jefferson Health, as currently constituted, anticipates that the number of its available staffed beds will decrease from the current total of 2,509 to less than 2,100 over the next two to four years. Jefferson Health also has a goal over the next several years of having a Jefferson Health facility located within 10 minutes of every person who lives in Jefferson Health’s PSA.
FINANCIAL INFORMATION AND DISCUSSION
Due to the timing of various mergers (as described in “INTRODUCTION - History of TJU”), TJU’s audited consolidated financial statements for Fiscal Year 2017 included as Appendix B-1 to this Official Statement do not include the results of Philadelphia University, Kennedy Health System and Magee (and the Fiscal Year 2016 comparative information included in TJU’s audited consolidated financial statements for Fiscal Year 2017 do not include the results of Aria Health). Unaudited consolidated schedules of selected balance sheet information and the results of operation for TJU for Fiscal Years 2017 and 2016 on a pro forma basis (assuming TJU, as currently constituted, existed during such periods) are included below and certain consolidating schedules are included in Appendix B-2. In addition, audited financial statements for such entities for such periods, and Aria Health for Fiscal Year 2016, may be found at the MSRB’S EMMA website but such audited financial statements are not incorporated into this Official Statement by such reference.
The following summaries should be read in conjunction with data included under the subheading “MANAGEMENT DISCUSSION AND ANALYSIS – Unaudited Operating Results as of February 28, 2018 and 2017,” as well as TJU’S audited consolidated financial statements, related notes and supplementary information for fiscal years ended June 30, 2017 and 2016 provided in Appendix B-1 to this Official Statement.
Unaudited Consolidated Balance Sheet
The following table sets forth the unaudited consolidated balance sheet of the University as of February 28, 2018.
[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]
A-38
UNAUDITED CONSOLIDATED BALANCE SHEET ($000s)
Assets: February 28, 2018 Current Assets: Cash and Cash Equivalents $ 500,728 Short-Term Investments 1,339,996 Accounts Receivable, less Allowance for Doubtful Accounts 652,922 Insurance Recoverable 31,340 Pledges Receivable 24,810 Inventory 67,046 Assets whose Use is Limited, Current 18,872 Other Current Assets 74,964 Total Current Assets 2,710,678 Assets whose Use is Limited 473,444 Insurance Recoverable 181,521 Assets held by an Affiliated Foundation 97,794 Pledges Receivable 109,749 Loans Receivable from Students, Net 27,458 Land, Buildings and Equipment, Net 2,265,676 Long-term Investments 1,150,033 Other Noncurrent Assets 207,099 Total Assets $7,223,451
Liabilities and Net Assets: Current Liabilities: Current Portion of: Deferred Revenues $ 92,789 Long-Term Obligations 32,449 Accrued Professional Liability Claims 49,758 Accrued Workers’ Compensation Claims 14,175 Accrued Payroll and Related Costs 276,457 Accounts Payable and Accrued Expenses 408,489 Grant and Contract Advances 23,684 Total Current Liabilities 897,801 Long-Term Obligations 1,435,951 Accrued Pension Liability 502,050 Accrued Professional Liability Claims 427,087 Federal Student Loan Advances 11,100 Deferred Revenues 11,215 Accrued Workers’ Compensation Claims 24,041 Other Noncurrent Liabilities 53,228 Total Liabilities 3,362,474
Net Assets: Unrestricted 2,999,204 Noncontrolling Interest in Joint Ventures 75,704 Temporarily Restricted 429,053 Permanently Restricted 357,016 Total Net Assets 3,860,977 Total Liabilities and Net Assets $7,223,451
A-39
Unaudited Pro Forma Consolidated Statement of Operations
The following table sets forth the unaudited pro forma consolidated statement of operations for the University for the fiscal years ending June 30, 2017 and 2016 (assuming the University, as currently constituted, existed during such periods).
UNAUDITED PRO FORMA CONSOLIDATED STATEMENT OF OPERATIONS ($000s)
Fiscal Year Ended June 30, 2017 2016 Operating Revenues, Gains and Other Support: Net Patient Service Revenue $4,233,057 $4,030,976 Provision for Bad Debts (157,338) (160,661) Net Patient Service Revenue Less Bad Debt 4,075,719 3,870,315 Grants and Contracts 101,546 92,529 Tuition and Fees, Net 209,783 198,642 Investment Income 50,804 25,811 Contributions 5,835 4,501 Other Revenues 250,891 265,025 Net Assets Released from Restriction 42,404 38,870 Total Operating Revenues, Gains and Other Support 4,736,982 4,495,693
Operating Expenses: Salaries, Wages and Employee Benefits 2,675,244 2,493,748 Supplies and Other 1,624,492 1,524,123 Depreciation and Amortization 236,341 228,049 Interest 43,777 43,305 Insurance 90,350 81,011 Total Operating Expenses 4,670,204 4,370,236
Income from Operations $ 66,778 $ 125,457
The following table shows the calculation of pro forma operating income available for debt service and pro forma debt service coverage for the fiscal years ending June 30, 2017 and 2016 for the University (assuming the University, as currently constituted, existed during such periods and assuming the University’s estimated Fiscal Year 2019 debt service after the issuance of the Series 2018 Bonds (as defined herein) as the applicable debt service for the pro forma calculation).
[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]
A-40
UNAUDITED PRO FORMA DEBT SERVICE COVERAGE ($000s)
Fiscal Year Ended June 30, 2017 2016 Income from Operations $66,778 $125,457 Add back: Interest Expense 43,777 43,305 Depreciation and Amortization Expense 236,341 228,049 Operating Income Available for Debt Service 346,896 396,811
Pro Forma Fiscal Year 2019 Debt Service1 $78,035 $78,035 Pro Forma Debt Service Coverage 4.4x 5.1x
MANAGEMENT DISCUSSION AND ANALYSIS
Management developed a consolidated Fiscal Year 2018 operating budget that fully integrates the budgets of the Academic and Clinical Divisions of the University. The development of a consolidated budget promoted the ability to identify various business practice efficiency opportunities, cost reductions and revenue improvement opportunities (via integration initiatives), that were incorporated into the Fiscal Year 2018 budget.
Unaudited Operating Results as of February 28, 2018 and 2017
Provided below is a summary of the Unaudited Pro Forma Consolidated Statement of Operations for the eight-month periods ended February 28, 2018 and 2017 for the University (assuming the University, as currently constituted, existed during such periods). See Appendix B-2 for the unaudited pro forma consolidating statements of operations for the same eight-month periods. The University’s full-year Fiscal Year 2018 budget provides for approximately $4.8 billion of operating revenue, approximately $4.8 billion of operating expenses, and approximately $296 million of earnings before interest, depreciation and amortization (“EBIDA”), along with a baseline breakeven income from operations. (The University’s full-year Fiscal Year 2018 budget information was not prepared with a view toward compliance with published guidelines of the Securities and Exchange Commission or the guidelines established by the American Institute of Certified Public Accountants for preparation or presentation of prospective financial information. The University’s full-year Fiscal Year 2018 budget information included in this document has been prepared by, and is the responsibility of, the University’s management. PricewaterhouseCoopers LLP has not audited, reviewed, examined, compiled nor applied agreed-upon procedures with respect to the University’s full-year Fiscal Year 2018 budget information and, accordingly, PricewaterhouseCoopers LLP does not express an opinion or any other form of assurance with respect thereto. The PricewaterhouseCoopers LLP report included in this document relates to the University’s previously issued financial statements. It does not extend to the University’s full-year Fiscal Year 2018 budget information and should not be read to do so.)
[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]
1 See “OUTSTANDING INDEBTEDNESS OF THE OBLIGATED GROUP – Estimated Debt Service Requirements” in the front part of the Official Statement, including with respect to certain interest rate assumptions related to estimated annual debt service. A-41
UNAUDITED PRO FORMA CONSOLIDATED STATEMENT OF OPERATIONS ($000s)
Eight Months Ended February 28, 2018 2017 Operating Revenues, Gains and Other Support: Net Patient Service Revenue $2,852,501 $2,793,669 Provision for Bad Debts (96,313) (94,620) Net Patient Service Revenue less provision for Bad Debts 2,756,187 2,699,049 Grants and Contracts 69,804 65,757 Tuition and Fees, net 141,849 134,715 Investment Income 20,374 19,158 Contributions 3,747 3,872 Other Revenue 180,384 168,350 Net Assets Released from Restrictions 26,728 27,093 Total Operating Revenues, Gains and Other Support 3,199,074 3,117,992
Operating Expenses: Salaries, Wages and Employee Benefits 1,812,262 1,757,038 Supplies and Other 1,144,307 1,058,307 Depreciation and Amortization 164,690 155,933 Interest 31,358 28,675 Insurance 56,842 66,919 Total Operating Expenses 3,209,458 3,066,872
(Loss) Income from Operations ($ 10,385) $ 51,120
For the eight-month period ending February 28, 2018, University operations incurred a $10.4 million loss (-0.3% margin) compared to a $51.2 million gain (1.6% margin) for the comparable period in the prior year. Total operating revenue grew by 2.6% or $81.1 million over the prior year, but was outstripped by the 4.6% growth in total operating expenses of $142.6 million. Total University operating revenue was $37.9 million (1.2%) below budget. The shortfall was primarily due to unfavorable net patient service revenue from fewer hospital admissions and outpatient visits than projected. Total University operating expenses were $50.0 million or 1.6% less than budget. This favorable variance is driven by compensation ($20.0 million or 1.1%), supplies ($13.0 million or 2.6%) and insurance ($15.7 million or 22.2%).
The full fiscal year 2018 operating budget is set at a breakeven level of operating income. For full Fiscal Year 2018, TJU’s management projects achieving the operating budget target. TJU management, in consultation with its strategic partner, GE Healthcare (“GEHC”), has identified a series of operating performance enhancement initiatives aimed at Fiscal Year 2018 operating income improvements. The initiatives encompass a variety of growth opportunity strategies and targeted improvement in the management of revenue cycle, workforce and supply chain operations, including those related to integrating the operations of the recently combined members of the Jefferson clinical and academic enterprise. See “Notable Activities - One Jefferson GE Healthcare Strategic Relationship” below for a more detailed description of TJU’s relationship with GEHC.
The University’s balance sheet has been further strengthened through strategic acquisitions. From June 30, 2014 to February 28, 2018, Total Assets increased from $2.9 billion to $7.2 billion and Net Assets increased from $1.4 billion to $3.9 billion. For the eight-month period ending February 28, 2018, Total Net Assets increased $829.5 million. Net Assets at February 28, 2018 include the accounts of Philadelphia University, Kennedy Health System and Magee. Of the total increase in Net Assets of $829.5 million, $699.3 million is due to these acquisitions. Of the increase in Total Assets of $1,395.3
A-42 million from June 30, 2017 to February 28, 2018, $1,099.4 million is due to the Philadelphia University, Kennedy Health System and Magee acquisitions.
Organizational Structure
TJU has organized the combined business enterprise around four “pillars” – Academic, Clinical, Innovation and Philanthropy. These pillars are designed to establish clear leadership roles, responsibilities and accountability for results. Each pillar is supported by enterprise or corporate services (Information Services & Technology, Finance, Legal, Integration, Human Resources and Marketing) to fulfill the pillar missions.
Integrated Strategic Financial Planning Process
In order to support enterprise growth and integration, TJU has implemented a disciplined strategy development and execution process titled the Integrated Strategic and Financial Planning Process (the “ISFP,” as depicted on the following page). The ISFP has been launched enterprise wide and provides a structured planning approach that is being used by the University including all clinical, academic, and corporate services. Input from the ISFP process will be incorporated into the Fiscal Year 2019 Operating and Capital Plans and the Five Year Strategic Financial Plan.
Key ISFP outputs used to develop the Five Year Strategic Financial Plan include:
• Projected baseline operating performance and EBIDA targets • One Jefferson Strategic initiatives (Capital/ROI expectations) . Service line (Clinical) . Divisions (Clinical and Academic) . Corporate (includes Philanthropy & Innovation) . Operational Improvement Initiatives (supply cost reductions, workforce management, etc.) • One Jefferson Integration and Operational Improvement Plan • Enterprise Master Facilities Plan A-43
• Capital Plan development using the Capital Management Policy and Allocation Policy established in Fiscal Year 2018. The Policy provides for a process that establishes capital spending constraints, provides for the equitable allocation of baseline capital requirements (projects < $1 million) and provides a disciplined quantitative/qualitative process for analysis and selection of projects valued at > $1 million.
The ISFP generated inputs/outputs are then used to update Jefferson’s Five-Year Strategic Financial Plan (Financial Plan). Using the Fiscal Year 2019 Operating and Capital Budget Plans as the baseline year, the forecast will incorporate ISFP’s inputs/outputs to develop a Five-Year Strategic Financial Plan. The guiding principle of the Financial Plan’s financial outcome is to achieve, by the end of the Financial Plan’s fifth year, an EBIDA performance and liquidity profile that is generally consistent with the Moody’s and S&P A1/A+ medians.
Development of the Fiscal Year 2019 Strategic Financial Plan will take into account management’s view that Fiscal Year 2018 has been a transition year that follows numerous large acquisitions over the previous three years. Using the process discussed above, TJU management will appropriately incorporate ISFP inputs into the Fiscal Year 2019 Financial Plan update in satisfaction of the performance commitments made by management to the TJU Board. During intra-cycle measurement periods, when future considerations of large and small initiatives become known, management will take such action to incorporate such initiative(s) into the Financial Plan in order to analyze their impact on TJU’s ability to produce a sufficient cash flow and operating margin, and liquidity necessary to meet the established performance targets.
Notable Activities
One Jefferson GE Healthcare Strategic Relationship
TJU entered into an eight year strategic relationship with GEHC, in order to accelerate the pace of integration activity across the enterprise. The primary goals of the One Jefferson initiative are to:
• Enable clinical and operational interoperability; • Standardize and gain efficiencies and cost; and • Deliver outcomes through seamless coordination.
In order to ensure the success of the One Jefferson initiative, TJU’s agreement with GEHC places a meaningful portion of GEHC’s annual compensation at risk for the delivery of projected outcomes. GEHC is fully embedded with TJU teams and is coordinating the identification of improvement opportunities that align with the strategies and outcomes identified in TJU’s strategic and financial plan.
Financial Management Integration Initiatives
In line with the broader integration theme, TJU’s financial management team has been active with regard to Financial Management Integration initiatives. These initiatives include the following:
• Debt Consolidation. Since the merger of TJU and TJUH System, management has sought where appropriate, to restructure acquired debt to ensure that it best positions TJU’s debt from a security document, rate/debt service profile, variable/fixed rate and product diversification perspective. As described in the forepart of the Official Statement, effective December 1, 2017, TJU obtained the requisite 51% bondholder consent and all legacy master trust indenture and security document regimes were terminated. The Series 2018D Bonds and the Series 2018A/B/C Bonds (as defined in the forepart of the Official Statement and collectively referred to as the “Series 2018 Bonds”) and future obligations issued by or on behalf of TJU (and the other Members of the
A-44
Obligated Group) will be issued and/or secured, as applicable, in accordance with the Master Indenture.
• Enterprise Integrated Risk Financial Framework (“IRFF”). TJU completed an analysis that cataloged the material enterprise risks and anticipated responses to define a resource deployment approach that brings balance to the risk pursuits of TJU:
. Identify potential claims on liquidity sourcing from operations, spending, debt, and investments; . Assess TJU’s ability to carry risk given its available risk resources, including unrestricted cash and investments; and . Merge these concepts to allow TJU to assess the implications of a risk-adjusted resource deployment strategy
The IRFF initiative has resulted in the following activities, each of which has generated significant fee savings and increased return potentials:
. As of January 1, 2018, four legacy entity Defined Benefit Plan assets were consolidated into a new Jefferson Defined Benefit Plan. The consolidation did not change the underlying legacy plan’s pension benefit structures. . The consolidation of 11 disparate legacy investment programs down to three programs based on the risk profiles identified through the IRFF process (working capital, Intermediate Fund, Long-term Pool).
Labor Analytics Implementation
TJU implemented an enterprise wide Labor Analytics tool that allows clinical and corporate departments to measure productivity against the productivity benchmarks set to achieve organizational productivity index of between 98% and 110% relative to the benchmarks. When a department is under the 98% productivity index there is an opportunity for FTE reductions. When a department is over the 110% productivity index there is opportunity to add FTEs.
Installation of Epic Electronic Health Record System
TJU has installed the Epic Electronic Health Record (“Epic”) ambulatory and inpatient software system at the Center City Campus. TJU’s goal is to provide a unified, consistent and complete Jefferson Health chart for every patient which will ensure a seamless flow of information where and when needed. The first phase of the Epic installation (Ambulatory model) was completed on November 26, 2016 and the second phase (Inpatient model) was completed on April 1, 2017. Within six months after going live, Epic awarded TJU level 8 in its Gold Star program. The recognition places TJU in the top 6% of organizations that are live with Epic. TJU was also successful in achieving Healthcare Information and Management Systems Society EMRAM (Electronic Medical Record Adoption Model) Stage 6 for both ambulatory and inpatient settings, reflecting TJU’s implementation of best practices for the use of healthcare technology. TJU is extending its successful implementation of Epic to the three hospitals that make up Jefferson/New Jersey with a planned go-live in the Fall of 2019.
Einstein Health Letter of Intent
TJU has entered into a letter of intent with Albert Einstein Healthcare Network (“EHN”) dated March 28, 2018 (the “Letter of Intent”), which sets forth certain binding and non-binding obligations relating to a potential transaction (the “Transaction”), whereby TJU and EHN would combine assets and operations.
A-45
EHN, through its controlled affiliates, operates a comprehensive healthcare network in southeastern Pennsylvania, southern New Jersey and Delaware. EHN’s network includes four inpatient hospital facilities with a total of 965 licensed beds and an independent academic medical center with over 400 residents and fellows throughout its facilities. A more detailed description of EHN and its operations may be found at the MSRB’s EMMA website but such information has not been verified by TJU and is not incorporated into this Official Statement by such reference.
The fundamental rationale for the Transaction include: (i) preserving and enhancing TJU’s teaching and research mission by expanding its current footprint at EHN’s facilities; (ii) enhancing TJU’s and EHN’s ability to care for the populations in the greater Philadelphia region, including the underserved and those on Medicaid; and (iii) integrating operations to provide high quality care at a lower cost than would otherwise be possible.
If consummated as currently contemplated, TJU would become the sole member of EHN through amendments to the corporate governance documents of EHN and its controlled affiliates in a similar fashion to the other recent TJU acquisition transactions described herein, including the appointment of EHN representatives to the TJU Board. Otherwise, EHN’s corporate structure would remain the same.
Pursuant to the Letter of Intent, the parties will begin conducting their respective due diligence and the preparation of a definitive agreement (the “Definitive Agreement”) setting forth the detailed terms of the Transaction and containing customary representations, warranties and conditions to closing.
At this point, it is not possible to determine whether the parties will enter into a Definitive Agreement and, if so, what the terms will be. It is currently anticipated that it could take one to two years to consummate the Definitive Agreement, in part, because such agreement will be subject to numerous conditions to closing, including receipt of all necessary regulatory approvals. Accordingly, there can be no assurance that the Transaction will ultimately be consummated. At this point, the parties cannot determine whether TJU and EHN will become liable for or guarantee one another’s debt.
Other Potential Transactions
In addition to the foregoing, as part of its ongoing strategic planning process, from time to time, the University considers and will consider potential mergers, joint ventures, affiliations, acquisitions, divestitures and similar transactions. Such transactions may result in additional entities becoming part of the University or its subsidiaries/affiliates in the future; in addition, in certain cases, existing entities may no longer be part of the University in the future. There can be no assurance as to the impact that any such transaction would have on the operations, properties and financial results of the University.
INDEBTEDNESS
Outstanding Debt
The total outstanding long term bonds and notes of the University as reported in the University’s consolidated unaudited balance sheet as of February 28, 2018, was approximately $1.5 billion. The Series 2018 Bonds are expected to refund the Refunded Obligations (as defined in the front part of the Official Statement) in addition to providing approximately $236.5 million for new capital projects. See “OUTSTANDING INDEBTEDNESS OF THE OBLIGATED GROUP – Estimated Debt Service Requirements” in the front part of the Official Statement for a table setting forth the expected fiscal year debt service requirements for the University’s outstanding bond indebtedness prior to the issuance of the Series 2018 Bonds and the refunding of the Refunded Obligations.
Interest Rate Derivatives
The University entered into derivative transactions for the purpose of reducing the impact of fluctuations in interest rates under the terms of various interest rate swap contracts. See Note 11 to the A-46 financial statements attached as Appendix B-1 for a list of such transactions and the primary terms thereof. To the extent permitted by the Master Indenture, regularly scheduled swap payments for such existing swaps are secured on a parity basis by a pledge of the gross revenues of certain Members of the Obligated Group, but not TJU itself; provided however, swap termination payments are secured under the Master Indenture as Subordinated Obligations. Under certain circumstances, the University’s swaps may be terminated early, in which case it may become obligated to make a substantial payment to one or more swap counterparties. In certain circumstances, TJU may have an obligation under the swaps to post collateral with the swap counterparties depending, among other things, on TJU’s then-current bond ratings and the then-current mark-to-market value of the swaps and subject to compliance with the Master Indenture.
CASH AND INVESTMENTS
The market value of the University’s cash and investment assets as reported in the University’s consolidated unaudited balance sheet as of February 28, 2018 was approximately $2.86 billion. The table below illustrates the consolidated unaudited cash and investments of the University under the indicated classifications.
CONSOLIDATED CASH AND INVESTMENTS ($000s)
As of February 28, 2018 Temporarily & Permanently Unrestricted Restricted Total Cash and Cash Equivalents $ 500,728 - $ 500,728 Short-Term Investments 1,279,322 $ 60,675 1,339,996 Long-Term Investments 621,712 528,321 1,150,033 Assets whose Use is Limited 466,972 25,343 492,315 Totals $2,868,734 $614,339 $3,483,073 Unrestricted Days Cash1 230.1 days
Asset Allocation
A summary of the pro forma asset allocation (assuming the University, as currently constituted, existed during such period) as of December 31, 2017 is set forth below.
[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]
1 Calculated as unrestricted cash and investments divided by ((annual operating expenses less depreciation, amortization and other non-cash charges for restructuring and other nonrecurring expenses) divided by 365 or 366, as applicable). A-47
PRO FORMA CONSOLIDATED ASSET ALLOCATION ($000s)
December 31, 2017 % of Total Equity Securities Domestic $852,401 26.3% International 403,715 12.5 Fixed Income Securities 974,137 30.0 Hedge Funds 158,177 4.9 Private Markets 159,660 4.9 Other Strategies 86,559 2.7 External Trusts 133,273 4.1 Cash and Cash Equivalents 474,068 14.6 Totals $3,241,989 100.0%
Liquidity
Private equity investments have limited liquidity or redemption options. Liquidity for private investments can be accomplished via a secondary sale transaction. When available, distributions typically take place on a quarterly basis. TJU has made commitments to various private equity and real asset limited partnerships. The total amount of unfunded commitments is $78.1 million at December 31, 2017. TJU expects these commitments to be called over the next three to five years.
Hedge funds provide quarterly liquidity with 60 to 90 days’ notice prior to the quarter’s end limiting TJU’s ability to respond quickly to changes in market conditions. Liquidity of individual hedge funds vary based on various factors and may include “gates”, “holdbacks” and “side pockets” imposed by the manager of the hedge fund, as well as redemption fees which may also apply.
Investment Policy, Management and Oversight
University management developed an Integrated Risk Financial Framework process to support the risk-related decision making process for the organization. This work effort produces a point-in-time risk analysis based on an examination of the difference between how the University’s unrestricted investment assets were currently invested versus how they might be deployed within an active risk- management framework. The philosophy behind the framework recognizes that the University is comprised of operating companies first and that (i) balance sheet resources should be integrated with, and focused on, supporting the University’s operating core, and (ii) unrestricted invested assets should be allocated first, to hedging liquidity risk not covered by dedicated offsets/strategies, and second, to the pursuit of risk-appropriate return.
The University’s investments are overseen by the Investment Committee of TJU, which is composed of seven members from the TJU Board and senior staff of TJU. The Committee has oversight over asset allocation, manager selection and review of University investment management. The University primarily uses Russell Consulting, a division of Russell Investments, and Concord Advisors as its primary investment consultants. In this capacity, Russell Consulting provides investment consulting (policy construction, manager searches, strategy shift, and education) and risk management services concerning the University’s long-term portfolios. Investment categories include domestic equities, international equities, fixed income assets, and alternative assets.
All investment programs must conform to investment restrictions established by the University’s Investment Committee. The portfolio is structured to conform to the allocation targets established by the Investment Committee. These restrictions concern asset class, asset allocation liquidity, duration, average maturity, diversification, and credit risk. If necessary, there is a monthly rebalancing of assets to ensure that the portfolio remains within its target bands. In assessing potential alternative asset investments, management, supported by the consultants, identify potential alternative asset investment opportunities. Significant due diligence is conducted on these potential investments, including manager interviews, on- A-48 site visits and reference checks. No commitments to investment are permitted without the approval of the Investment Committee.
Endowment Spending
The Commonwealth of Pennsylvania has not adopted the Uniform Management of Institutional Funds Act or the Uniform Prudent Management of Institutional Funds Act. As a result, the University’s endowment spending is governed by Act 141 of 1998. In accordance with the Pennsylvania Act, the objective of the University’s investment policy is to provide a level of spendable income that is sufficient to meet the current and future budgetary requirements of the University consistent with the goal of protecting the purchasing power of the investments. The University’s calculation of spendable income is based on 75% of the prior year spendable income and 25% of the calculated two-year moving average of the portfolio’s market value multiplied by 4.75%; the sum of which is adjusted by an inflation factor.
BENEFITS
The University provides retirement benefits to eligible employees through defined contribution and defined benefit plans. The defined benefit plans are frozen to new entrants. The plans are employee benefit plans intended to comply with all applicable federal laws and regulations, including the Code, and the Employee Retirement Income Security Act of 1974, as amended (“ERISA”).
Defined Contribution Plans
The University’s primary retirement programs are offered through various defined contribution plans. Retirement benefits are provided for employees through direct employer contributions to multiple externally administered, multi-asset class investment platforms. Fund selection and oversight is conducted by the Chief Investment Officer, an external consultant and the Investment Committee of the TJU Board.
Defined Benefit Plans
On January 1, 2018, TJU consolidated all of its non-contributory defined benefit pension plans for certain full-time employees into a new plan named “Jefferson Defined Benefit Plan” (the “Plan”). The Plan represents the consolidation of TJU, TJUH System, Jefferson/Abington, Jefferson/Aria and Jefferson/New Jersey’s’ defined benefit plans. Magee, which integrated with TJU after January 1, 2018, maintains the Magee Rehabilitation Hospital Defined Benefit Pension Plan. That plan has been amended to close participation for new employees hired (or rehired) on and after January 1, 2015 (in light of Magee’s adoption of a new 403(b) plan structure for new employees). Philadelphia University does not have a defined benefit plan. While each of the legacy plans has been frozen to new participants, some are still in a contributory status for a group of active legacy employees that meet certain age and years of service thresholds. Though all of the legacy plans have been combined under the Plan, an employee’s benefits under the Plan will still be based on their legacy organization’s benefit structure and the employee’s years of service and compensation during their years preceding retirement at the legacy organization. Contributions to the plan are designed to meet the minimum funding requirements of ERISA. During Fiscal Year 2018, TJU expects to contribute $37.8 million, Aria expects to contribute $6.0 million and Magee expects to contribute $1.5 million. Kennedy Health System, which currently has a fiscal year ending on December 31, expects to contribute $9.0 million during its fiscal year 2018. See “Employee Benefit Plans” footnotes in audited financial statements in Appendix B-1 for additional information regarding the University’s defined benefit pension plans, its accumulated projected benefit obligations, the asset allocation of the plans, the funded status of the plans and related assumptions.
In addition to the formality of the Plan’s consolidation documentation, the Investment and Finance Committees of the TJU Board authorized management to consolidate the investable assets of the four legacy plans under a single trustee. Consolidation of assets was completed on January 26, 2018. Management and the Plan’s actuary are currently conducting an asset/liability study for the Plan, which A-49
will inform a new allocation profile for the Plan. It is anticipated that a new asset allocation will be in place by June 30, 2018.
Participation in Multiemployer Defined Benefit Pension Plan
TJU is a participating employer in The Pension Fund for Hospital and Health Care Employees – Philadelphia and Vicinity (the “Pension Fund”), a jointly-trusted multiemployer defined benefit pension plan. The Pension Fund is operated for the benefit of Chapter 1199C of the American Federation of State, County and Municipal Employees. For a discussion of the Pension Fund, see “Participation in Multiemployer Defined Benefit Pension Plan” in Note 13 to the financial statements attached as Appendix B-1.
FUNDRAISING AND CONTRIBUTIONS
Philanthropy is a key pillar of the University’s strategic plan. In the last several years, the University has significantly increased its fundraising efforts and results. In Fiscal Year 2017, the University received eleven pledges from multiple donors that totaled just over $21 million dollars. The pledges were given to support efforts in the lung center, alumni center, education, research, professorships and medicine. In Fiscal Year 2014, the University received a $110.0 million pledge from the Sidney Kimmel Foundation to endow and fund activities within the Sidney Kimmel Medical College. Of that pledge total, $80.1 million was recognized as contribution revenue in Fiscal Year 2014. This was the fifth largest gift to an American medical school.
The total revenue from contributions for the University for the past five fiscal years is summarized in the table below on a pro forma basis (assuming the University, as currently constituted, existed during such periods).
PRO FORMA CONSOLIDATED CONTRIBUTION REVENUES ($000s)
Fiscal Year Ended June 30, 2017 2016 2015 2014 2013 Unrestricted $15,594 $ 4,619 $ 6,840 $ 3,797 $ 5,109 Restricted for Operations or Capital 47,644 68,985 38,608 78,747 32,462 Permanently Restricted 11,392 12,334 6,327 36,301 7,669 Totals $74,630 $85,938 $51,775 $118,845 $45,240
CAPITAL PROGRAM AND PLANNING
On a pro forma basis over the last three years (assuming, the University, as currently constituted, existed during such period), the University has spent an annual average of approximately $246 million on “regular” capital expenditures and the University expects to continue regular capital expenditures at roughly this level in the future. In addition, the ISFP process is expected to generate strategic capital opportunities in the future in addition to regular capital expenditures.
Except with respect to the New Money Project described in the front part of the Official Statement, no additional strategic capital projects have been identified and submitted to the TJU Board for approval. Future regular and strategic capital will be funded from available cash and, in some cases, may, be funded through future debt issuances.
A-50
INSURANCE
The University maintains professional liability insurance coverage using a combination of self- insurance and commercial insurance/reinsurance. The Pennsylvania hospitals, residents and employed physicians (healthcare providers) maintain professional liability insurance coverage with limits required by the Commonwealth of Pennsylvania Medical Care Availability and Reduction of Error Act 13 of 2002. In addition, an individual $1,000,000 per medical incident and $3,000,000 annual aggregate limit is provided for each scheduled dentist, as well as physicians and residents practicing in other states including but not limited to Delaware and New Jersey. Non-healthcare provider entities are provided with a shared $1,000,000 per incident and $3,000,000 annual aggregate professional limit of liability. The University and/or the individual member health system entity has ongoing claims and risk management/patient safety programs in accordance with the requirements of Act 13.
Jefferson/New Jersey maintains professional liability coverage using commercial insurance with limits of $1,000,000 per claim and $3,000,000 annual aggregate. In addition, using commercial insurance coverage, the scheduled Jefferson/New Jersey employed physicians, hospitalists, allied health professionals and KMGP are provided with individual limits of $1,000,000 each claim and $3,000,000 annual aggregate.
The University and/or individual entities also maintain other types of insurance, including coverage for general liability, property, directors’ and officers’ liability, workers compensation/employer’s liability, cyber/privacy and security liability, excess/umbrella liability with limits/retentions/terms and conditions that are deemed reasonable and customary for universities and health systems of comparable size and scope of services. See Notes 14 and 15, respectively, to the audited consolidated financial statements included in Appendix B-1 to this Official Statement for additional information. For a more detailed discussion of medical professional liability insurance, see “CERTAIN INVESTMENT CONSIDERATIONS – Medical Professional Liability Insurance Market” in the forepart of the Official Statement.
LITIGATION
Lawsuits and claims are filed against the University in the ordinary course of business. While the outcome of many of these actions is not presently determinable, it is the opinion of management that any resulting liability from these actions or, to its knowledge, any threatened actions, will not have a material adverse effect on the consolidated results of operations or the consolidated financial position of the University. Moreover, the University has a comprehensive program for primary and excess insurance, summarized above. If, however, a final judgment were entered in any action in excess of its insurance coverage, the University would be liable for the excess. Management of the University believes that any currently pending or, to its knowledge, threatened, lawsuits subjecting the University to liability not covered by insurance would not have a materially adverse effect on the University’s consolidated operations, finances or properties.
A-51 [THIS PAGE INTENTIONALLY LEFT BLANK]
APPENDIX B-1
THOMAS JEFFERSON UNIVERSITY CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2017 AND 2016
[THIS PAGE INTENTIONALLY LEFT BLANK] Thomas Jefferson University
Consolidated Financial Statements June 30, 2017 and 2016 Thomas Jefferson University Table of Contents June 30, 2017 and 2016
Pages
Report of Independent Auditors 1 - 2
Consolidated Balance Sheets 3
Consolidated Statements of Operations and Changes in Unrestricted Net Assets 4
Consolidated Statements of Changes in Net Assets 5
Consolidated Statements of Cash Flows 6
Notes to Consolidated Financial Statements 7 - 43
Supplemental Information:
Unaudited Pro Forma Information 44
Unaudited Consolidating Balance Sheets 45
Unaudited Consolidating Statements of Operations and Changes in Unrestricted Net Assets 46 Report of Independent Auditors
To the Board of Trustees Thomas Jefferson University:
We have audited the accompanying consolidated financial statements of Thomas Jefferson University and its subsidiaries (the “University”), which comprise the consolidated balance sheets as of June 30, 2017 and 2016, and the related consolidated statements of operations and changes in unrestricted net assets, of changes in net assets and of cash flows for the years then ended.
Management's Responsibility for the Consolidated Financial Statements
Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.
Auditors’ Responsibility
Our responsibility is to express an opinion on the consolidated financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.
An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on our judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, we consider internal control relevant to the University’s preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the University’s internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.
Opinion
In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of Thomas Jefferson University and its subsidiaries as of June 30, 2017 and 2016, and the changes in their net assets and their cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.
Other Matter
Our audits were conducted for the purpose of forming an opinion on the consolidated financial statements taken as a whole. The consolidating information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The consolidating information has been subjected to the auditing procedures applied in the audit of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting
PricewaterhouseCoopers LLP, Two Commerce Square, Suite 1800, 2001 Market Street, Philadelphia, PA 19013-7045 T: (267) 330 - 3000, F: (267) 330 - 3300, www.pwc.com/us
and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves and other additional procedures, in accordance with auditing standards generally accepted in the United States of America. In our opinion, the consolidating information is fairly stated, in all material respects, in relation to the consolidated financial statements taken as a whole. The consolidating information is presented for purposes of additional analysis of the consolidated financial statements rather than to present the financial position, changes in net assets and cash flows of the individual entities and is not a required part of the consolidated financial statements. Accordingly, we do not express an opinion on the financial position, changes in net assets and cash flows of the individual entities.
Philadelphia, Pennsylvania September , 2017